EP2683693B1 - Rorgammat inhibitors - Google Patents

Rorgammat inhibitors Download PDF

Info

Publication number
EP2683693B1
EP2683693B1 EP12744370.3A EP12744370A EP2683693B1 EP 2683693 B1 EP2683693 B1 EP 2683693B1 EP 12744370 A EP12744370 A EP 12744370A EP 2683693 B1 EP2683693 B1 EP 2683693B1
Authority
EP
European Patent Office
Prior art keywords
indazol
chloro
trifluoromethyl
benzoyl
benzoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12744370.3A
Other languages
German (de)
French (fr)
Other versions
EP2683693A4 (en
EP2683693A1 (en
Inventor
Willem Frederik Johan Karstens
Mario van der STELT
Jos CALS
Rita Corte Real Goncalves AZEVEDO
Kenneth Jay BARR
Hongjun Zhang
Richard Thomas Beresis
Dongshan Zhang
Xiaobang DUAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme BV
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme BV, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme BV
Priority to EP12744370.3A priority Critical patent/EP2683693B1/en
Publication of EP2683693A1 publication Critical patent/EP2683693A1/en
Publication of EP2683693A4 publication Critical patent/EP2683693A4/en
Application granted granted Critical
Publication of EP2683693B1 publication Critical patent/EP2683693B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • T helper cells Upon activation by antigen-presenting cells na ⁇ ve T helper cells undergo clonal expansion and will ultimately differentiate in cytokine secreting effector T cells, such as Th1 and Th2 subtypes.
  • cytokine secreting effector T cells such as Th1 and Th2 subtypes.
  • a third and distinct effector subset has been identified, which plays a key role in providing immunity to bacteria and fungi at mucosal surfaces ( Kastelein et al., Annu. Rev. Immunol. 25: 221-242, 2007 ).
  • This effector T helper cell subset can be distinguished based on its ability to produce large quantities of IL-17/F, IL-21 and IL-22, and is named Th17 ( Miossec et al., New Eng. J. Med. 2361: 888-898, 2009 ).
  • Th1 and Th2 effector cells express Tbet and GATA3, respectively.
  • a Thymocyte/T cell specific variant of Retinoic Acid Receptor-related Orphan Receptor (ROR), RORgammaT is highly expressed in Th17 cells ( He et al., Immunity 9: 797-806, 1998 ).
  • RORgammaT belongs to the nuclear hormone receptor superfamily ( Hirose et al., Biochem. Biophys. Res. Comm. 205: 1976-1983, 1994 ).
  • RORgammaT is a truncated form of RORgamma, lacking the first N-terminal 21 amino acids and is, in contrast to RORgamma which is expressed in multiple tissues (heart, brain, kidney, lung, liver and muscle), exclusively expressed in cells of the lymphoid lineage and embryonic lymphoid tissue inducers ( Sun et al., Science 288: 2369-2372, 2000 ; Eberl et al., Nat Immunol. 5: 64-73, 2004 ).
  • RORgammaT was shown to play a crucial role in non-Th17 lymphoid cells.
  • RORgammaT was critically important in innate lymphoid cells expressing Thy1, SCA-1 and IL-23R proteins. Genetic disruption of RORgamma in a mouse colitis model dependent on these innate lymphoid cells, prevented colitis development ( Buonocore et al., Nature 464: 1371-1375, 2010 ).
  • RORgammaT was shown to play a crucial role in other non-Th17 cells, such as mast cells ( Hueber et al., J. Immunol. 184: 3336-3340, 2010 ).
  • RORgammaT Based on the role of IL-17 producing cells (either Th17 or non-Th17 cells) RORgammaT has been identified as a key mediator in the pathogenesis of several diseases ( Louten et al., J. Allergy Clin. Immunol. 123: 1004-1011, 2009 ; Annuziato et al., Nat. Rev. Rheumatol. 5: 325-331, 2009 ). This was confirmed using several disease models representative of autoimmune diseases.
  • autoimmune diseases such as, but not limited to rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Crohn's disease, and asthma ( Annunziato et al., Nat. Rev. Immunol. 5: 325-331, 2009 ; Louten et al., J. Allergy Clin. Immunol. 123: 1004-1011, 2009 ).
  • Inhibition of RORgammaT may also be beneficial in other diseases, which are characterized by increased levels of Th17 cells and/or elevated levels of Th17 hallmark cytokines such as IL-17, IL-22 and IL-23.
  • diseases are Kawasaki Disease ( Jia et al., Clin. Exp. Immunol. 162: 131-137, 2010 ) and Hashimoto's thyroiditis ( Figueroa-Vega et al., J. Clin. Endocrinol. Metab. 95: 953-62, 2010 ).
  • Another example includes infectious diseases, such as, but not limited to, mucosal leishmaniasis ( Boaventura et al., Eur. J. Immunol. 40: 2830-2836, 2010 ).
  • the inhibition may be enhanced by simultaneous inhibition of RORalpha.
  • agonists include T0901317 and SR1078 ( Wang et al., ACS Chem. Biol. 5:1029-1034, 2010 ).
  • antagonist have been reported such as 7-oxygenated sterols ( Wang et al., J. Biol. Chem. 285: 5013-5025, 2009 ) and compounds described in EP2181710 A1 .
  • psoriasis One exemplary immue disorder in need of better therapy is psoriasis.
  • Various therapeutics have been developed in an attempt to treat psoriasis.
  • the traditional therapies for psoriasis often have toxic adverse effects.
  • An exemplary inflammatory disorder in need of better treatment is rheumatoid arthritis. Numerous therapeutics have been developed in an attempt to treat this disorder. However, some patients develop resistance to current therapies.
  • the present invention provides compounds which inhibit RORgammaT, said compounds for use in a method of treatment of RORgammaT-mediated diseases or conditions, in particular autoimmune diseases and inflammatory diseases, as well as pharmaceutical compositions comprising such compounds and pharmaceutical carriers.
  • the present invention provides a compound according to Formula I or a pharmaceutically acceptable salt or solvate thereof wherein,
  • This invention also provides a compound according to Formula Ia or a pharmaceutically acceptable salt or solvate thereof
  • a 4 , A 5 , A 6 , A 7 are selected from the group consisting of: (i) CR 4 , CR 5 , CR 6 , CR 7 ; (ii) N, CR 5 , CR 6 , CR 7 ; (iii) CR 4 , N, CR 6 , CR 7 ; (iv) CR 4 , CR 5 , N, CR 7 ; (v) CR 4 CR 5 , CR 6 , N; (vi) N, N, CR 6 , CR 7 ; (vii) CR 4 , N, N, CR 7 ; (viii) CR 4 , CR 5 , N, N; (ix) N, CR 5 , N, CR 7 ; (x) CR 4 , N, CR 6 , N; and (xi) N, CR 5 , CR 6 , N.
  • a 4 , A 5 , A 6 , A 7 are selected from the group consisting of: (i) CR 4 , CR 5 , CR 6 , CR 7 ; (ii) N, CR 5 , CR 6 , CR 7 ; and (iii) CR 4 , N, CR 6 , CR 7 .
  • a 4 , A 5 , A 6 , A 7 is (i) CR 4 , CR 5 , CR 6 , CR 7 , or (ii) N, CR 5 , CR 6 , CR 7 ; and Y is N.
  • X is C(O) or SO 2 ;
  • R 1 is (i) (C 3-7 )cycloalkyl or (C 3-5 )heterocycloalkyl, both optionally substituted with one or more groups selected from (C 1-4 )alkyl or halogen; (ii) (C 2-9 )heteroaryl, optionally substituted with one or more groups selected from halogen, amino or (C 1-4 )alkyl; or (iii) (C 6-14 )aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl, (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl and (C 1-3 )alkoxy are optionally substituted with one or more halogens.
  • R 1 is (C 2-9 )heteroaryl or (C 6-14 )aryl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl and (C 1-3 )alkoxy are optionally substituted with one or more halogen.
  • R1 is (C 6-14 )aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, or (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, all optionally substituted with one or more halogen.
  • R 1 is phenyl, naphthyl, pyridinyl, quinolinyl, benzooxadiazolyl, thiophenyl, or isoxazolyl, each optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl and (C 1-3 )alkoxy are optionally substituted with one or more halogens.
  • R 1 is phenyl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl or (C 1-3 )alkoxy, wherein (C 1-3 )alkoxycarbonyl, (C 1-4 )alkyl and (C 1-3 )alkoxy are optionally substituted with one or more halogens.
  • a tenth subset of the invention relates to compounds according to Formula I and Ia wherein Y is N.
  • a second embodiment of the compound of Formula I is a compound having Formula Ib and a pharmaceutically acceptable salt or solvate thereof, wherein A 4 -A 7 , R 1 -R 3 , X, Y and n are defined as set forth hereinabove for Formula I.
  • a third embodiment of the compound of Formula I is a compound having Formula Ic or a pharmaceutically acceptable salt or solvate thereof wherein,
  • a fourth embodiment of the compound of Formula I is a compound having Formula Id and a pharmaceutically acceptable salt or solvate thereof, wherein A 4 -A 7 , R 2 , R 3 , X, Y and n are defined as set forth hereinabove for Formula I.
  • a fifth embodiment of the compound of Formula I is a compound having Formula Ie and a pharmaceutically acceptable salt or solvate thereof, wherein A 4 -A 7 , R 3 , X and n are defined as set forth hereinabove for Formula I.
  • Ia, Ib, Ic, Id, and Ie are compounds wherein R 4 is selected from H, halogen, amino, and (C 1-4 )alkyl optionally substituted with one or more halogen; R 5 is H; R 6 is selected from H, dimethylaminocarbonyl, -CH2NH2, cyano, each optionally substituted with one or more halogen, hydroxyl, or methoxy; and R7 is selected from H and halogen.
  • a still further embodiment of the compounds of Formula I, Ia, Ib, Ic, Id, and Ie, are compounds wherein one of R 4 , R 5 and R 7 is other than hydrogen.
  • the invention also relates to those compounds wherein all specific definitions for A 1 through A 4 , R 1 through R 8 , X, Y, n and x and all substituent groups in the various aspects of the inventions defined here above occur in any combination within the definition of the compound of Formula I.
  • Non-limiting examples of the compunds of the present invention include:
  • alkyl includes both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbon atoms; for example, “C 1-6 alkyl” (or “C 1 -C 6 alkyl”) includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl.
  • Alkylene refers to both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbons, and having two terminal end chain attachments; for example, the term “A-C 4 alkylene-B” represents, for example, A-CH 2 -CH 2 -CH 2 -CH 2 -B, A-CH 2 -CH 2 -CH(CH 3 )-CH 2 -B, A-CH 2 -CH(CH 2 CH 3 )-B, A-CH 2 -C(CH 3 )(CH 3 )-B, and the like.
  • Alkoxy represents a linear or branched alkyl group of indicated number of carbon atoms attached through an oxygen bridge; for example “C 1 -C 6 alkoxy” includes -OCH 3 , -OCH 2 CH 3 , -OCH(CH 3 ) 2 , -O(CH 2 ) 5 CH 3 , and the like.
  • alkyl groups are unsubstituted or substituted with 1 to 3 substituents on each carbon atom, with halo, C 1 -C 20 alkyl, CF 3 , NH 2 , N(C 1 -C 6 alkyl) 2 , NO 2 , oxo, CN, N 3 , -OH, -O(C 1 -C 6 alkyl), C 3 -C 10 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, (C 0 -C 6 alkyl) S(O) 0-2 -, (C 0 -C 6 alkyl)S(O) 0-2 (C 0 -C 6 alkyl)-, (C 0 -C 6 alkyl)C(O)NH-, H 2 N-C(NH)-, H 2 N-C(O)(NH)(NH)(NH)(NH)(NH)(NH)(NH)(NH)-
  • alkenyl means a straight or branched carbon chain having the specified number of carbon atoms with at least one carbon-carbon double bond.
  • alkenyl include, but are not limited to, vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, 2,4-hexadienyl, and the like.
  • alkynyl means a straight or branched carbon chain having the specified number of carbon atoms with at least one carbon-carbon triple bond.
  • alkynyl include, but are not limited to ethynyl, propargyl, 1-propynyl, 2-butynyl, and the like.
  • carbocycle (and variations thereof such as “carbocyclic” or “carbocyclyl”) as used herein, unless otherwise indicated, refers to (i) a C 3 to C 8 monocyclic, saturated or unsaturated ring or (ii) a C 7 to C 12 bicyclic saturated or unsaturated ring system. Each ring in (ii) is either attached via a bond to, or fused (including spirofused) to, the other ring, and each ring is saturated or unsaturated.
  • the carbocycle may be attached to the rest of the molecule at any carbon atom which results in a stable compound.
  • Saturated carbocyclics form a subset of carbocycles in which the entire ring system (mono- or polycyclic) is saturated.
  • Saturated monocyclic carbocyclic rings are also referred to as cycloalkyl rings, e.g., cyclopropyl, cyclobutyl, etc.
  • the fused bicyclic carbocycles are a further subset of the carbocycles in which a C 7 to C 10 bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms (or in the case of spirofused, one carbon atom) are shared by each of the rings in the ring system.
  • a saturated bicyclic carbocycle is one in which both rings are saturated.
  • An unsaturated bicyclic carbocycle is one in which one ring is unsaturated and the other is unsaturated or saturated. Unless otherwise noted, carbocycle is unsubstituted or substituted with C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, aryl, halogen, NH 2 or OH.
  • a subset of the fused bicyclic unsaturated carbocycles are those bicyclic carbocycles in which one ring is a benzene ring and the other ring is saturated or unsaturated, with attachment via any carbon atom that results in a stable compound. Representative examples of this subset include the following:
  • Aromatic carbocycles form another subset of the carbocycles.
  • aryl refers to aromatic mono- and poly-carbocyclic ring systems in which the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond. Suitable aryl groups include phenyl, naphthyl, and biphenyl.
  • cycloalkyl means a cyclic ring of an alkane having the specified total ring carbon atoms; for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • heterocycle broadly refers to (i) a stable 4- to 8-membered, saturated or unsaturated monocyclic ring, or (ii) a stable 7- to 12-membered bicyclic ring system, wherein each ring in (ii) is either attached via a bond to, or fused (including spirofused) to, the other ring, and each ring is saturated or unsaturated, and the monocyclic ring or bicyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) selected from N, O and S and a balance of carbon atoms (the monocyclic ring typically contains at least one carbon atom and the ring systems typically contain at least two carbon atoms); and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally oxidized, and any one or more of the nitrogen heteroatoms is optionally
  • the heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure.
  • the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
  • saturated heterocyclics form a subset of the heterocycles; i.e., the term “saturated heterocyclic” generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is saturated.
  • saturated heterocyclic ring refers to a 4- to 8-membered saturated monocyclic ring or a stable 7- to 12-membered bicyclic ring system which consists of carbon atoms and one or more heteroatoms selected from N, O and S.
  • Representative examples include piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, 1,4-dioxanyl, 1,4-thioxanyl, tetrahydropyranyl, tetrahydrofuryl (or tetrahydrofuranyl), tetrahydrothienyl, and tetrahydrothiopyranyl.
  • Heteroaromatics form another subset of the heterocycles; i.e., the term “heteroaromatic” (alternatively “heteroaryl”) generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is an aromatic ring system.
  • the term “heteroaromatic ring” refers a 5- or 6-membered monocyclic aromatic ring or a 7- to 12-membered bicyclic aromatic ring, and which consists of carbon atoms and one or more heteroatoms selected from N, O and S.
  • substituted heteroaryl rings containing at least one nitrogen atom e.g., pyridine
  • substitutions can be those resulting in N-oxide formation.
  • monocyclic heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl.
  • bicyclic heteroaromatic rings examples include benzotriazolyl, indolyl, benzoxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzimidazolyl, isoindolyl, indazolyl, quinoxalinyl, quinazolinyl, cinnolinyl, quinolinyl, isoquinolinyl, naphthyridinyl, pyrazolo[3,4-b]pyridine, imidazo[2,1-b](1,3)thiazole, (i.e., ), 6-(1-pyrrolyl)-3-pyridyl, 4-(1-pyrrolyl)phenyl, 4-(pyrid-3-yl)phenyl, and 4-(pyrid-4-yl)phenyl.
  • heterocycles are unsaturated heterocycles in which one or both rings are unsaturated (provided the entire ring system is not aromatic).
  • unsaturated heterocycles include dihydrofuranyl, dihydrothienyl, dihydropyranyl, dihydroimidazolyl, indolinyl, isoindolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydronaphthyridinyl, 2,3-dihydrobenzofuranyl, 1,4-benzoxazinyl, 1,3-benzoxazolinyl, 2,3-dihydrobenzo-1,4-dioxinyl (i.e., ), and benzo-1,3-dioxolyl (i.e., ).
  • phenyl having as a substituent
  • cycloalkyl Unless otherwise specifically noted as only unsubstituted or only substituted, cycloalkyl, cycloalkenyl, cycloalkyl, aryl (including phenyl) and heteroaryl groups are unsubstituted or substituted (also referred to as "optionally substituted").
  • substituents for substituted or optionally substituted cycloalkyl, cycloalkenyl, aryl (including phenyl, and as an isolated substituent or as part of a substituent such as in aryloxy and aralkyl), heteroaryl (as an isolated substituent or as part of a substituent such as in heteroaryloxy and heteroaralkyl) are one to three groups independently selected from halogen (or halo), C 1 -C 6 alkyl optionally substituted with one to five fluorine, NH 2 , N(C 1 -C 6 alkyl) 2 , NO 2 , oxo, CN, N 3 , -OH, -O(C 1 -C 6 alkyl) optionally substituted with one to five fluorine, C 3 -C 10 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, (C 0 -C 6 al
  • halogen refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro (F), chloro (Cl), bromo (Br), and iodo (I)).
  • haloalkyl means alkyl having the specified number of carbon atoms in which from one to all of the hydrogen atoms have been replaced by a halogen atom.
  • aralkyl and “heteroaralkyl” refer to an aryl/heteroaryl linked to the rest of the molecule via a C 1 to C 4 alkylene.
  • C 0 as employed in expressions such as "C 0-6 alkylene” means a direct covalent bond; or when employed in experessions such as “C 0-6 alkyl” means hydrogen.
  • an integer defining the presence of a certain number of atoms in a group is equal to zero, it means that the atoms adjacent thereto are connected directly by a bond; for example, in the structure wherein s is an integer equal to zero, 1 or 2, the structure is when s is zero; or it means that the indicated atom is absent; for example -S(O) 0 - means -S-.
  • an “unsaturated” ring is a partially or fully unsaturated ring.
  • an “unsaturated monocyclic C 6 carbocycle” refers to cyclohexene, cyclohexadiene, and benzene.
  • heterocycle described as containing from “1 to 4 heteroatoms” means the heterocycle can contain 1, 2, 3 or 4 heteroatoms.
  • variable definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • variable definitions containing terms having repeated terms e.g., (CRiRj) r , where r is the integer 2, Ri is a defined variable, and Rj is a defined variable
  • the value of Ri may differ in each instance in which it occurs, and the value of Rj may differ in each instance in which it occurs.
  • Ri and Rj are independently selected from the group consisting of methyl, ethyl, propyl and butyl, then (CRiRj) 2 can be
  • (C 1-6 )alkyl as used hereinabove means a branched or unbranched alkyl group having 1-6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, n-pentyl and n-hexyl. Preferred is (C 1-4 )alkyl.
  • (C 1-5 )alkyl means a branched or unbranched alkyl group having 1-5 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and n-pentyl.
  • (C 1-4 )alkyl as used herein means a branched or unbranched alkyl group having 1-4 carbon atoms, being methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
  • (C 1-3 )alkoxy means an alkoxy group having 1-3 carbon atoms, the alkyl moiety being branched or unbranched.
  • (C 1-3 )alkoxycarbonyl means an alkoxycarbonyl group having 1-3 carbon atoms in the alkoxy moiety, the alkoxy moiety having the same meaning as previously defined.
  • (di)(C 1-6 )alkylaminocarbonyl means an alkylaminocarbonyl group, the amino group of which is monosubstituted or disubstituted independently with an alkyl group which contains 1-6 carbon atoms and which has the same meaning as previously defined.
  • Preferred alkyl group is (C 1-4 )alkyl.
  • (C 3-7 )cycloalkyl means a cycloalkyl group having 3-7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. 5-6 Carbon atoms are preferred.
  • (C 3-5 )heterocycloalkyl means a heterocycloalkyl group having 3-5 carbon atoms, including 1-3 heteroatoms selected from N, O and/or S, which may be attached via a nitrogen if feasible, or a carbon atom.
  • Preferred number of heteroatoms is one or two. Most preferred number is one.
  • Preferred heteroatoms are N or O. Most preferred are piperazinyl, tetrahydropyranyl, morpholinyl and pyrrolidinyl.
  • (C 2-9 )heteroaryl means an aromatic group having 2-9 carbon atoms and 1-3 heteroatoms selected from N, O and S, like imidazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, thiophenyl or furyl, pyrazolyl, isoxazolyl or quinolyl. Preferred number of heteroatoms is one or two. Preferred heteroaryl groups are pyrazolyl, thiophenyl, isoxazolyl, pyridyl and quinolyl.
  • the (C 2-5 )heteroaryl group may be attached via a carbon atom or a nitrogen, if feasible.
  • (C 6-14 )aryl means an aromatic hydrocarbon group having 6-14 carbon atoms, such as phenyl, naphthyl, tetrahydronaphthyl, indenyl, anthracyl, More preferred are (C 6-10 )aryl groups.
  • the most preferred aromatic hydrocarbon group is phenyl.
  • X a -X b shall have the same meaning as the term "X a - b ", wherein X is any atom and a and b are any integers.
  • C 1 -C 4 shall have the same meaning as “C 1-4 ".
  • a x shall have the same meaning, and be interchangeable with, “AX”, wherein “A” is any atom and “x” or “X” are any integer.
  • R 1 shall have the same meaning, and be interchangeable with, "R1".
  • the attachment point is at the last group.
  • substituted means that one or more hydrogens on the designated atom/atoms is/are replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • Stable compound or “stable structure” is defined as a compound or structure that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • effective amount refers to an amount of the compound of Formula (I) and/or an additional therapeutic agent, or a composition thereof, that is effective in producing the desired therapeutic, ameliorative, inhibitory or preventative effect when administered to a subject suffering from an RORgammaT-mediated disease or disorder.
  • effective amount can refer to each individual agent or to the combination as a whole, wherein the amounts of all agents administered are together effective, but wherein the component agent of the combination may not be present individually in an effective amount.
  • a “subject” is a human or non-human mammal. In one embodiment, a subject is a human. In another embodiment, a subject is a chimpanzee.
  • the compounds of this invention include the hydrates or solvates of the compounds.
  • the compounds of Formula I may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention.
  • Compounds described herein may contain an asymmetric center and may thus exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereomers.
  • the present invention includes all such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers.
  • the above Formula I is shown without a definitive stereochemistry at certain positions.
  • the present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof.
  • Diastereoisomeric pairs of enantiomers may be separated by, for example, fractional crystallization from a suitable solvent, and the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid or base as a resolving agent or on a chiral HPLC column. Further, any enantiomer or diastereomer of a compound of the general Formula I may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g. chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g. hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g. chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • some of the compounds of Formula (I) may be atropisomers (e.g. substituted biaryls) and are considered as part of this invention.
  • Enantiomers can also be separated by use of chiral HPLC column.
  • All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds including those of the salts, solvates, esters of the compounds), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention.
  • Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
  • the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
  • pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases.
  • Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Preferred are the ammonium, calcium, magnesium, potassium and sodium salts.
  • Salts prepared from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines derived from both naturally occurring and synthetic sources.
  • organic non-toxic bases from which salts can be formed include, for example, arginine, betaine, caffeine, choline, N,N'-dibenzyl-ethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, dicyclohexylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
  • the compound of the present invention When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic inorganic and organic acids.
  • Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • Preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.
  • the compounds of Formula I can form salts which are also within the scope of this invention.
  • Reference to a compound of Formula I herein is understood to include reference to salts thereof, unless otherwise indicated.
  • pharmaceutically acceptable salt represents those salts which are, within the scope of medical judgement, suitable for use in contact for the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art.
  • the free base function may be obtained during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable mineral acid such as hydrochloric acid, phosphoric acid, or sulfuric acid, or with an organic acid such as for example ascorbic acid, citric acid, tartaric acid, lactic acid, maleic acid, malonic acid, fumaric acid, glycolic acid, succinic acid, propionic acid, acetic acid, methanesulfonic acid, and the like.
  • the acid function can be reacted with an organic or a mineral base, like sodium hydroxide, potassium hydroxide, calcium hydroxide, calcium carbonate, ammonium (e.g. diethylamine) or lithium hydroxide.
  • solvate refers to a complex of variable stoichiometry formed by a solute (i.e., a compound of Formula I) or a pharmaceutically acceptable salt thereof and a solvent that does not interfere with the biological activity of the solute.
  • solvents include, but are not limited to water, ethanol, and acetic acid.
  • the solvent is water, the solvate is known as hydrate; hydrate includes, but is not limited to, hemi-, mono, sesqui-, di-and trihydrates.
  • the compounds of the invention may form hydrates or solvates. It is known to those of skill in the art that charged compounds form hydrated species when lyophilized with water, or form solvated species when concentrated in a solution with an appropriate organic solvent.
  • One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
  • “Solvate” may also mean a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding.
  • solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • Solvate encompasses both solution-phase and isolatable solvates.
  • suitable solvates include ethanolates, methanolates, and the like.
  • “Hydrate” is a solvate wherein the solvent molecule is H 2 O.
  • prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.
  • various conditions described herein may be treated with a compound of formula I or with a compound which may not be a compound of formula I, but which converts to a compound of formula I in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in " Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985 .
  • prodrugs means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of Formula I or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g. by metabolic or chemical processes), such as, for example, through hydrolysis in blood.
  • prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987 .
  • the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
  • the present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I.
  • different isotopic forms of hydrogen (H) include protium ( 1 H) and deuterium ( 2 H).
  • Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
  • Isotopically-enriched compounds within generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
  • Compounds of the present invention are inhibitors of Retinoic Acid Receptor-related Orphan Receptor gamma t (RORgammaT), and as such are useful in the treatment of diseases and conditions in which inhibition of RORgammaT is desirable, such as autoimmune and inflammatory diseases and disorders.
  • RORgammaT Retinoic Acid Receptor-related Orphan Receptor gamma t
  • another embodiment of the present invention provides a compound having Formula I, Ia, Ib, Ic , Id or Ie or a pharmaceutically acceptable salt or solvate thereof for use in a method for treating a disease or condition mediated by RORgammaT in a subject comprising administering to the subject an amount of a compound having Formula I, Ia, Ib, Ic, Id or Ie or a pharmaceutically acceptable salt or solvate thereof, that is effective for treating the disease or condition mediated by RORgammaT in a subject.
  • the compounds according to the invention can be used in therapy.
  • Another aspect of the invention resides in the compounds or a pharmaceutically acceptable salt thereof having the general formula I for use in the treatment of autoimmune diseases, in particular those diseases in which Th17 cells and non-Th17 cells, which express Th17 hallmark cytokines play a prominent role.
  • autoimmune diseases include, but are not limited to, the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn's disease and multiple sclerosis.
  • compounds or a pharmaceutically acceptable salt thereof having the general formula I can be used for treatment of inflammatory diseases in which Th17 cells and/or non-Th17 cells, which express Th17 hallmark cytokines play a prominent role such as, but not limited to respiratory diseases, osteoarthritis and asthma.
  • compounds or a pharmaceutically acceptable salt thereof having the general formula I can be used for treatment of infectious diseases in which Th17 cells and/or non-Th17 cells, which express Th17 hallmark cytokines play a prominent role such as, but not limited to mucosal leishmaniasis.
  • Compounds or a pharmaceutically acceptable salt thereof having the general formula I can also be used for treatment of other diseases in which Th17 cells and/or non-Th17 cells, which express Th17 hallmark cytokines play a prominent role such as, but not limited to Kawasaki disease and Hashimoto's thyroiditis.
  • the disease or condition is an autoimmune disease or inflammatory disease.
  • the disease or condition includes, but is not limited to, multiple sclerosis, inflammatory bowel disease, Crohn's disease, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis or mucosal leishmaniasis.
  • the compounds according to the invention can be used in therapies to treat or prevent multiple sclerosis, inflammatory bowel disease, Crohn's disease, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis and mucosal leishmaniasis.
  • the compounds according to the invention can be used to treat or prevent psoriasis.
  • the compounds according to the invention can be used to treat inflammatory bowel disease.
  • This aspect of the present invention includes a compound of Formula I, Ia, Ib, Ic, Id or Ie, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a disease or condition mediated by RORgammaT.
  • the compounds of this invention can be administered for the treatment or prevention of afflictions, diseases and illnesses according to the invention by any means that effects contact of the active ingredient compound with the site of action in the body of a warm-blooded animal.
  • administration can be oral, topical, including transdermal, ocular, buccal, intranasal, inhalation, intravaginal, rectal, intracisternal and parenteral.
  • parenteral refers to modes of administration which include subcutaneous, intravenous, intramuscular, intraarticular injection or infusion, intrasternal and intraperitoneal.
  • a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
  • the compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the dosage administered will be dependent on the age, health and weight of the recipient, the extent of disease, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.
  • a daily dosage of active ingredient compound will be from about 1.0-2000 milligrams per day. Ordinarily, from 10 to 500 milligrams per day in one or more applications is effective to obtain desired results.
  • These dosages are the effective amounts for the treatment and prevention of afflictions, diseases and illnesses described above, e.g., autoimmune and inflammatory diseases and disorders.
  • compositions include e.g. those suitable for oral, sublingual, subcutaneous, intravenous, intramuscular, nasal, local, or rectal administration, and the like, all in unit dosage forms for administration.
  • the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like.
  • the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like.
  • the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophilized) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.
  • the active agent may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories.
  • the active agent can be applied as a fluid composition, e.g. as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
  • solid dosage units For making solid dosage units, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used. Suitable carriers with which the active agent of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. For parenteral administration, aqueous suspensions, isotonic saline solutions and sterile injectable solutions may be used, containing pharmaceutically acceptable dispersing agents and/or wetting agents, such as propylene glycol or butylene glycol.
  • compositions comprising a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable excipients.
  • excipient and “carrier” may be used interchangeably.
  • composition as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of Formula I, additional active ingredient(s), and pharmaceutically acceptable excipients.
  • compositions of the present invention comprise a compound represented by Formula I (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants.
  • the compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered.
  • the pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, troches, dragees, granules and powders, or in liquid dosage forms, such as elixirs, syrups, emulsions, dispersions, and suspensions.
  • the active ingredient can also be administered parenterally, in sterile liquid dosage forms, such as dispersions, suspensions or solutions.
  • dosages forms that can also be used to administer the active ingredient as an ointment, cream, drops, transdermal patch or powder for topical administration, as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration, as an aerosol spray or powder composition for inhalation or intranasal administration, or as a cream, ointment, spray or suppository for rectal or vaginal administration.
  • Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
  • powdered carriers such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
  • Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
  • water a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene gycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances.
  • Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
  • citric acid and its salts and sodium EDTA are also used.
  • parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
  • Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.
  • the compounds of the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers.
  • the compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device.
  • the preferred delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a compound of Formula I in suitable propellants, such as fluorocarbons or hydrocarbons.
  • MDI metered dose inhalation
  • an ophthalmic preparation may be formulated with an appropriate weight percent solution or suspension of the compounds of Formula I in an appropriate ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye.
  • Useful pharmaceutical dosage-forms for administration of the compounds of this invention include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral injectables, and oral suspensions.
  • a large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
  • a mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient.
  • the capsules are washed and dried.
  • a large number of tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose.
  • Appropriate coatings may be applied to increase palatability or delay absorption.
  • a parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized.
  • An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredient, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.
  • the same dosage forms can generally be used when the compounds of this invention are administered stepwise or in conjunction with another therapeutic agent.
  • the dosage form and administration route should be selected depending on the compatibility of the combined drugs.
  • coadministration is understood to include the administration of the two agents concomitantly or sequentially, or alternatively as a fixed dose combination of the two active components.
  • the present invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof having the general formula I in admixture with pharmaceutically acceptable auxiliaries and optionally other therapeutic agents.
  • the auxiliaries must be "acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
  • the invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
  • the exact dose and regimen of administration of the active ingredient, or a pharmaceutical composition thereof, may vary with the particular compound, the route of administration, and the age and condition of the individual subject to whom the medicament is to be administered.
  • a dosage for humans preferably contains 0.0001-100 mg per kg body weight.
  • the desired dose may be presented as one dose or as multiple subdoses administered at appropriate intervals throughout the day.
  • the dosage as well as the regimen of administration may differ between a female and a male recipient.
  • Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, and the use of at least one other pharmaceutically active agent.
  • the compound(s) of formula (I) and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately this may occur simultaneously or sequentially in any order.
  • a compound of formula (I) may be combined with one or more other active agents such as: (1) TNF-a inhibitors; (2) non- selective COX-I/COX-2 inhibitors; (3) COX-2 inhibitors; (4) other agents for treatment of inflammatory and autoimmune diseases including glucocorticoids, methotrexate, leflunomide, sulfasalazine, azathioprine, cyclosporin, tacrolimus, penicillamine, bucillamine, actarit, mizoribine, lobenzarit, ciclesonide, hydroxychloroquine
  • the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl esters, or as solvates, for example hydrates, to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient. It will be clear also that, where appropriate, the therapeutic ingredients may be used in optically pure form.
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention.
  • These combinations are of particular interest in respiratory diseases and are conveniently adapted for inhaled or intranasal delivery.
  • the individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical compositions.
  • the individual compounds will be administered simultaneously in a combined pharmaceutical composition.
  • Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.
  • compositions of the present invention include those that also comprise at least one additional therapeutically active agent, in addition to the compound of Formula I, Ia, Ib, Ic, Id or Ie.
  • the invention further includes a compound of Formula I in combination with one or more other drug(s).
  • Table 1 below lists commercial sources, and previously disclosed synthetic routes, for chemical materials employed in the synthesis of intermediates and examples of the instant invention. This list is not intended to be exhaustive, exclusive, or limiting in any way.
  • Table 1 Structure Source Oakwood Aldrich Frontier Oakwood Sinova Sinova Aldrich Sinova Sinova Aldrich Sinova Alfa Bioorganic & Medicinal Chemistry Letters, 2006, 695-700 Acros Combi-blocks Combi-blocks Alfa Combi-blocks Alfa Combi-blocks Combi-blocks Alfa Combi-blocks Anichem Aobchem Chemmaker Combi-blocks Combi-blocks Anisyn Anisyn Alfa Aldrich
  • Example i-7 methyl 5-fluoro-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxa borolan-2-yl)benzoate (i-7)
  • heterocyclic derivatives of Formula I wherein A 4 to A 7 , R 1 , R 2 , R 3 , X and Y are as previously defined, can be prepared from compounds II.
  • Palladium catalyzed Suzuki-Miyaura arylation of compounds II using appropriately substituted phenylboronic acids III-a (corresponding boronic esters III-b may also be used) directly affords the desired compounds I.
  • aqueous NaOH, K 2 CO 3 or the like) and an aryl boronic acid of general Formula III-a or aryl boronic ester of general formula III-b in a suitable solvent such as dioxane or toluene/EtOH, is heated under an atmosphere of nitrogen under microwave irradiation or using conventional heating.
  • compound I may be obtained from compounds of Formula IV, in which FG is a functional group (e.g . ester, cyano, protected tetrazole) that can be easily converted to groups defined for R 2 .
  • suitable functional groups in compounds IV are a tert -butyl ester or methyl ester or a tetrazole, containing an acid labile group such as a para-methoxy benzyl protecting group, which can be treated with acid or base to afford compounds of Formula I-a or I-b in which R 2 is carboxyl or 5-tetrazolyl, respectively.
  • Compounds II are prepared by straightforward acylation or sulfonylation of compounds V.
  • a strong base such as potassium tert- butoxide or NaH
  • a suitable solvent such as DMF or THF
  • treatment of V with sulfonyl chlorides and a tertiary amine base e.g. DiPEA or triethylamine
  • acid chlorides are not available, they can be easily prepared from the corresponding carboxylic acids using known methods (e.g . treatment with SOCl 2 or similar reagents).
  • Compounds V are commercially available or prepared by methods know in the art, such as halogenation of compounds VI.
  • Compounds VI are also commercially available or easily prepared by standard organic synthesis techniques.
  • Compounds IV can be prepared in the same way as compounds I, by Suzuki-Miyaura reaction between compounds of general Formula II and an appropriately substituted arylboronic acid or ester.
  • Example 25A Preparation of sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl) -6-(2-hydroxy ethylcarbamoyl)- 1H -indazol-3-yl)benzoate (25A)
  • Example 26 Preparation of 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro- 1H- indazol-3-yl)-2-hydroxybenzoic acid (26A), 2-acetoxy-4-(1-(2-chloro-6-(trifluoromethyl) benzoyl)-4-fluoro- 1H- indazol-3-yl) benzoic acid (26B) and sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro- 1H -indazol-3-yl)-2-hydroxy benzoate (26C)
  • the compounds of the invention inhibit RORgammaT activity.
  • Activation of RORgammaT activity can be measured using e.g. biochemical TR-FRET assay.
  • TR-FRET assay
  • interaction of cofactor-derived peptides with human RORgammaT-Ligand Binding Domain (LBD) can be measured.
  • LBD RORgammaT-Ligand Binding Domain
  • the TR-FRET technique is a sensitive biochemical proximity assay that will give information concerning the interaction of a ligand with the LBD, in the presence of cofactor derived peptides ( Zhou et al., Methods 25:54-61, 2001 ).
  • a peptide from Steroid Receptor Co-factor 1 box 2 is aminoterminal biotinylated (biotinyl-CPSSHSSLTERHKILHRLLQEGSPS, NEOMPS, France) and the applied RORgamma-LBD contains a 6-His and GST tag.
  • the 6His(GST)RORgamma-LBD was expressed and purified from baculovirus infected Sf-21 insect cells (Bac-to-BAC, Invitrogen) and purified using glutathione sepharose chromatography (GE healthcare).
  • TR-FRET buffer [50 mM KCl, 50 mM TRIS, 1 mM Na-EDTA, 0.1 mM DTT, (pH 7.0)]; 6His(GST)RORgamma-LBD 10 nM, Anti-6His-Eu 1.25 nM, SRC1_2 peptide 0.1 ⁇ M, Strep-APC 8 nM. Changes in peptide binding caused by dose-curves of compounds added to the reaction mixture (DMSO concentration 0.1 %), can likewise be monitored.
  • HIS-tagged ROR ⁇ -LBD was recombinantly expressed in SF9 cells using a baculovirus expression system. The protein was not purified. Cells were lysed and the lysate was used as a source for ROR ⁇ -LBD for the assay. A 1:80 dilution of ROR ⁇ -LBD lysate in assay buffer (25 mM HEPES pH 7.0, 100 mM NaCl, 0.01% Tween, 0.1% BSA) was prepared and 5 ⁇ L was added to each well (ROR ⁇ -LBD final concentration ⁇ 10 nM). Control wells received lysate from SF9 cells not expressing ROR ⁇ -LBD. Compounds to be tested were diluted to 100x final test concentration in DMSO and further diluted to 4x final test concentration using assay buffer to provide the test compound mixture. An aliquot (5 ⁇ L) of the test compound mixture was added to each well.
  • a 4x stock of biotinylated-LXXLL peptide from SRC1-2 was prepared in assay buffer and a 5 ⁇ L aliquot added to each well (450 nM final concentration).
  • a 4x solution of europium tagged anti-HIS antibody (2 nM final concentration) and APC conjugated streptavidin (60 nM final concentration) were prepared and a 5 ⁇ L aliquot added to each well.
  • IC50 values for test compounds were calculated from the quotient of the fluorescence signal at 665 nm divided by the fluorescence signal at 615 nm using GraphPad Prism software.
  • HIS-tagged ROR ⁇ -LBD protein was expressed in SF9 cells using a baculovirus expression system.
  • the ROR ⁇ -LBD protein was purified by glutathione sepharose chromatography. Separately, SF9 cells not expressing any recombinant protein were lysed and the lysate was added to the purified ROR ⁇ -LBD at 0.25 ⁇ l lysate (from 10,000 SF9 cells)/nM purified protein. The mixture was then diluted in assay buffer (50 mM Tris pH 7.0, 50 mM KCl, 1 mM EDTA, 0.1 mM DTT) to obtain ROR ⁇ -LBD final concentration of 3 nM in 384-well assay plate.
  • assay buffer 50 mM Tris pH 7.0, 50 mM KCl, 1 mM EDTA, 0.1 mM DTT
  • a stock of biotinylated-LXXLL peptide from coactivator SRC1 (Biotin-CPSSHSSLTERHKILHRLLQEGSPS) was prepared in assay buffer and added to each well (100 nM final concentration).
  • Table 7 below tabulates the biological data disclosed for Examples 24A-29 as a range of Fret IC 50 values, which was reported as ranges according to the annotation delineated below:

Description

    BACKGROUND OF THE INVENTION
  • Upon activation by antigen-presenting cells naïve T helper cells undergo clonal expansion and will ultimately differentiate in cytokine secreting effector T cells, such as Th1 and Th2 subtypes. A third and distinct effector subset has been identified, which plays a key role in providing immunity to bacteria and fungi at mucosal surfaces (Kastelein et al., Annu. Rev. Immunol. 25: 221-242, 2007). This effector T helper cell subset can be distinguished based on its ability to produce large quantities of IL-17/F, IL-21 and IL-22, and is named Th17 (Miossec et al., New Eng. J. Med. 2361: 888-898, 2009).
  • Different T helper subsets are characterized by the expression of lineage specific master transcription factors. Th1 and Th2 effector cells express Tbet and GATA3, respectively. A Thymocyte/T cell specific variant of Retinoic Acid Receptor-related Orphan Receptor (ROR), RORgammaT, is highly expressed in Th17 cells (He et al., Immunity 9: 797-806, 1998). RORgammaT belongs to the nuclear hormone receptor superfamily (Hirose et al., Biochem. Biophys. Res. Comm. 205: 1976-1983, 1994). RORgammaT is a truncated form of RORgamma, lacking the first N-terminal 21 amino acids and is, in contrast to RORgamma which is expressed in multiple tissues (heart, brain, kidney, lung, liver and muscle), exclusively expressed in cells of the lymphoid lineage and embryonic lymphoid tissue inducers (Sun et al., Science 288: 2369-2372, 2000; Eberl et al., Nat Immunol. 5: 64-73, 2004).
  • Studies using heterozygous knock-in mice replacing the RORgammaT open reading frame with GFP, revealed a constitutive expression of GFP in approximately 10% of the CD4+ T cells in the small intestinal lamina propria (LP), co-expressing the Th17 cytokines IL-17/F and IL-22 (Ivanov et al., Cell 126: 1121-1133, 2006). In mice deficient for RORgammaT, the number of Th17 cells was markedly decreased in the LP and in vitro stimulation of CD4+ T cells, under Th17 polarizing conditions resulted in a drastic decrease of IL-17 expression. These results were further substantiated via forced expression of RORgammaT in naïve CD4+ T cells, which resulted in an induction of IL-17/F and IL-22 (Ivanov et al., Cell 126: 1121-1133, 2006). Taken together demonstrating the importance of RORgammaT in differentiation and stabilization of the Th17 lineage. In addition, a ROR family member, RORalpha has been demonstrated to be involved in Th17 differentiation and stabilization (Yang et al., Immunity 28: 29-39, 2008).
  • Recently, RORgammaT was shown to play a crucial role in non-Th17 lymphoid cells. In these studies, RORgammaT was critically important in innate lymphoid cells expressing Thy1, SCA-1 and IL-23R proteins. Genetic disruption of RORgamma in a mouse colitis model dependent on these innate lymphoid cells, prevented colitis development (Buonocore et al., Nature 464: 1371-1375, 2010). In addition, RORgammaT was shown to play a crucial role in other non-Th17 cells, such as mast cells (Hueber et al., J. Immunol. 184: 3336-3340, 2010). Finally, RORgammaT expression and secretion of Th17-type of cytokines was reported for Lymphoid Tissue Inducer cells, NK T-cells, NK cells (Eberl et al., Nat. Immunol. 5: 64-73, 2004) and gamma-delta T-cells (Sutton et al., Nat. Immunol. 31: 331-341, 2009; Louten et al., J. Allergy Clin. Immunol. 123: 1004-1011, 2009), suggesting an important function for RORgammaT in these subtypes of cells.
  • Based on the role of IL-17 producing cells (either Th17 or non-Th17 cells) RORgammaT has been identified as a key mediator in the pathogenesis of several diseases (Louten et al., J. Allergy Clin. Immunol. 123: 1004-1011, 2009; Annuziato et al., Nat. Rev. Rheumatol. 5: 325-331, 2009). This was confirmed using several disease models representative of autoimmune diseases. Genetic ablation of the RORgamma gene in mice prevented the development of experimental autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE) and colitis (Ivanov et al., Cell 126:1121-33, 2006; Buonocore et al., Nature 464: 1371-1375, 2010).
  • Being a critical mediator in Th17-cells and other non-Th17 cells, inhibition of RORgammaT is expected to have a beneficial effect on autoimmune diseases, such as, but not limited to rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Crohn's disease, and asthma (Annunziato et al., Nat. Rev. Immunol. 5: 325-331, 2009; Louten et al., J. Allergy Clin. Immunol. 123: 1004-1011, 2009). Inhibition of RORgammaT may also be beneficial in other diseases, which are characterized by increased levels of Th17 cells and/or elevated levels of Th17 hallmark cytokines such as IL-17, IL-22 and IL-23. Examples of such diseases are Kawasaki Disease (Jia et al., Clin. Exp. Immunol. 162: 131-137, 2010) and Hashimoto's thyroiditis (Figueroa-Vega et al., J. Clin. Endocrinol. Metab. 95: 953-62, 2010). Another example includes infectious diseases, such as, but not limited to, mucosal leishmaniasis (Boaventura et al., Eur. J. Immunol. 40: 2830-2836, 2010). In each of the above examples the inhibition may be enhanced by simultaneous inhibition of RORalpha.
  • Compounds modulating RORgammaT have been reported. Examples of agonists include T0901317 and SR1078 (Wang et al., ACS Chem. Biol. 5:1029-1034, 2010). In addition, antagonist have been reported such as 7-oxygenated sterols (Wang et al., J. Biol. Chem. 285: 5013-5025, 2009) and compounds described in EP2181710 A1 .
  • Numerous immune and inflammatory disorders continue to afflict millions of patients worldwide. Although significant advances have been made in treating these disorders, current therapies do not provide satisfactory results for all patients due to, for example, detrimental side effects or insufficient efficacy. One exemplary immue disorder in need of better therapy is psoriasis. Various therapeutics have been developed in an attempt to treat psoriasis. However, the traditional therapies for psoriasis often have toxic adverse effects. An exemplary inflammatory disorder in need of better treatment is rheumatoid arthritis. Numerous therapeutics have been developed in an attempt to treat this disorder. However, some patients develop resistance to current therapies.
  • Accordingly, a need exists for improved treatments for immune disorders and inflammatory disorders. The present invention addresses this need and provides other related advantages.
    • SUMMARY OF THE INVENTION
  • The present invention provides compounds which inhibit RORgammaT, said compounds for use in a method of treatment of RORgammaT-mediated diseases or conditions, in particular autoimmune diseases and inflammatory diseases, as well as pharmaceutical compositions comprising such compounds and pharmaceutical carriers.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides a compound according to Formula I
    Figure imgb0001
     or a pharmaceutically acceptable salt or solvate thereof wherein,
    • X is C(O), SO or SO2,
    • Y is CH or N;
    • n = 0, 1, 2, 3 or 4;
    • A4-A7 are independently N or CR4, CR5, CR6 or CR7, respectively, with the proviso that no more than two of the four positions A4-A7 can be simultaneously N;
    • R1 is (i) (C3-7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogens; (ii) (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogens; or (iii) (C6-14)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy are optionally substituted with one or more halogens;
    • R2 is C(O)OH, 5-tetrazoylyl, HOC(CF3)2, or (C1-10)alkylsulfoxyaminocarbonyl;
    • R3 is hydrogen, halogen, cyano, nitro, hydroxy, (C1-3)alkylC(O)O-, (C1-4)alkyl, or (C1-4)alkoxy, wherein (C1-4)alkyl and (C1-4)alkoxy are optionally substituted with one or more halogens;
    • R4-R7 independently are H, halogen, amino, cyano, hydroxy, (C1-3)alkoxy, (C1-4)alkyl, (C0-10)alkyl)aminocarbonyl, (di)(C1-6)alkylaminocarbonyl or amino(C1-4)alkyl, wherein (C1-3)alkoxy, (C1-4)alkyl, (C0-10)alkyl)aminocarbonyl, (di)(C1-6)alkylaminocarbonyl and amino(C1-4)alkyl are optionally substituted with one or more halogen, hydroxyl or (C1-3)alkoxy; or a group having the formula
      Figure imgb0002
       optionally substituted with one or more of the following: (C1-10)alkyl, halogen, amino, cyano, hydroxy, (C1-3)alkoxy, and wherein m is 1, 2, 3, or 4.
  • This invention also provides a compound according to Formula Ia
    Figure imgb0003
     or a pharmaceutically acceptable salt or solvate thereof
    • wherein X represents C(O), SO or SO2,
    • Y is CH or N;
    • A4-A7 are independently N or CR4, CR5, CR6 or CR7, respectively, with the proviso that no more than two of the four positions A4-A7 can be simultaneously N;
    • R1 is (C3-7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, hydroxy, H2NC(O)-, or (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, all optionally substituted with one or more halogens or;
    • R1 is (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, or (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, all optionally substituted with one or more halogens or;
    • R1 is (C6-14)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, or (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, all optionally substituted with one or more halogens; R2 is C(O)OH, 5-tetrazoylyl, or HOC(CF3)2;
    • R3 is independently selected from hydrogen, halogen, cyano, nitro or (C1-4)alkyl, optionally substituted with one or more halogens; and
    • R4-R7 independently are H, halogen, amino, cyano, hydroxy, (C1-3)alkoxy, (C1-4)alkyl, optionally substituted with one or more halogens.
  • In the first embodiment of the compounds of Formula I and Ia are compounds wherein A4, A5, A6, A7 are selected from the group consisting of: (i) CR4, CR5, CR6, CR7; (ii) N, CR5, CR6, CR7; (iii) CR4, N, CR6, CR7; (iv) CR4, CR5, N, CR7; (v) CR4 CR5, CR6, N; (vi) N, N, CR6, CR7; (vii) CR4, N, N, CR7; (viii) CR4, CR5, N, N; (ix) N, CR5, N, CR7; (x) CR4, N, CR6, N; and (xi) N, CR5, CR6, N.
  • In a subset of the first embodiment are compounds wherein A4, A5, A6, A7 are selected from the group consisting of: (i) CR4, CR5, CR6, CR7; (ii) N, CR5, CR6, CR7; and (iii) CR4, N, CR6, CR7.
  • In a second subset of the first embodiment are compounds wherein A4, A5, A6, A7 is (i) CR4, CR5, CR6, CR7, or (ii) N, CR5, CR6, CR7; and Y is N.
  • In a third subset of the first embodiment are compounds wherein
    X is C(O) or SO2;
    R1 is (i) (C3-7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from (C1-4)alkyl or halogen; (ii) (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino or (C1-4)alkyl; or (iii) (C6-14)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C1-3)alkoxycarbonyl, (C1-4)alkyl, (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogens.
  • In a fourth subset of the first embodiment are compounds wherein R1 is (C2-9)heteroaryl or (C6-14)aryl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C1-3)alkoxycarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogen.
  • In a fifth subset of th first embodiment are compounds according to Formula I wherein R1 is (C6-14)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, or (C1-3)alkoxycarbonyl, (C1-4)alkyl or (C1-3)alkoxy, all optionally substituted with one or more halogen.
  • In a sixth subset of the first embodiment are compounds wherein R1 is phenyl, naphthyl, pyridinyl, quinolinyl, benzooxadiazolyl, thiophenyl, or isoxazolyl, each optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C1-3)alkoxycarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogens.
  • In a seventh subset of the first embodiment are compounds according to Formula I and Ia wherein (C6-14)aryl in R1 is phenyl.
  • In an eighth subset of the of the first embodiment are compounds wherein R1 is phenyl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C1-3)alkoxycarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogens.
  • In a ninth subset of the first embodiment, are compounds wherein R2 is C(O)OH.
  • A tenth subset of the invention relates to compounds according to Formula I and Ia wherein Y is N.
  • In a second embodiment of the compound of Formula I is a compound having Formula Ib
    Figure imgb0004
     and a pharmaceutically acceptable salt or solvate thereof, wherein A4-A7, R1-R3, X, Y and n are defined as set forth hereinabove for Formula I.
  • In a third embodiment of the compound of Formula I is a compound having Formula Ic
    Figure imgb0005
     or a pharmaceutically acceptable salt or solvate thereof wherein,
    • X is C(O) or SO2
    • R8 is selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy are optionally substituted with one or more halogens;
    • x is 0, 1, 2, 3, 4 or 5; and
    • A4-A7, R1-R3, Y and n are defined as set forth hereinabove for Formula I.
  • In a fourth embodiment of the compound of Formula I is a compound having Formula Id
    Figure imgb0006
     and a pharmaceutically acceptable salt or solvate thereof, wherein A4-A7, R2, R3, X, Y and n are defined as set forth hereinabove for Formula I.
  • In a fifth embodiment of the compound of Formula I is a compound having Formula Ie
    Figure imgb0007
    Figure imgb0008
     and a pharmaceutically acceptable salt or solvate thereof, wherein A4-A7, R3, X and n are defined as set forth hereinabove for Formula I.
  • In a further embodiment of the compounds of Formula I, Ia, Ib, Ic, Id, and Ie, are compounds wherein
    R4 is selected from H, halogen, amino, and (C1-4)alkyl optionally substituted with one or more halogen;
    R5 is H;
    R6 is selected from H, dimethylaminocarbonyl, -CH2NH2, cyano,
    Figure imgb0009
     each optionally substituted with one or more halogen, hydroxyl, or methoxy; and
    R7 is selected from H and halogen.
  • A still further embodiment of the compounds of Formula I, Ia, Ib, Ic, Id, and Ie, are compounds wherein one of R4, R5 and R7 is other than hydrogen.
  • The invention also relates to those compounds wherein all specific definitions for A1 through A4, R1 through R8, X, Y, n and x and all substituent groups in the various aspects of the inventions defined here above occur in any combination within the definition of the compound of Formula I.
  • Non-limiting examples of the compunds of the present invention include:
    • 4-(1-(2,6-dichlorobenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,6-dichlorobenzoyl)-5-fluoro-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,6-dichlorobenzoyl)-7-fluoro-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,6-dichlorobenzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,6-dichlorobenzoyl)-6-fluoro-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,6-dichlorobenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    • 4-(1-(2-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    • 4-(1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-b]pyridin-3-yl)benzoic acid;
    • 4-(1-(2,6-dichlorobenzoyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid;
    • 1,1,1,3,3,3-hexafluoro-2-(4-(1-(2-(trifluoromethyl)phenylsulfonyl)-1H-indazol-3-yl)phenyl)propan-2-ol;
    • 4-(1-(2-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(3,5-dichloroisonicotinoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-bromobenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-(methoxycarbonyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(cyclohexanecarbonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-bromo-6-chlorobenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-fluoro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,4,6-trichlorobenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,6-dimethylbenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-ethoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,3-dichlorobenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chlorobenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-methyl-6-nitrobenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-(trifluoromethyl)phenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(quinolin-8-ylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-bromophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,5-dichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(3-chloro-2-methylphenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,3-dichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,3,4-trichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-cyanophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-(trifluoromethoxy)phenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(naphthalen-1-ylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2,6-dichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(benzo[c][1,2,5]oxadiazol-4-ylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-cyano-5-methylphenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(3,5-dimethylphenylsulfonyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • 4-(1-(3,5-dimethylphenylsulfonyl)-1H-indazol-3-yl)-2-(trifluoromethyl)benzoic acid;
    • 4-(1-(2-chlorophenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid;
    • 3-(4-(1H-tetrazol-5-yl)phenyl)-1-(3-chlorophenylsulfonyl)-1H-indazole;
    • methyl 3-(3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-ylsulfonyl)thiophene-2-carboxylate;
    • 3-(4-(1H-tetrazol-5-yl)phenyl)-1-(2-bromo-4-fluorophenylsulfonyl)-1H-indazole;
    • 3-(4-(1H-tetrazol-5-yl)phenyl)-1-(3-bromo-5-chlorothiophen-2-ylsulfonyl)-1H-indazole;
    • 4-(3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-ylsulfonyl)-3,5-dimethylisoxazole;
    • (3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-yl)(2,6-dichlorophenyl)methanone;
    • (3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-yl)(2,3-dichlorophenyl)methanone;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • Sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3-fluorobenzoate;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    • sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoate;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoic acid;
    • sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoate;
    • (2-chloro-6-(trifluoromethyl)phenyl)(4-fluoro-3-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-1H-indazol-1-yl)methanone;
    • 3-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid;
    • 2-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid;
    • Sodium 3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)benzoate;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluoro-5-methylbenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3-methylbenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-methoxybenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluorobenzoic acid;
    • sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluorobenzoate;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-methylbenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3-methoxybenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2,6-difluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-isopropylbenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3,5-dimethoxybenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-cyano benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2,3-difluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2,5-difluorobenzoic acid;
    • 2-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-5-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-5-fluoro-2-methoxybenzoic acid;
    • 5-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-hydroxybenzoic acid;
    • 3-fluoro-4-(4-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(4-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 3-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl) benzoic acid;
    • (2-chloro-6-(trifluoromethyl)phenyl)(3-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methanone;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-methylbenzoic acid;
    • 3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-methoxybenzoic acid;
    • 2-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-5-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2,5-difluorobenzoic acid;
    • 5-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-hydroxybenzoic acid;
    • 4-(1-(2-fluoro-6-methoxybenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    • 3-fluoro-4-(1-(2-fluoro-6-methoxybenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-(trifluoromethyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-2-isopropylbenzoic acid;
    • sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-2-fluoro benzoate;
    • sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-3-fluoro benzoate;
    • 3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    • 3-fluoro-4-(1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    • sodium 3-fluoro-4-(1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoate;
    • 4-(7-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 3-fluoro-4-(7-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(6-bromo-1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl) benzoic acid;
    • 4-(6-bromo-1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-methoxy-1H-indazol-3-yl) benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-1H-indazol-3-yl)benzoic acid;
    • sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-1H-indazol-3-yl) benzoate;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-hydroxy-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-hydroxy-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(hydroxymethyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(hydroxymethyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(methoxymethyl)-1H-indazol-3-yl)benzoic acid;
    • 1-(2-chloro-6-(trifluoromethyl)benzoyl)-3-(4-(methoxy carbonyl)phenyl)-1H-indazole-6-carboxylic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxy ethylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    • sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)benzoate;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    • sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)benzoate;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)-3-fluorobenzoate;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)-2-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)-2-fluorobenzoic acid;
    • 3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    • 3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-hydroxypropylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-hydroxypropylcarbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-methoxypropylcarbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxypropylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(4-hydroxybutylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-hydroxyethyl)(methyl)carbamoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-hydroxyethyl)(methyl)carbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-methoxyethyl)(methyl)carbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-fluoroazetidine-1-carbonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3,3-difluoroazetidine-1-carbonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(pyrrolidine-1-carbonyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(6-(azetidine-1-carbonyl)-1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-hydroxybenzoic acid;
    • 2-acetoxy-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid;
    • sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-hydroxybenzoate;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluoro-6-hydroxybenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3-hydroxybenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-5-fluoro-2-hydroxybenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3,6-difluoro-2-hydroxybenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-hydroxybenzoic acid;
    • 2-acetoxy-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)-2-hydroxybenzoic acid;
    • 4-(6-(aminomethyl)-1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid; 4-(6-(aminomethyl)-1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-2-(difluoro methyl)benzoic acid; and
    • 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-cyano-1H-indazol-3-yl)benzoic acid.
  • The terms used herein have their ordinary meaning and the meaning of such terms is independent at each occurrence thereof. That notwithstanding, and except where stated otherwise, the following definitions apply throughout the specification and claims. Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. These definitions apply regardless of whether a term is used by itself or in combination with other terms, unless otherwise indicated. Hence, the definition of "alkyl" applies to "alkyl" as well as the "alkyl" portions of "hydroxyalkyl," "fluoroalkyl," "alkoxy", etc.
  • As used herein, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:
    • The term "alkyl," as used herein, refers to an aliphatic hydrocarbon group having one of its hydrogen atoms replaced with a bond having the specified number of carbon atoms. In different embodiments, an alkyl group contains, for example, from 1 to 6 carbon atoms (C1-C6 alkyl) or from 1 to 3 carbon atoms (C1-C3 alkyl). Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, neopentyl, isopentyl, n-hexyl, isohexyl and neohexyl. In one embodiment, an alkyl group is linear. In another embodiment, an alkyl group is branched.
  • Unless specified otherwise, "alkyl" includes both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbon atoms; for example, "C1-6 alkyl" (or "C1-C6 alkyl") includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. "Alkylene" refers to both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbons, and having two terminal end chain attachments; for example, the term "A-C4alkylene-B" represents, for example, A-CH2-CH2-CH2-CH2-B, A-CH2-CH2-CH(CH3)-CH2-B, A-CH2-CH(CH2CH3)-B, A-CH2-C(CH3)(CH3)-B, and the like. "Alkoxy" represents a linear or branched alkyl group of indicated number of carbon atoms attached through an oxygen bridge; for example "C1-C6 alkoxy" includes -OCH3, -OCH2CH3, -OCH(CH3)2, -O(CH2)5CH3, and the like.
  • Unless otherwise specifically noted as only "unsubstituted" or only "substituted", alkyl groups are unsubstituted or substituted with 1 to 3 substituents on each carbon atom, with halo, C1-C20 alkyl, CF3, NH2, N(C1-C6 alkyl)2, NO2, oxo, CN, N3, -OH, -O(C1-C6 alkyl), C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, (C0-C6 alkyl) S(O)0-2-, (C0-C6 alkyl)S(O)0-2(C0-C6 alkyl)-, (C0-C6 alkyl)C(O)NH-, H2N-C(NH)-, H2N-C(O)(NH)-, -O(C1-C6 alkyl)CF3, (C0-C6 alkyl)C(O)-, (C0-C6 alkyl)OC(O)-, (C0-C6 alkyl)O(C1-C6 alkyl)-, (C0-C6 alkyl)C(O)1-2(C0-C6 alkyl)-, (C0-C6 alkyl)OC(O)NH-, -NH(C1-C6 alkyl)NHC(O)NH(C1-C6 alkyl), NHC(O)OC1-C6 alkyl, -NH(C1-C6 alkyl)NHSO2(C1-C6 alkyl), -(C0-C6 alkyl)NHSO2(C1-C6 alkyl), aryl, aralkyl, heterocycle, heterocyclylalkyl, halo-aryl, halo-aralkyl, halo-heterocycle, halo-heterocyclylalkyl, cyano-aryl, cyano-aralkyl, cyano-heterocycle and cyano-heterocyclylalkyl.
  • The term "alkenyl" means a straight or branched carbon chain having the specified number of carbon atoms with at least one carbon-carbon double bond. Examples of alkenyl include, but are not limited to, vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, 2,4-hexadienyl, and the like.
  • The term "alkynyl" means a straight or branched carbon chain having the specified number of carbon atoms with at least one carbon-carbon triple bond. Examples of alkynyl include, but are not limited to ethynyl, propargyl, 1-propynyl, 2-butynyl, and the like.
  • The term "carbocycle" (and variations thereof such as "carbocyclic" or "carbocyclyl") as used herein, unless otherwise indicated, refers to (i) a C3 to C8 monocyclic, saturated or unsaturated ring or (ii) a C7 to C12 bicyclic saturated or unsaturated ring system. Each ring in (ii) is either attached via a bond to, or fused (including spirofused) to, the other ring, and each ring is saturated or unsaturated. The carbocycle may be attached to the rest of the molecule at any carbon atom which results in a stable compound.
  • Saturated carbocyclics form a subset of carbocycles in which the entire ring system (mono- or polycyclic) is saturated. Saturated monocyclic carbocyclic rings are also referred to as cycloalkyl rings, e.g., cyclopropyl, cyclobutyl, etc. The fused bicyclic carbocycles are a further subset of the carbocycles in which a C7 to C10 bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms (or in the case of spirofused, one carbon atom) are shared by each of the rings in the ring system. A saturated bicyclic carbocycle is one in which both rings are saturated. An unsaturated bicyclic carbocycle is one in which one ring is unsaturated and the other is unsaturated or saturated. Unless otherwise noted, carbocycle is unsubstituted or substituted with C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, aryl, halogen, NH2 or OH. A subset of the fused bicyclic unsaturated carbocycles are those bicyclic carbocycles in which one ring is a benzene ring and the other ring is saturated or unsaturated, with attachment via any carbon atom that results in a stable compound. Representative examples of this subset include the following:
    Figure imgb0010
    Figure imgb0011
  • Aromatic carbocycles form another subset of the carbocycles. The term "aryl" refers to aromatic mono- and poly-carbocyclic ring systems in which the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond. Suitable aryl groups include phenyl, naphthyl, and biphenyl.
  • The term "cycloalkyl" means a cyclic ring of an alkane having the specified total ring carbon atoms; for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
  • The term "heterocycle" (and variations thereof such as "heterocyclic" or "heterocyclyl") broadly refers to (i) a stable 4- to 8-membered, saturated or unsaturated monocyclic ring, or (ii) a stable 7- to 12-membered bicyclic ring system, wherein each ring in (ii) is either attached via a bond to, or fused (including spirofused) to, the other ring, and each ring is saturated or unsaturated, and the monocyclic ring or bicyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) selected from N, O and S and a balance of carbon atoms (the monocyclic ring typically contains at least one carbon atom and the ring systems typically contain at least two carbon atoms); and wherein any one or more of the nitrogen and sulfur heteroatoms is optionally oxidized, and any one or more of the nitrogen heteroatoms is optionally quaternized. Unless otherwise specified, the heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure. Unless otherwise specified, when the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
  • Saturated heterocyclics form a subset of the heterocycles; i.e., the term "saturated heterocyclic" generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is saturated. The term "saturated heterocyclic ring" refers to a 4- to 8-membered saturated monocyclic ring or a stable 7- to 12-membered bicyclic ring system which consists of carbon atoms and one or more heteroatoms selected from N, O and S. Representative examples include piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, 1,4-dioxanyl, 1,4-thioxanyl, tetrahydropyranyl, tetrahydrofuryl (or tetrahydrofuranyl), tetrahydrothienyl, and tetrahydrothiopyranyl.
  • Heteroaromatics form another subset of the heterocycles; i.e., the term "heteroaromatic" (alternatively "heteroaryl") generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is an aromatic ring system. The term "heteroaromatic ring" refers a 5- or 6-membered monocyclic aromatic ring or a 7- to 12-membered bicyclic aromatic ring, and which consists of carbon atoms and one or more heteroatoms selected from N, O and S. In the case of substituted heteroaryl rings containing at least one nitrogen atom (e.g., pyridine), such substitutions can be those resulting in N-oxide formation. Representative examples of monocyclic heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl (or thiophenyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl. Examples of bicyclic heteroaromatic rings include benzotriazolyl, indolyl, benzoxazolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzimidazolyl, isoindolyl, indazolyl, quinoxalinyl, quinazolinyl, cinnolinyl, quinolinyl, isoquinolinyl, naphthyridinyl, pyrazolo[3,4-b]pyridine, imidazo[2,1-b](1,3)thiazole, (i.e.,
    Figure imgb0012
     ), 6-(1-pyrrolyl)-3-pyridyl, 4-(1-pyrrolyl)phenyl, 4-(pyrid-3-yl)phenyl, and 4-(pyrid-4-yl)phenyl.
  • Another subset of heterocycles are unsaturated heterocycles in which one or both rings are unsaturated (provided the entire ring system is not aromatic). Representative examples of unsaturated heterocycles include dihydrofuranyl, dihydrothienyl, dihydropyranyl, dihydroimidazolyl, indolinyl, isoindolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydronaphthyridinyl, 2,3-dihydrobenzofuranyl, 1,4-benzoxazinyl, 1,3-benzoxazolinyl, 2,3-dihydrobenzo-1,4-dioxinyl (i.e.,
    Figure imgb0013
     ), and benzo-1,3-dioxolyl (i.e.,
    Figure imgb0014
     ). In certain contexts herein,
    Figure imgb0015
     is alternatively referred to as phenyl having as a substituent methylenedioxy attached to two adjacent carbon atoms. Also included are groups such as chromone and coumarin.
  • Unless otherwise specifically noted as only unsubstituted or only substituted, cycloalkyl, cycloalkenyl, cycloalkyl, aryl (including phenyl) and heteroaryl groups are unsubstituted or substituted (also referred to as "optionally substituted"). Unless the substituents are specifically provided, substituents for substituted or optionally substituted cycloalkyl, cycloalkenyl, aryl (including phenyl, and as an isolated substituent or as part of a substituent such as in aryloxy and aralkyl), heteroaryl (as an isolated substituent or as part of a substituent such as in heteroaryloxy and heteroaralkyl) are one to three groups independently selected from halogen (or halo), C1-C6 alkyl optionally substituted with one to five fluorine, NH2, N(C1-C6 alkyl)2, NO2, oxo, CN, N3, -OH, -O(C1-C6 alkyl) optionally substituted with one to five fluorine, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, (C0-C6 alkyl)S(O)0-2-, aryl-S(O)0-2-, (C0-C6 alkyl)S(O)0-2(C0-C6 alkylene)-, (C0-C6 alkyl)C(O)NH-, H2N-C(NH)-, (C0-C6 alkyl)C(O)-, (C0-C6 alkyl)OC(O)-, (C0-C6alkyl)O(C1-C6 alkylene)-, (C0-C6 alkyl)-C(O)1-2(C0-C6 alkylene)-, (C0-C6 alkyl)2NC(O)-, (C0-C6 alkyl)OC(O)NH-, aryl, aralkyl, heteroaryl, heteroaralkyl, halo-aryl, halo-aralkyl, halo-heteroaryl, halo-heteroaralkyl, cyano-aryl, cyano-aralkyl, cyano-heteroaryl and cyano-heteroaralkyl.
  • The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro (F), chloro (Cl), bromo (Br), and iodo (I)).
  • The term "haloalkyl" means alkyl having the specified number of carbon atoms in which from one to all of the hydrogen atoms have been replaced by a halogen atom.
  • The terms "aralkyl" and "heteroaralkyl" refer to an aryl/heteroaryl linked to the rest of the molecule via a C1 to C4 alkylene.
  • The term "C0" as employed in expressions such as "C0-6 alkylene" means a direct covalent bond; or when employed in experessions such as "C0-6 alkyl" means hydrogen. Similarly, when an integer defining the presence of a certain number of atoms in a group is equal to zero, it means that the atoms adjacent thereto are connected directly by a bond; for example, in the structure
    Figure imgb0016
     wherein s is an integer equal to zero, 1 or 2, the structure is
    Figure imgb0017
     when s is zero; or it means that the indicated atom is absent; for example -S(O)0- means -S-.
  • Unless expressly stated to the contrary, an "unsaturated" ring is a partially or fully unsaturated ring. For example, an "unsaturated monocyclic C6 carbocycle" refers to cyclohexene, cyclohexadiene, and benzene.
  • Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heterocycle described as containing from "1 to 4 heteroatoms" means the heterocycle can contain 1, 2, 3 or 4 heteroatoms.
  • When any variable occurs more than one time in any constituent or in any formula depicting and describing compounds of the invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. For variable definitions containing terms having repeated terms, e.g., (CRiRj)r, where r is the integer 2, Ri is a defined variable, and Rj is a defined variable, the value of Ri may differ in each instance in which it occurs, and the value of Rj may differ in each instance in which it occurs. For example, if Ri and Rj are independently selected from the group consisting of methyl, ethyl, propyl and butyl, then (CRiRj)2 can be
    Figure imgb0018
  • The term (C1-6)alkyl as used hereinabove means a branched or unbranched alkyl group having 1-6 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, n-pentyl and n-hexyl. Preferred is (C1-4)alkyl.
  • The term (C1-5)alkyl means a branched or unbranched alkyl group having 1-5 carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, tert-butyl and n-pentyl.
  • The term (C1-4)alkyl as used herein means a branched or unbranched alkyl group having 1-4 carbon atoms, being methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
  • The term (C1-3)alkoxy means an alkoxy group having 1-3 carbon atoms, the alkyl moiety being branched or unbranched.
  • The term (C1-3)alkoxycarbonyl means an alkoxycarbonyl group having 1-3 carbon atoms in the alkoxy moiety, the alkoxy moiety having the same meaning as previously defined.
  • The term (di)(C1-6)alkylaminocarbonyl means an alkylaminocarbonyl group, the amino group of which is monosubstituted or disubstituted independently with an alkyl group which contains 1-6 carbon atoms and which has the same meaning as previously defined. Preferred alkyl group is (C1-4)alkyl.
  • The term (C3-7)cycloalkyl means a cycloalkyl group having 3-7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. 5-6 Carbon atoms are preferred.
  • The term (C3-5)heterocycloalkyl means a heterocycloalkyl group having 3-5 carbon atoms, including 1-3 heteroatoms selected from N, O and/or S, which may be attached via a nitrogen if feasible, or a carbon atom. Preferred number of heteroatoms is one or two. Most preferred number is one. Preferred heteroatoms are N or O. Most preferred are piperazinyl, tetrahydropyranyl, morpholinyl and pyrrolidinyl.
  • The term (C2-9)heteroaryl means an aromatic group having 2-9 carbon atoms and 1-3 heteroatoms selected from N, O and S, like imidazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, thiophenyl or furyl, pyrazolyl, isoxazolyl or quinolyl. Preferred number of heteroatoms is one or two. Preferred heteroaryl groups are pyrazolyl, thiophenyl, isoxazolyl, pyridyl and quinolyl. The (C2-5)heteroaryl group may be attached via a carbon atom or a nitrogen, if feasible.
  • The term (C6-14)aryl means an aromatic hydrocarbon group having 6-14 carbon atoms, such as phenyl, naphthyl, tetrahydronaphthyl, indenyl, anthracyl, More preferred are (C6-10)aryl groups. The most preferred aromatic hydrocarbon group is phenyl.
  • As used herein, the term "Xa-Xb", shall have the same meaning as the term "Xa-b", wherein X is any atom and a and b are any integers. For example, "C1-C4" shall have the same meaning as "C1-4". Additionally, when referring to a functional group generically, "Ax" shall have the same meaning, and be interchangeable with, "AX", wherein "A" is any atom and "x" or "X" are any integer. For example, "R1" shall have the same meaning, and be interchangeable with, "R1".
  • In the above definitions with multifunctional groups, the attachment point is at the last group.
  • The term "substituted" means that one or more hydrogens on the designated atom/atoms is/are replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. "Stable compound" or "stable structure" is defined as a compound or structure that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • When, in the definition of a substituent, is indicated that "all of the alkyl groups" of said substituent are optionally substituted, this also includes the alkyl moiety of an alkoxy group.
  • The term "optionally substituted" means optional substitution with the specified groups, radicals or moieties.
  • The use of the terms "salt", "solvate", "ester" and the like, is intended to equally apply to the salt, solvate, and ester of enantiomers, stereoisomers, rotamers, tautomers, or racemates of the inventive compounds.
  • The term "effective amount" as used herein, refers to an amount of the compound of Formula (I) and/or an additional therapeutic agent, or a composition thereof, that is effective in producing the desired therapeutic, ameliorative, inhibitory or preventative effect when administered to a subject suffering from an RORgammaT-mediated disease or disorder. In the combination therapies of the present invention, as effective amount can refer to each individual agent or to the combination as a whole, wherein the amounts of all agents administered are together effective, but wherein the component agent of the combination may not be present individually in an effective amount.
  • A "subject" is a human or non-human mammal. In one embodiment, a subject is a human. In another embodiment, a subject is a chimpanzee.
  • It should be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
  • The compounds of this invention include the hydrates or solvates of the compounds.
    • Optical Isomers - Diastereomers - Geometric Isomers - Tautomers
  • The compounds of Formula I may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures, form part of the present invention.
  • Compounds described herein may contain an asymmetric center and may thus exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereomers. The present invention includes all such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers. The above Formula I is shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof. Diastereoisomeric pairs of enantiomers may be separated by, for example, fractional crystallization from a suitable solvent, and the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid or base as a resolving agent or on a chiral HPLC column. Further, any enantiomer or diastereomer of a compound of the general Formula I may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
  • When compounds described herein contain olefinic double bonds, unless specified otherwise, such double bonds are meant to include both E and Z geometric isomers.
  • Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. For example, compounds including carbonyl -CH2C(O)- groups (keto forms) may undergo tautomerism to form hydroxyl - CH=C(OH)- groups (enol forms). Both keto and enol forms, individually as well as mixtures thereof, are included within the scope of the present invention.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g. chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g. hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g. substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column.
  • It is also possible that the compounds of Formula I may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.
  • All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters of the compounds), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
    • Salts
  • The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts prepared from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines derived from both naturally occurring and synthetic sources. Pharmaceutically acceptable organic non-toxic bases from which salts can be formed include, for example, arginine, betaine, caffeine, choline, N,N'-dibenzyl-ethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, dicyclohexylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
  • When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.
  • The compounds of Formula I can form salts which are also within the scope of this invention. Reference to a compound of Formula I herein is understood to include reference to salts thereof, unless otherwise indicated.
  • The term pharmaceutically acceptable salt represents those salts which are, within the scope of medical judgement, suitable for use in contact for the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. They may be obtained during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable mineral acid such as hydrochloric acid, phosphoric acid, or sulfuric acid, or with an organic acid such as for example ascorbic acid, citric acid, tartaric acid, lactic acid, maleic acid, malonic acid, fumaric acid, glycolic acid, succinic acid, propionic acid, acetic acid, methanesulfonic acid, and the like. The acid function can be reacted with an organic or a mineral base, like sodium hydroxide, potassium hydroxide, calcium hydroxide, calcium carbonate, ammonium (e.g. diethylamine) or lithium hydroxide.
    • Solvates
  • The present invention includes within its scope solvates of compounds of Formula I.As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (i.e., a compound of Formula I) or a pharmaceutically acceptable salt thereof and a solvent that does not interfere with the biological activity of the solute. Examples of solvents include, but are not limited to water, ethanol, and acetic acid. When the solvent is water, the solvate is known as hydrate; hydrate includes, but is not limited to, hemi-, mono, sesqui-, di-and trihydrates.
  • The compounds of the invention may form hydrates or solvates. It is known to those of skill in the art that charged compounds form hydrated species when lyophilized with water, or form solvated species when concentrated in a solution with an appropriate organic solvent. One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. "Solvate" may also mean a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H2O.
    • Prodrugs
  • In general, prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound. Thus, various conditions described herein may be treated with a compound of formula I or with a compound which may not be a compound of formula I, but which converts to a compound of formula I in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985.
  • A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of Formula I or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g. by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
    • Isotopes
  • In the compounds of generic Formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I. For example, different isotopic forms of hydrogen (H) include protium (1H) and deuterium (2H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
    • Utilities
  • Compounds of the present invention are inhibitors of Retinoic Acid Receptor-related Orphan Receptor gamma t (RORgammaT), and as such are useful in the treatment of diseases and conditions in which inhibition of RORgammaT is desirable, such as autoimmune and inflammatory diseases and disorders.
  • Accordingly, another embodiment of the present invention provides a compound having Formula I, Ia, Ib, Ic , Id or Ie or a pharmaceutically acceptable salt or solvate thereof for use in a method for treating a disease or condition mediated by RORgammaT in a subject comprising administering to the subject an amount of a compound having Formula I, Ia, Ib, Ic, Id or Ie or a pharmaceutically acceptable salt or solvate thereof, that is effective for treating the disease or condition mediated by RORgammaT in a subject.
  • The compounds according to the invention can be used in therapy.
  • Another aspect of the invention resides in the compounds or a pharmaceutically acceptable salt thereof having the general formula I for use in the treatment of autoimmune diseases, in particular those diseases in which Th17 cells and non-Th17 cells, which express Th17 hallmark cytokines play a prominent role. These include, but are not limited to, the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, Crohn's disease and multiple sclerosis.
  • In another aspect, compounds or a pharmaceutically acceptable salt thereof having the general formula I can be used for treatment of inflammatory diseases in which Th17 cells and/or non-Th17 cells, which express Th17 hallmark cytokines play a prominent role such as, but not limited to respiratory diseases, osteoarthritis and asthma. Also, compounds or a pharmaceutically acceptable salt thereof having the general formula I can be used for treatment of infectious diseases in which Th17 cells and/or non-Th17 cells, which express Th17 hallmark cytokines play a prominent role such as, but not limited to mucosal leishmaniasis.
  • Compounds or a pharmaceutically acceptable salt thereof having the general formula I can also be used for treatment of other diseases in which Th17 cells and/or non-Th17 cells, which express Th17 hallmark cytokines play a prominent role such as, but not limited to Kawasaki disease and Hashimoto's thyroiditis.
  • In one aspect is the disease or condition is an autoimmune disease or inflammatory disease. The disease or condition includes, but is not limited to, multiple sclerosis, inflammatory bowel disease, Crohn's disease, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis or mucosal leishmaniasis.
  • In another aspect, the compounds according to the invention can be used in therapies to treat or prevent multiple sclerosis, inflammatory bowel disease, Crohn's disease, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis and mucosal leishmaniasis.
  • In another aspect the compounds according to the invention can be used to treat or prevent psoriasis.
  • In yet another aspect the compounds according to the invention can be used to treat inflammatory bowel disease.
  • This aspect of the present invention includes a compound of Formula I, Ia, Ib, Ic, Id or Ie, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a disease or condition mediated by RORgammaT.
    • Route of Administration/Dosage
  • The compounds of this invention can be administered for the treatment or prevention of afflictions, diseases and illnesses according to the invention by any means that effects contact of the active ingredient compound with the site of action in the body of a warm-blooded animal. For example, administration can be oral, topical, including transdermal, ocular, buccal, intranasal, inhalation, intravaginal, rectal, intracisternal and parenteral. The term "parenteral" as used herein refers to modes of administration which include subcutaneous, intravenous, intramuscular, intraarticular injection or infusion, intrasternal and intraperitoneal. For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
  • The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • The dosage administered will be dependent on the age, health and weight of the recipient, the extent of disease, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired. Usually, a daily dosage of active ingredient compound will be from about 1.0-2000 milligrams per day. Ordinarily, from 10 to 500 milligrams per day in one or more applications is effective to obtain desired results. These dosages are the effective amounts for the treatment and prevention of afflictions, diseases and illnesses described above, e.g., autoimmune and inflammatory diseases and disorders.
  • Compositions include e.g. those suitable for oral, sublingual, subcutaneous, intravenous, intramuscular, nasal, local, or rectal administration, and the like, all in unit dosage forms for administration.
  • For oral administration, the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like.
  • For oral administration, the active ingredient may be presented as discrete units, such as tablets, capsules, powders, granulates, solutions, suspensions, and the like. For parenteral administration, the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophilized) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.
  • Mixed with such pharmaceutically acceptable auxiliaries, e.g. as described in the standard reference, Gennaro, A.R. et al., Remington: The Science and Practice of Pharmacy (20th Edition., Lippincott Williams & Wilkins, 2000, see especially Part 5: Pharmaceutical Manufacturing), the active agent may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories. By means of pharmaceutically acceptable liquids the active agent can be applied as a fluid composition, e.g. as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
  • For making solid dosage units, the use of conventional additives such as fillers, colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used. Suitable carriers with which the active agent of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. For parenteral administration, aqueous suspensions, isotonic saline solutions and sterile injectable solutions may be used, containing pharmaceutically acceptable dispersing agents and/or wetting agents, such as propylene glycol or butylene glycol.
    • Pharmaceutical Compositions
  • Another aspect of the present invention provides pharmaceutical compositions comprising a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable excipients. The term "excipient" and "carrier" may be used interchangeably. The term "composition", as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of Formula I, additional active ingredient(s), and pharmaceutically acceptable excipients.
  • The pharmaceutical compositions of the present invention comprise a compound represented by Formula I (or pharmaceutically acceptable salts thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, troches, dragees, granules and powders, or in liquid dosage forms, such as elixirs, syrups, emulsions, dispersions, and suspensions. The active ingredient can also be administered parenterally, in sterile liquid dosage forms, such as dispersions, suspensions or solutions. Other dosages forms that can also be used to administer the active ingredient as an ointment, cream, drops, transdermal patch or powder for topical administration, as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration, as an aerosol spray or powder composition for inhalation or intranasal administration, or as a cream, ointment, spray or suppository for rectal or vaginal administration.
  • Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
  • Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
  • In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene gycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
  • Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.
  • For administration by inhalation, the compounds of the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers. The compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device. The preferred delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a compound of Formula I in suitable propellants, such as fluorocarbons or hydrocarbons.
  • For ocular administration, an ophthalmic preparation may be formulated with an appropriate weight percent solution or suspension of the compounds of Formula I in an appropriate ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye.
  • Useful pharmaceutical dosage-forms for administration of the compounds of this invention include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral injectables, and oral suspensions.
  • A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
  • A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried.
  • A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.
  • A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized.
  • An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredient, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.
  • The same dosage forms can generally be used when the compounds of this invention are administered stepwise or in conjunction with another therapeutic agent. When drugs are administered in physical combination, the dosage form and administration route should be selected depending on the compatibility of the combined drugs. Thus the term coadministration is understood to include the administration of the two agents concomitantly or sequentially, or alternatively as a fixed dose combination of the two active components.
  • The present invention also relates to a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof having the general formula I in admixture with pharmaceutically acceptable auxiliaries and optionally other therapeutic agents. The auxiliaries must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
  • The invention further includes a pharmaceutical composition, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
  • The exact dose and regimen of administration of the active ingredient, or a pharmaceutical composition thereof, may vary with the particular compound, the route of administration, and the age and condition of the individual subject to whom the medicament is to be administered.
  • In general parenteral administration requires lower dosages than other methods of administration which are more dependent upon absorption. However, a dosage for humans preferably contains 0.0001-100 mg per kg body weight. The desired dose may be presented as one dose or as multiple subdoses administered at appropriate intervals throughout the day. The dosage as well as the regimen of administration may differ between a female and a male recipient.
    • Combination Therapy
  • Compounds of the present invention, and their salts and solvates, and physiologically functional derivatives thereof, may be employed alone or in combination with other therapeutic agents for the treatment of diseases and conditions associated with inappropriate IL-17 pathway activity. Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, and the use of at least one other pharmaceutically active agent. The compound(s) of formula (I) and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately this may occur simultaneously or sequentially in any order. The amounts of the compound(s) of formula (I) and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect. For the treatment of the inflammatory and autoimmune diseases, rheumatoid arthritis, psoriasis, inflammatory bowel disease, SLE, uveitis, atopic dermatitis, COPD, asthma and allergic rhinitis a compound of formula (I) may be combined with one or more other active agents such as: (1) TNF-a inhibitors; (2) non- selective COX-I/COX-2 inhibitors; (3) COX-2 inhibitors; (4) other agents for treatment of inflammatory and autoimmune diseases including glucocorticoids, methotrexate, leflunomide, sulfasalazine, azathioprine, cyclosporin, tacrolimus, penicillamine, bucillamine, actarit, mizoribine, lobenzarit, ciclesonide, hydroxychloroquine, d-penicillamine, aurothiomalate, auranofin or parenteral or oral gold, cyclophosphamide, Lymphostat-B, BAFF/APRIL inhibitors and CTLA-4-Ig or mimetics thereof; (5) leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist; (6) LTD4 receptor antagonist; (7) PDE4 inhibitor; (8) antihistamine HI receptor antagonists; (9) al- and a2-adrenoceptor agonist; (10) anticholinergic agents; (1 1) β-adrenoceptor agonists; (12) insulin-like growth factor type I (IGF-1) mimetic; (13) glucocorticosteroids; (14) kinase inhibitors such as inhibitors of the Janus Kinases (JAK 1 and/or JAK2 and/or JAK 3 and/or TYK2), p38 MAPK and IKK2; (15) B-cell targeting biologies such as rituximab; (16) selective costimulation modulators such as abatacept; (17) interleukin inhibitors, such as IL-1 inhibitor anakinra, IL-6 inhibitor tocilizumab, and IL12/IL-23 inhibitor ustekinumab. It could also be combined with anti-IL17 antibodies to obtain additive/synergistic responses for the treatment of inflammatory and autoimmune diseases.
  • It will be clear to a person skilled in the art that, where appropriate, the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl esters, or as solvates, for example hydrates, to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient. It will be clear also that, where appropriate, the therapeutic ingredients may be used in optically pure form.
  • The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical composition and thus pharmaceutical compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention. These combinations are of particular interest in respiratory diseases and are conveniently adapted for inhaled or intranasal delivery.
  • The individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical compositions. Preferably, the individual compounds will be administered simultaneously in a combined pharmaceutical composition. Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.
  • Accordingly, the pharmaceutical compositions of the present invention include those that also comprise at least one additional therapeutically active agent, in addition to the compound of Formula I, Ia, Ib, Ic, Id or Ie.
  • The invention further includes a compound of Formula I in combination with one or more other drug(s).
    • Synthesis
  • Table 1 below lists commercial sources, and previously disclosed synthetic routes, for chemical materials employed in the synthesis of intermediates and examples of the instant invention. This list is not intended to be exhaustive, exclusive, or limiting in any way. Table 1
    Structure Source
    Figure imgb0019
         		Oakwood
    Figure imgb0020
         		Aldrich
    Figure imgb0021
         		Frontier
    Figure imgb0022
         		Oakwood
    Figure imgb0023
         		Sinova
    Figure imgb0024
         		Sinova
    Figure imgb0025
         		Aldrich
    Figure imgb0026
         		Sinova
    Figure imgb0027
         		Sinova
    Figure imgb0028
         		Aldrich
    Figure imgb0029
         		Sinova
    Figure imgb0030
         		Alfa
    Figure imgb0031
         		Alfa
    Figure imgb0032
         		Bioorganic & Medicinal Chemistry Letters, 2006, 695-700
    Figure imgb0033
         		Acros
    Figure imgb0034
         		Combi-blocks
    Figure imgb0035
         		Combi-blocks
    Figure imgb0036
         		Alfa
    Figure imgb0037
         		Combi-blocks
    Figure imgb0038
         		Alfa
    Figure imgb0039
         		Combi-blocks
    Figure imgb0040
         		Combi-blocks
    Figure imgb0041
         		Alfa
    Figure imgb0042
         		Combi-blocks
    Figure imgb0043
         		Anichem
    Figure imgb0044
         		Aobchem
    Figure imgb0045
         		Chemmaker
    Figure imgb0046
         		Combi-blocks
    Figure imgb0047
         		Combi-blocks
    Figure imgb0048
         		Anisyn
    Figure imgb0049
         		Anisyn
    Figure imgb0050
         		Alfa
    Figure imgb0051
         		Aldrich
  • Abbreviations used herein are as follows: Boc: tert-butoxycarbonyl; CDCl3: chloroform-d; DiPEA: N,N-diisopropylethylamine; DMAP: 4-dimethylaminopyridine; DMF: N,N-dimethylformamide; Et3N or TEA: triethyl amine; HPLC: high performance liquid chromatography; TFA: trifluoro acetic acid; MS: mass spectrum; (PPh3)4Pd: tetrakis-(triphenylphosphine)palladium(0); THF: tetrahydrofuran; TLC: thin layer chromatography; SiO2: silica-gel; DME: dimethoxy ethane; m: molar; t-BuOK; potassium tert-butoxide; APCI-MS: atmospheric pressure chemical ionization mass spectrometry; ESI-MS; electronspray ionization-mass spectroscopy; EtOAc: Ethyl acetate; PE: Petroleum ether; EA: Ethyl acetate; DCM: Dichloro methane; Dppf: 1,1• Bis(diphenylphosphino)ferrocene; AcOH:Acetic acid; DMAC: N,N -Dimethylacetamide; PYAOP: (7-Azabenzotriazol-1-yloxy)tripyrrolid in ophosphonium hexafluorophosphate; Pd(dppf)Cl2: [1,1'-Bis(diphenylphosphino) ferrocene ]dichloropalladium (II); BnBr: Benzyl bromide; DAST: (Diethylamino)sulfur trifluoride; Ac2O: Acetic an hydride; LiHMDS: Lithium bis(trimethylsilyl)amide; PhNTf2: N-Phenyl-bis(trifluoro methanesulfonimide); S-Phos: 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl; X-Phos: 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl; CPME: Cyclopentyl methyl ether.
    • Intermediates Example i-1: Preparation of methyl 2-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (i-1)
  • Figure imgb0052
  • i) Preparation of methyl 4-(benzyloxy)-2-hydroxybenzoate (i-1b). To a solution of methyl 2,4-dihydroxybenzoate (i-1a) (1.68 g, 10 mmol) in acetone (30 mL) was added K2CO3 (2.76 g, 20 mmol). The mixture was stirred at rt for 5 h, followed by the addition of BnBr (1.88 g, 11 mmol). The mixture was heated at 60 °C for 24 h. The reaction mixture was cooled down, filtered. The filtrate was concentrated to afford the title compound. LCMS (ESI) calc'd for C15H14O4 [M+H]+: 259.1, found: 259.1.
    • ii) Preparation of methyl 4-(benzyloxy)-2-(trifluoromethylsulfonyloxy)benzoate (i-1c).
  • To a solution of methyl 4-(benzyloxy)-2-hydroxybenzoate (i-1b) (1.1 g, 4.26 mmol) in THF (20 ml) at -78 °C was added LiHMDS (1M in THF, 5.1 ml, 5.1 mmol) dropwise. Then the mixture was warmed up to -40 °C and stirred at this temperature for 3 h. PhNTf2 (1.52 g, 4.26 mmol) was added, and the mixture was stirred at rt for 24 h. The mixture was then diluted with H2O and extracted with EtOAc. The organic layer was dried, concentrated, and purified by flash chromatography (PE/EA=10:1) to afford the title compound. LCMS (ESI) calc'd for C16H13F3O6S [M+H]+: 391, found: 391.
  • iii) Preparation of methyl 4-(benzyloxy)-2-(prop-1-en-2-yl)benzoate (i-1d). Methyl 4-(benzyloxy)-2-(trifluoromethylsulfonyloxy)benzoate (i-1c) (6.8 g, 17.4 mmol), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (2.9 g, 17.4 mmol), Pd(OAc)2 (195 mg, 0.87 mmol), S-Phos (71 mg, 0.174 mmol) and K3PO4 (11 g, 52 mmol) were mixed in THF (70 ml). The mixture was stirred at 75 °C for 24 h. The mixture was diluted with H2O, and extracted with EtOAc. The combined organics were dried and concentrated. The residue was purified by flash chromatography (PE/EA=10:1) to afford the title compound. LCMS (ESI) calc'd for C18H18O3 [M+H]+: 391, found: 391.
  • iv) Preparation of methyl 4-hydroxy-2-isopropylbenzoate (i-1e). To a solution of methyl 4-(benzyloxy)-2-(prop-1-en-2-yl)benzoate (i-ld) (4.6 g, 16.3 mmol) in methanol (100ml) was added Pd/C (0.46 g). The mixture was stirred at rt under H2 atmosphere for 24 h. Then the mixture was filtered, and the filtrate was concentrated to afford the title compound. LCMS (ESI) calc'd for C11H14O3 [M+H]+: 195.1, found: 195.1.
  • v) Preparation of methyl 2-isopropyl-4-(trifluoromethylsulfonyloxy)benzoate (i-1f). To a solution of methyl 4-hydroxy-2-isopropylbenzoate (i-le) (2.45 g, 12.6 mmol) in THF (100 ml) at -78 °C was added LiHMDS (1M in THF, 15 ml, 15 mmol) dropwise. Then the mixture was warmed up to -40 °C and stirred for 3 h. PhNTf2 (4.5 g, 12.6 mmol) was added and the mixture was stirred at rt for 24 h. The reaction mixture was diluted with H2O and extracted with EtOAc. The organic layer was dried and concentrated. The residue was purified by flash chromatography (PE/EA=8:1) to afford the title compound. LCMS (ESI) calc'd for C12H13F3O5S [M+H]+: 327, found: 327.
  • vi) Preparation of methyl 2-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)benzoate (i-1). Methyl 2-isopropyl-4-(trifluoromethylsulfonyloxy)benzoate (i-1f) (1.5 g, 4.6 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.75 g, 6.9 mmol), Pd(dppf)Cl2.CH2Cl2 (188 mg, 0.23 mmol), dppf (102 mg, 0.184 mmol) and KOAc (1.13 g, 11.5 mmol) were mixed in 1,4-dioxane (35 ml). The mixture was stirred at 80 °C for 24 h. The mixture was then cooled down and concentrated under reduced pressure. The residue was diluted with H2O, extracted with EtOAc. The combined organics were dried and concentrated. The residue was purified by flash chromatography (PE/EA=10:1) to afford the title compound. LCMS (ESI) calc'd for C17H25BO4 [M+H]+: 305.2, found: 305.2.
    • Example i-2: Preparation of methyl 2-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (i-2)
  • Figure imgb0053
  • i) Preparation of methyl 4-bromo-2-fluoro-5-methylbenzoate (i-2b). To a solution of 4-bromo-2-fluoro-5-methylbenzoic acid (i-2a) (1.87 g, 8 mmol) in CH3OH (50 mL) at 0 °C was added SOCl2 (6 mL, 80 mmol) dropwise. Then the mixture was heated to 80 °C for 2 h. The solvent was removed in vacuo and the residue was diluted with EtOAc and washed with H2O brine, dried over anhydrous Na2SO4, and concentrated. The resulting crude solid was washed with PE to give the title compound as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.80 (1H, d), 7.37 (1H, d), 3.92 (3H, s), 2.39 (3H, s).
  • ii) Preparation of methyl 2-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxa borolan-2-yl)benzoate (i-2). To a flask was added compound (i-2b) (830 mg, 3.3 mmol), compound (i-2c) (915 mg, 3.6 mmol), dppf (25 mg, 0.132 mmol), Pd(dppf)Cl2*CH2Cl2 (134 mg, 0.165 mmol) and 1,4-dioxane (20 mL). The reaction mixture was heated at 80 °C for 2 h. The mixture was diluted with H2O, and the organic layer was separated. The aqueous layer was extracted with CH2Cl2. The combined organics were washed with H2O and brine, dried over Na2SO4, and concentrated. The residue was purified by flash chromatography (Pentane/EtOAc) to afford the title compound. LCMS (ESI) calc'd for C15H20BFO4 [M+H]+: 295.1, found: 295.1.
    • Example i-3: Preparation of methyl 3,5-dimethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (i-3)
  • Figure imgb0054
    • i) Preparation of methyl 4-bromo-3,5-dimethoxybenzoate (i-3b).
  • Prepared following a similar procedure of compound i-2b
    LCMS (ESI) calc'd for C10H11BrO4 [M+H]+: 275.1, found: 275.1.
    • ii) Preparation of methyl 3,5-dimethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxa borolan-2-yl)benzoate (i-3)
  • Prepared following a similar procedure of compound i-2
    LCMS (ESI) calc'd for C16H23BO6 [M+H]+: 323.2, found: 323.2.
    • Example i-4: Preparation of methyl 2,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (i-4)
  • Figure imgb0055
  • i) Preparation of methyl 2-fluoro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxa borolan-2-yl)benzoate (i-4). To a flask was added compound (i-4a) (412 mg, 2.0 mmol), compound (i-2c) (1.52 g, 6 mmol), X-Phos (95 mg, 0.2 mmol), Pd(OAc)2 (44 mg, 0.2 mmol) and CPME (20 mL). The reaction mixture was heated at 85 °C for 2 h. The mixture was then cooled down, diluted with H2O, and the organic layer was separated. The aqueous layer was extracted with Et2O. The combined organics were washed with H2O and brine, dried over Na2SO4, and concentrated. The residue was purified by flash chromatography (DCM) to afford the title compound. LCMS (ESI) calc'd for C14H17BF2O4 [M+H]+: 299.1, found: 299.1.
    • Example i-5: Preparation of 3-fluoro-5-methoxy-4-(methoxycarbonyl)phenyl boronic acid (i-5)
  • Figure imgb0056
    • i) Preparation of methyl 4-bromo-2,6-difluorobenzoate (i-5b)
  • Prepared following a similar procedure of compound i-2b
    LCMS (ESI) calc'd for C8H5BrF2O2 [M+H]+: 250.9, Found: 250.9.
    • ii) Preparation of methyl 4-bromo-2-fluoro-6-methoxybenzoate (i-5c).
  • To a solution of compound (i-5b) (827 mg, 3.3 mmol) in DMF (20 mL) at 0 °C was added a solution of sodium methoxide (25% in MeOH, 0.75 mL, 3.3 mmol). The reaction mixture was stirred at 0 °C for 10 min and then at rt for 30 min. The mixture was then brought back to 0 °C and quenched with EtOAc and 1M HCl. The organic layer was separated and the aqueous phase was extracted with EtOAc. The combined organics were dried over Na2SO4 and concentrated. The crude oil was purified by flash chromatography (Pentane/EtOAc) to afford the title compound. LCMS (ESI) calc'd for C9H8BrFO3 [M+H]+: 263.0, found: 263.0; 1H NMR (400 MHz, CDCl3) δ 6.98 (1H, t), 6.91 (1H, q), 3.76 (3H, s), 3.74 (3H, s).
    • ii) Preparation of 3-fluoro-5-methoxy-4-(methoxycarbonyl)phenylboronic acid (i-5)
  • Prepared following a similar procedure of compound i-2
    LCMS (ESI) calc'd for C9H10BFO5 [M+H]+: 229.1, found: 229.1.
    • Example i-6: Preparation of 4-borono-3,6-difluoro-2-methoxybenzoic acid (i-6)
  • Figure imgb0057
    • i) Preparation of 3,6-difluoro-2-methoxybenzoic acid (i-6b).
  • A solution of 1,4-difluoro-2-methoxybenzene (i-6a) (2.88 g , 20 mmol) in THF (5 mL) was added to a solution of LDA freshly prepared from n-BuLi (10M solution in hexane, 2.2 mL, 22 mmol) and diisopropylamine (2.28 g , 22.8 mmol) in THF (20 mL) at -60 °C. After 30min, a freshly prepared solution of CO2 in diethyl ether (20 mL) was quickly added. Then aq. H2SO4 was added, and the resulting precipitate was collected and washed with H2O, and dried to give the title compound (i-6b) as white crystals. LCMS (ESI) calc'd for C8H6F2O3 [M+H]+: 189, found: 189.
    • ii) Preparation of 4-borono-3,6-difluoro-2-methoxybenzoic acid (i-6).
  • To a solution of 3,6-difluoro-2-methoxybenzoic acid (i-6b) (0.94 g , 5 mmol) in THF (5 mL) at -70 °C was added a solution of LDA [freshly prepared from diisopropylamine (1.51 g, 15 mmol) and n-BuLi (10M solution in hexane, 1.5 mL, 15mol) in THF (15 mL). The resultant solution was stirred for 15 mins, followed by the addition of B(OEt)3 (1.46 g , 10 mmol). The mixture was stirred for 15mins and then hydrolyzed with dilute aq. H2SO4. The organic phase was separated and the aqueous layer was extracted with Et2O. The combined organics were concentrated and the residue solid was washed with H2O and hexane, dried to give the title compound as white crystals. LCMS (ESI) calc'd for C8H7BF2O5 [M+H]+: 233, found: 233.
    • Example i-7: methyl 5-fluoro-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxa borolan-2-yl)benzoate (i-7)
  • Figure imgb0058
    • i) Preparation of 4-bromo-2,5-difluorobenzoic acid (i-7b)
  • To a solution of 1,4-dibromo-2,5-difluorobenzene (i-7a) (1.1 g , 4 mmol) in Et2O (10 mL) at - 78 °C was added n-BuLi (2.5M in hexane, 1.6 mL, 4 mmol) dropwise. The mixture was stirred for 30 min at -78 °C and then quenched with an excess of freshly crushed dry ice. After 15 min, the mixture was brought to rt and diluted with H2O. The aqueous layer was separated, and the organic layer was extracted with 10% aq. Na2CO3. The combined aqueous layers were acidified with 1M HCl and extracted with EtOAc. The combined organic layers were dried with Na2SO4 and concentrated to give the title compound. LCMS (ESI) calc'd for C7H3BrF2O2 [M+H]+: 237, found: 237.
    • ii) Preparation of methyl 4-bromo-2,5-difluorobenzoate (i-7c)
  • A mixture of 4-bromo-2,5-difluorobenzoic acid (i-7b) (0.48 g, 2 mmol) and methanol (10 mL, saturated with gaseous HCl) was heated at 65 °C for 2 h. The mixture was concentrated. Then MeOH was added and the mixture was concentrated again. The residue was purified by flash chromatography (Pentane/EtOAc=4:1) to give the title compound. LCMS (ESI) calc'd for C8H5BrF2O2 [M+H]+: 251, found: 251.
    • iii) Preparation of methyl 4-bromo-5-fluoro-2-methoxybenzoate (i-7d)
  • To a solution of methyl 4-bromo-2,5-difluorobenzoate (i-7c) (0.5 g, 2 mmol) in DMF (5 mL) at 0 °C was added NaOMe (25% in MeOH, 0.45 mL, 2 mmol). The reaction mixture was stirred at 0 °C for 10 min and then at rt for 30min. The mixture was then brought back to 0 °C and quenched with EtOAc and 1M HCl. The organic layer was separated, and the aqueous phase was extracted with EtOAc, dried over Na2SO4, concentrated and purified by flash chromatography (Pentane/EtOAc=9:1) to give the title compound. LCMS (ESI) calc'd for C9H8BrFO3 [M+H]+: 263, found: 263
    • iv) Preparation of methyl 5-fluoro-2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxa borolan-2-yl)benzoate (i-7)
  • A mixture of Bis(pinacolato)diboron (0.72 g, 2.86 mmol), Pd(OAc)2 (50mg), X-Phos (100 mg), methyl 4-bromo-5-fluoro-2-methoxybenzoate (i-7d) (0.5 g, 1.9 mmol), and KOAc (100 mg) in DMAC (20 mL) were heated at 80 °C for 24 h. The mixture was then cooled down, diluted with EtOAc and H2O. The organic layer was separated and the aqueous layer was extracted with EtOAc. The organics were combined, dried, concentrated and purified by flash chromatography (Pentane/EtOAc=10:1) to give the title compound. LCMS (ESI) calc'd for C15H20BFO5 [M+H]+: 311, found: 311
    • Example i-8: Preparation of (2-chloro-6-(trifluoromethyl)phenyl)(3-iodo-6-(methoxymethyl)-1H-indazol-1-yl)methanone (i-8)
  • Figure imgb0059
  • i) Preparation of (2-chloro-6-(trifluoromethyl)phenyl)(6-(hydroxymethyl)-3-iodo- 1H-indazol-1-yl)methanone (i-8b). To a solution of compound (i-8a) (prepared following the procedure of Scheme D) (175 mg, 0.35 mmol) in THF (20 mL) was added BH3·THF (1.75 mL, 1.75 mmol) and the mixture was refluxed for 12 h. The mixture was cooled down and quenched with excess MeOH. The mixture was concentrated to give the title compound. LCMS (ESI) calc'd for C16H9ClF3IN2O2 [M+H]+: 480.9, found: 480.9.
  • ii) Preparation of (2-chloro-6-(trifluoromethyl)phenyl)(3-iodo-6-(methoxy methyl)-1H-indazol-1-yl)methanone (i-8). To a mixture of (i-8b) (0.2 g, 0.416 mmol) in THF (5 mL) was added NaH (25 mg, 0.62 mmol) and the mixture was stirred at room temperature for 30 min. Then iodomethane (0.1 mL, 0.83 mmol) was added dropwise. The reaction mixture was stirred at rt for 24 h. Ammonium Hydroxide (5 mL) was added to quench the reaction. The solvent was removed under reduced pressure and the residue was diluted with aq. NH4Cl. The mixture was extracted with EtOAc, and the combined organics were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep-TLC (PE:EA 4:1) to provide the title compound as a pale yellow solid. LCMS (ESI) calc'd for C17H11ClF3IN2O2 [M+H]+: 495, found: 495.
    • Method for Preparing Compounds of the Invention
  • Methods for preparing the compounds of this invention are illustrated in the following schemes. Other synthetic protocols will be readily apparent to those skilled in the art. The examples illustrate the preparation of the compounds of Formula I and as such are not to be considered as limiting the invention set forth in the claims appended hereto. Unless otherwise indicated, all variables are as previously defined.
    Figure imgb0060
  • The heterocyclic derivatives of Formula I, wherein A4 to A7, R1, R2, R3, X and Y are as previously defined, can be prepared from compounds II. Palladium catalyzed Suzuki-Miyaura arylation of compounds II using appropriately substituted phenylboronic acids III-a (corresponding boronic esters III-b may also be used) directly affords the desired compounds I. In a typical procedure, a mixture of compound II, a palladium catalyst (e.g. Pd(PPh3)4), base (e.g. aqueous NaOH, K2CO3 or the like) and an aryl boronic acid of general Formula III-a or aryl boronic ester of general formula III-b in a suitable solvent such as dioxane or toluene/EtOH, is heated under an atmosphere of nitrogen under microwave irradiation or using conventional heating.
    Figure imgb0061
  • Alternatively, compound I may be obtained from compounds of Formula IV, in which FG is a functional group (e.g. ester, cyano, protected tetrazole) that can be easily converted to groups defined for R2. Non limiting examples of suitable functional groups in compounds IV are a tert-butyl ester or methyl ester or a tetrazole, containing an acid labile group such as a para-methoxy benzyl protecting group, which can be treated with acid or base to afford compounds of Formula I-a or I-b in which R2 is carboxyl or 5-tetrazolyl, respectively.
    Figure imgb0062
  • Compounds II are prepared by straightforward acylation or sulfonylation of compounds V. For example, treatment of compounds V with a strong base (such as potassium tert-butoxide or NaH) and the appropriately substituted sulfonyl chlorides in a suitable solvent such as DMF or THF will give compounds II-a in which X = SO2. Alternatively, treatment of V with sulfonyl chlorides and a tertiary amine base (e.g. DiPEA or triethylamine) in a solvent such as dichloromethane can also give compounds II-a. Treatment of V with acyl chlorides in pyridine or Et3N will yield compounds II-b, in which X = CO. In case the acid chlorides are not available, they can be easily prepared from the corresponding carboxylic acids using known methods (e.g. treatment with SOCl2 or similar reagents). Compounds V are commercially available or prepared by methods know in the art, such as halogenation of compounds VI. Compounds VI are also commercially available or easily prepared by standard organic synthesis techniques.
    Figure imgb0063
  • Compounds IV can be prepared in the same way as compounds I, by Suzuki-Miyaura reaction between compounds of general Formula II and an appropriately substituted arylboronic acid or ester.
    Figure imgb0064
  • Alternatively, a Suzuki reaction on compounds VII (obtained by Boc-protection of compounds V) will give compounds VIII (in most cases the Boc-group is cleaved under the reaction conditions, although a separate deprotection may be necessary). Now, acylation or sulfonylation as described for the conversion of V to II, yields compounds IV. The functional group (FG in formula IV) may be a tert-butyl ester, or a para-methoxy benzyl protected tetrazole, which after treatment with trifluoro acetic acid will give a carboxylate or 5-tetrazolyl, respectively, as required for compounds I. Finally, a Suzuki reaction on unprotected compounds V, may also directly lead to compounds VIII. The invention is illustrated by the following examples.
    • General
  • The following procedure was used for Examples 1-23. 1H NMR spectra were recorded on a Bruker spectrometer (400 MHz) with deuterochloroform as the solvent unless stated otherwise. Chemical shifts are reported as δ values (parts per million) relative to tetramethylsilane as an internal standard.
    MS: Electro Spray spectra were recorded on the Applied Biosystems API-165 single quad MS in alternating positive and negative ion mode using Flow Injection. The mass range was 120-2000 Da and scanned with a step rate of 0.2 Da. and the capillary voltage was set to 5000 V. N2-gas was used for nebulasation.
    LC-MS spectrometer (Waters) Detector: PDA (200-320 nm), Mass detector: ZQ
    Eluens : A: acetonitrile with 0.05% trifluoroacetic acid, B: acetronitrile / water = 1/9 (v/v) with 0.05% trifluoroacetic acid
    Column 1: Chromolith Performance, RP-18e, 4.6x100 mm,
    Gradient method: Flow: 4 mL/min
    Time (min) A (%) B (%)
    0,0 100 0
    3.60 0 100
    4.00 0 100
    4.05 100 0
    6.00 100 0

    Column 2: XBridge C18, 3.5µm, 4.6x20mm
    Gradient method: Flow: 4 ml/min
    Time (min.) A (%) B (%)
    0.0 100 0
    1.60 0 100
    3.10 0 100
    3.20 100 0
    5.00 100 0

    UPLC : Water acquity UPLC system; Column : BEH C18 1.7 µm, 2.1 x 100 mm, Detector: PDA (200-320 nm), Mass detector: SQD
    Eluens : A: acetonitrile with 0.035% trifluoroacetic acid , B: acetronitrile / water = 1/9 (v/v) with 0.035% trifluoroacetic acid
    Method 60 100 Method 40_80 Method 0 60
    Flow: 0.75 mL/min Flow: 0.65 mL/min Flow: 0.60 mL/min
    Time (min) A (%) B (%) A (%) B (%) A (%) B(%)
    0.0 40 60 60 40 100 0
    3.00 0 100 20 80 40 60
    3.20 0 100 0 100 0 100
    3.69 0 100 0 100 0 100
    3.70 40 60 60 40 100 0
  • All target compounds were characterized and determined as at least >95% pure by 1H NMR, MS and analyticakl HPLC.
    • Examples Example 1
  • Figure imgb0065
    • 4-(1-(2,6-dichlorobenzoyl)-1H-indazol-3-yl)benzoic acid
    1. i) A solution of 3-bromo-4-azaindole (100 mg, 0.508 mmol) and 2,6-dichlorobenzoyl chloride (159 mg, 0.761 mmol) in 4 ml of pyridine was stirred for 1 h at 150 °C in a microwave reactor. After cooling to room temperature the reaction mixture was diluted with water and the product was extracted into CH2Cl2. The organic layer was washed with water, dried over a phase separation filter and concentrated under reduced pressure. The residue was purified on SiO2, using 10% ethylacetate in heptane as the eluent, to give (3-bromo-1H-indazol-1-yl)(2,6-dichlorophenyl)methanone (140 mg) as a yellow solid.
    2. ii) To a microwave reaction vial were added the product obtained in the previous step (53 mg, 0.143 mmol) in 2 ml dioxane, 4-(tert-butoxycarbonyl)phenylboronic acid (47.7 mg, 0.215 mmol) and a 2M aqueous solution of sodium carbonate (0.286 ml, 0.573 mmol). After purging the vial with nitrogen for about 5 minutes, Pd(PPh3)4 (8.28 mg, 7.16 µmol) was added and the reaction mixture was stirred for 30 minutes at 100 °C in a microwave reactor. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate and washed with water, brine and dried over magnesium sulfate.
      After filtration the solvent was evaporated under reduced pressure and the desired product, tert-butyl 4-(1-(2,6-dichlorobenzoyl)-1H-indazol-3-yl)benzoate, was obtained as a yellow solid (90 mg). The product was used in the next step without further purification.
    3. iii) A solution of the product obtained in the previous step (90 mg, 0.22 mmol) and trifluoroacetic acid (5 ml, 67.3 mmol) in 20 ml CH2Cl2 was stirred for 1h at room temperature After completion, the reaction mixture was concentrated under reduced pressure and the residue was purified on SiO2, using 10% ethylacetate in heptane as the eluent to give the title compound 4-(1-(2,6-dichlorobenzoyl)-1H-indazol-3-yl)benzoic acid as a white solid (50 mg). ESI MS = m/z 411 [M+H]+
    Example 2
  • Following a procedure analogous to that described in Example 1, starting from 3-bromo-5-fluoro-1H-indazole, the following compound was prepared.
    • 4-(1-(2,6-dichlorobenzoyl)-5-fluoro-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 429 [M+H]+
    Figure imgb0066
    • Example 3
  • Following a procedure analogous to that described in Example 1, starting from 3-bromo-7-fluoro-1H-indazole, the following compound was prepared.
    • 4-(1-(2,6-dichlorobenzoyl)-7-fluoro-1H-indazol-3-yl)benzoic acid
  • Figure imgb0067
     ESI MS = m/z 429 [M+H]+
    • Example 4
  • Following a procedure analogous to that described in Example 1, starting from 3-bromo-4-fluoro-1H-indazole, the following compound was prepared.
    • 4-(1-(2,6-dichlorobenzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid
  • Figure imgb0068
     ESI MS = m/z 429 [M+H]+
    • Example 5
  • Following a procedure analogous to that described in Example 1, starting from 3-bromo-6-fluoro-1H-indazole, the following compound was prepared.
    • 4-(1-(2,6-dichlorobenzoyl)-6-fluoro-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 429 [M+H]+
    • Example 6
  • Following a procedure analogous to that described in Example 1, starting from 3-bromo-1H-pyrazolo[4,3-b]pyridine, the following compounds were prepared.
    • 6A: 4-(1-(2,6-dichlorobenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid
  • ESI MS = m/z 412 [M+H]+
    Figure imgb0069
    • 6B: 4-(1-(2-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid
  • ESI MS = m/z 412 [M+H]+
    Figure imgb0070
    • Example 7
  • Following a procedure analogous to that described in Example 1, starting from 3-bromo-1H-pyrrolo[3,2-b]pyridine, the following compound was prepared.
    • 4-(1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-b]pyridin-3-yl)benzoic acid
  • ESI MS = m/z 412 [M+H]+
    Figure imgb0071
    • Example 8
  • Following a procedure analogous to that described in Example 1, starting from 3-bromo-1H-pyrazolo[4,3-c]pyridine the following compound was prepared.
    • 4-(1-(2,6-dichlorobenzoyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid
  • ESI MS = m/z 412 [M+H]+
    Figure imgb0072
    • Example 9
  • Figure imgb0073
    • 1,1,1,3,3,3-hexafluoro-2-(4-(1-(2-(trifluoromethyl)phenylsulfonyl)-1H-indazol-3-yl)phenyl)propan-2-ol
    1. i) To a suspension of 3-bromoindazole (500 mg, 2.54 mmol) in 8 ml CH2Cl2 was added triethyl amine (1.06 ml, 7.61 mmol) at room temperature. To this yellow solution was added 2-(trifluoromethyl)benzenesulfonyl chloride (0.392 ml, 2.54 mmol) and the reaction mixture was stirred for 3 h at room temperature. The reaction mixture was concentrated under reduced pressure and the residue was purified on SiO2 using 5% to 20% ethyl acetate in heptane to give 3-bromo-1-(2-(trifluoromethyl)phenylsulfonyl)-1H-indazole (894 mg)
    2. ii) Following a procedure analogous to that described in Example 1, step ii, using 1,1,1,3,3,3-hexafluoro-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-ol as the boronic ester, the title compound 1,1,1,3,3,3-hexafluoro-2-(4-(1-(2-(trifluoromethyl)phenylsulfonyl)-1H-indazol-3-yl)phenyl)propan-2-ol was prepared (9 mg).
      ESI MS = m/z 569 [M+H]+
    Example 10
  • Figure imgb0074
    • 4-(1-(2-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid
    1. i) To a mixture of tert-butyl 3-bromo-1H-indazole-1-carboxylate (5 g, 16.83 mmol,) and 4-(tert-butoxycarbonyl)phenylboronic acid (4.52 g, 20.36 mmol) in 30 ml of dioxane and 30 ml water was added sodium carbonate (50.5 mmol, 5.35 g). The mixture was purged with N2 and subsequently, Pd(PPh3)4 (0.486 g , 0.421 mmol) was added. The reaction mixture was heated to 100°C overnight under a nitrogen atmosphere.
      After cooling to room temperature, the reaction mixture was diluted with water and the product was extracted into ethyl acetate. The combined organic layers were washed with water, brine and dried over magnesium sulfate. After filtration, the solvent was removed under reduced pressure and the residue was purified on SiO2, using 0% to 25 % ethylacetate in heptane as the eluent, to give tert-butyl 4-(1H-indazol-3-yl)benzoate as a yellow solid.
    2. ii) To a solution of tert-butyl 4-(1H-indazol-3-yl)benzoate (40 mg, 0.136 mmol) in 1 ml of pyridine was added 2-(trifluoromethyl)benzoyl chloride (356 mg, 1.699 mmol).
      The reaction mixture was stirred at 150 °C in a microwave reactor for 1h
      After cooling, water was added and the product was extracted into ethylacetate. The organic layer was washed with water, brine and dried over magnesium sulfate. After filtration, the solvent was removed under reduced pressure and the residue was purified on SiO2, using 3% to 20% ethylacetate in heptane as the eluent, to give tert-butyl 4-(1-(2-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoate as a white solid.
    3. iii) A solution of the compound obtained in the previous step (19.4 mg, 0.042 mmol) and trifluoroacetic acid (0.5 ml, 6.73 mmol,) in 2 ml CH2Cl2 was stirred for 1h at room temperature.
      After the reaction was complete the reaction mixture was concentrated under reduced pressure to give the title compound 4-(1-(2-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid as a light yellow solid.
      ESI MS = m/z 411 [M+H]+
    Example 11
  • Following a procedure analogous to that described in Example 10, the following compounds were prepared.
    • 11A: 4-(1-(3,5-dichloroisonicotinoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 412 [M+H]+
    Figure imgb0075
    • 11B: 4-(1-(2-bromobenzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 421/423 [M+H]+
    Figure imgb0076
    • 11C: 4-(1-(2-(methoxycarbonyl)benzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 401 [M+H]+
    Figure imgb0077
    • 11D: 4-(1-(cyclohexanecarbonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 349 [M+H]+
    Figure imgb0078
    • 11E: 4-(1-(2-bromo-6-chlorobenzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 457 [M+H]+
    Figure imgb0079
    • 11F: 4-(1-(2-fluoro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 429 [M+H]+
    Figure imgb0080
    • 11G: 4-(1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 391 [M+H]+
    Figure imgb0081
    • 11H: 4-(1-(2,4,6-trichlorobenzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 445 / 447 [M+H]+
    Figure imgb0082
    • 11I: 4-(1-(2,6-dimethylbenzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 371 [M+H]+
    Figure imgb0083
    • 11J: 4-(1-(2-ethoxybenzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 387 [M+H]+
    Figure imgb0084
    • 11K: 4-(1-(2,3-dichlorobenzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 411 [M+H]+
    Figure imgb0085
    • 11L: 4-(1-(2-chlorobenzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 377 [M+H]+
    Figure imgb0086
    • 11M: 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 445 [M+H]+
    Figure imgb0087
    • 11N: 4-(1-(2-methyl-6-nitrobenzoyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 402 [M+H]+
    Figure imgb0088
    • Example 12 4-(1-(2-(trifluoromethyl)phenylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • Figure imgb0089
    1. i) To a solution of tert-butyl 4-(1H-indazol-3-yl)benzoate, Example 10, step i, (58 mg, 0.197 mmol) in 2 ml CH2Cl2 were added triethyl amine (60 mg, 0.592 mmol) and 2-(trifluoromethyl)benzenesulfonyl chloride (48 mg, 0.197 mmol). The reaction mixture was stirred overnight at room temperature. The reaction mixture was directly purified on SiO2 using 0% to 50% ethyl acetate in heptane as the eluent to give tert-butyl 4-(1-(2-(trifluoromethyl)phenylsulfonyl)-1H-indazol-3-yl)benzoate)102 mg) as a clear oil.
    2. ii) Following a procedure analogous to that described in Example 10, step iii, the title compound, 4-(1-(2-(trifluoromethyl)phenylsulfonyl)-1H-indazol-3-yl)benzoic acid, was prepapred (28 mg)
      ESI MS = m/z 447 [M+H]+
    Example 13
  • Following a procedure analogous to that described in Example 11, the following compounds were prepared.
    • 13A: 4-(1-(quinolin-8-ylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 429 [M+H]+
    Figure imgb0090
    • 13B: 4-(1-(2-bromophenylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 457/459 [M+H]+
    Figure imgb0091
    • 13C: 4-(1-(2,5-dichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 447 [M+H]+
    Figure imgb0092
    • 13D: 4-(1-(3-chloro-2-methylphenylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 427 [M+H]+
    Figure imgb0093
    • 13E: 4-(1-(2,3-dichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 447 [M+H]+
    Figure imgb0094
    • 13F: 4-(1-(2,3,4-trichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 481/483 [M+H]+
    Figure imgb0095
    • Example 14
  • Figure imgb0096
    • 4-(1-(2-cyanophenylsulfonyl)-1H-indazol-3-yl)benzoic acid
    1. i) To a solution of 3-bromo-1H-indazole (200 mg, 1.02 mmol) in 2 ml CH2Cl2 was added triethylamine (308 mg, 3.05 mmol) and 2-cyanobenzene-1-sulfonyl chloride (205 mg, 1.02 mmol). The reaction mixture was stirred overnight at room temperature. After completion the reaction mixture was concentrated under reduced pressure and the product was purified on SiO2 using 0% to 50% ethylacetate in heptane as the eluent to give 3-bromo-1-(2-cyanophenylsulfonyl)-1H-indazole (360 mg) as a yellow solid.
    2. ii) To a microwave reaction vial were added the product obtained in the previous step (50 mg, 0.138 mmol) in 2 ml toluene and 0.5 ml ethanol, 4-(tert-butoxycarbonyl)phenylboronic acid (50 mg, 0.166 mmol) and a 2M aqueous solution of potassium carbonate (0.345 ml, 0.690 mmol). After purging the vial with nitrogen for about 5 minutes, Pd(PPh3)4 (3.99 mg) was added and the reaction mixture was stirred for 30 minutes at 100 °C in a microwave reactor. After cooling to room temperature, the reaction mixture was diluted with water and product was extracted into ethyl acetate. The organic layer was washed with water, brine and dried over magnesium sulfate.
      After filtration the solvent was evaporated under reduced pressure and the product was purified on SiO2 using 0% to 50% ethylacetate in heptane as the eluent to give the desired product, tert-butyl 4-(1-2-cyanophenylsulfonyl)-1H indazol-3-yl)benzoate (12 mg).
    3. iii) Following a procedure analogous to that described in Example 10, step iii, the title compound, 4-(1-(2-cyanophenylsulfonyl)-1H-indazol-3-yl)benzoic acid, was prepapred (13 mg)
      ESI MS = m/z 404 [M+H]+
    Example 15
  • Following a procedure analogous to that described in Example 14, the following compounds were prepared.
    • 15A: 4-(1-(2-(trifluoromethoxy)phenylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 463 [M+H]+
    Figure imgb0097
    • 15B: 4-(1-(naphthalen-1-ylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 429 [M+H]+
    Figure imgb0098
    • 15C: 4-(1-(2,6-dichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 447 [M+H]+
    Figure imgb0099
    • 15D: 4-(1-(benzo[1,2,5]oxadiazol-4-ylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 421 [M+H]+
    Figure imgb0100
    • 15E: 4-(1-(2-cyano-5-methylphenylsulfonyl)-1H-indazol-3-yl)benzoic acid
  • ESI MS = m/z 418 [M+H]+
    Figure imgb0101
    • Example 16
  • Figure imgb0102
    • 4-(1-(2-chlorophenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid
    1. i) To a solution of 3-bromo-1H-pyrazolo[4,3-c]pyridine (198 mg, 1,0 mmol) in 10 ml THF was added portion wise at 0 °C sodium hydride (101 mg, 4 mmol, 95%). After addition was complete, 2-chlorobenzenesulfonyl chloride (495 mg, 2.347 mmol) was added and the reaction mixture was stirred overnight at room temperature. The reaction mixture was quenched by the addition of water. The product was extracted into ethyl acetate and the organic layer was washed with brine. The organic solvent was evaporated under reduced pressure to give 3-bromo-1-(2-chlorophenylsulfonyl)-1H-pyrazolo[4,3-c]pyridine as a yellow oil. The product was used in the next step without further purification.
    2. ii) To a microwave reaction vial were added the product obtained in the previous step (67 mg, 0.135 mmol) in 3 ml DME, tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (49.2 mg, 0.162 mmol) and 0.472 ml of a 2M aqueous solution of sodium carbonate (0.944 mmol). After purging the vial with nitrogen for about 5 minutes, Pd(PPh3)4 (31.2 mg, 0.027 mmol) was added and the reaction mixture was stirred for 40 minutes at 100 °C in a microwave reactor. After cooling to room temperature, the reaction mixture was diluted with water and washed with ethyl acetate. The organic layer was washed with water, brine and dried over magnesium sulfate.
      After filtration the solvent was evaporated under reduced pressure and the product was purified preparative HPLC using 20% to 100% CH3CN in water as the eluent to give tert-butyl 4-(1-(2-chlorophenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)benzoate as a yellow solid (16 mg).
    3. iii) Following a procedure analogous to that described in Example 10, step iii, the title compound, 4-(1-(2-chlorophenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid, was prepared (7 mg)
      ESI MS = m/z not measured [M+H]+
    Example 17
  • Figure imgb0103
    • 4-(1-(3,5-dimethylphenylsulfonyl)-1H-indazol-3-yl)-3-fluorobenzoic acid
    1. i) 3-bromo-1H-indazole (3 gram; 15 mmol) was dissolved in 30 ml DMF, followed by the addition of sodiumhydride (850 mg, 21 mmol). After stirring for 20 min at room temperature, 3,5-dimethylbenzene-1-sulfonyl chloride (4.4 gram, 21 mmol) was added and the reaction mixture was stirred for another 2 h at room temperature. The reaction was quenched by the addition of water and the formed solids were filtered off and washed with little methanol. The solids were dried to obtain 3-bromo-1-(3,5-dimethylphenylsulfonyl)-1H-indazole (2.1 gram) as a white solid.
    2. ii) The product obtained in the previous step (100 mg, 0.27 mmol), Pd(PPh3)4 (63 mg, 0.05 mmol) and 4-borono-3-fluorobenzoic acid (101 mg, 0.55 mmol) were stirred in 6.5 ml DME and 3.5 ml of an aqueous solution of NaHCO3 (69 mg, 0.82 mmol) was added. The reaction mixture was heated in a microwave reactor for 30 min at 100°C. After cooling, the reaction mixture was filtered over cotton and the volatiles were evaporated under reduced pressure. The crude material was purified by prep. HPLC (Gemini NX column (100 * 30 mm, 5µm); 40 ml/min; Eluens A: 20 mmol/L NH4HCO3 (aq) and Eluens B: acetonitrile; Gradient: 0-7 min 70%A and 30% B; 7-7.1 min 50%A and 50% B; 7.1-8.5 min 100% B) to give the title compound 4-(1-(3,5-dimethylphenylsulfonyl)-1H-indazol-3-yl)-3-fluorobenzoic acid (25 mg) as an off white solid.
      ESI MS m/z 425 [M+H]+
    Example 18
  • Following a procedure analogous to that described in Example 17, the following compounds was prepared.
    • 4-(1-(3,5-dimethylphenylsulfonyl)-1H-indazol-3-yl)-2-(trifluoromethyl)benzoic acid
  • ESI MS m/z 475 [M+H]+
    Figure imgb0104
    • Example 19 5-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-tetrazole
  • Figure imgb0105
    1. i) 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (8.0 g, 34.8 mmol), trimethylsilyl azide, (8.04 g, 69.8 mmol) and dibutyl-stannanone (868 mg, 3.5 mmol, 0.1 equiv) were dissolved in 1,2-dimethoxy ethane (110 ml). The mixture was divided in two portions and transferred in two microwave vessels then irradiated in a microwave reactor simultaneously at 150 °C for 10 min. After cooling to room temperature, trimethylsilyl azide (4.02 g, 35 mmol) and dibutyl-stannanone (434 mg, 1.75 mmol) were added into each microwave vessel and the mixtures were irradiated again at 150 °C for 10 min. After cooling to room temperature, the mixtures were combined and purified by column chromatography on florisil (200 g). It was first eluted with 20% dichloromethane in hexane to remove the impurities, then with 10% methanol in dichloromethane to elute the product. 1-(4-Methoxybenzyl)-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-tetrazole 2 was isolated as a white powder (8.01 g).
      APCI MS m/z 273 [M + H]+.
    2. ii) The product obtained in the previous step (8.40 g, 30.9 mmol) was dissolved in acetonitrile (150 ml). First potassium carbonate powder (5.12 g, 37.0 mmol, 1.2 equiv), then 4-methoxybenyl chloride (6.3 mL, 46.3 mmol) were added. After stirring at 40 °C for 12 hours the reaction mixture was diluted with ethyl-acetate (100 ml), washed with water (2 × 100 ml) and dried over magnesium sulfate. After filtration the solvent was evaporated under reduced pressure. The residue was suspended in hexane and the formed crystals were filtered. Title compound 1-(4-Methoxybenzyl)-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-tetrazole was obtained as a white powder as a mixture of regio-isomers (9.67 g). APCI MS m/z 393 [M + H]+.
    Example 20 3-(4-(1H-tetrazol-5-yl)phenyl)-1-(3-chlorophenylsulfonyl)-1H-indazole
  • Figure imgb0106
    1. i) Tert-butyl 3-bromo-1H-indazole-1-carboxylate (5.0 g, 16.8 mmol) and a mixture of the regio-isomers of 1-(4-methoxybenzyl)-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-tetrazole (Example 19, step ii) (7.92 g, 20.2 mmol) were dissolved in 100 ml of a 1 to 1 mixture of 1,4-dioxane and water under a nitrogen atmosphere. Sodium carbonate (5.35 g, 50.5 mmol) was added and the system was purged with nitrogen.. Then Pd(PPh3)4 (486 mg, 0.42 mmol) was added and the reaction mixture was heated overnight at reflux temperature under a nitrogen atmosphere. After cooling to room temperature the mixture was diluted with water and extracted with ethyl acetate. The combined organic phases were washed with brine, dried over magnesium sulfate. After filtration the solvent was removed under reduced pressure. The residue was purified on SiO2 using 20 to 30% ethyl acetate in hexane as the eluent to give 3-(4-(1-(4-methoxybenzyl)-1H-tetrazol-5-yl)phenyl)-1H-indazole as a mixture of two regioisomers in a 2 to 1 ratio (2.8 g) as a white solid. Major regio-isomer (1.91 g, 30%) as a white powder.
      APCI MS m/z 383 [M + H]+,
    2. ii) To a solution of the product obtained in the previous step (100 mg, 0.26 mmol) in 2ml anhydrous THF was added t-BuOK (32 mg, 0.29 mmol).After stirring the reaction mixture at room temperature for 20 min, 3-Chlorobenzene-1-sulfonyl chloride (41 mg, 0.29 mmol) was added and the mixture was stirred at room temperature for an additional 2 h. After completion, the solvent was evaporated under reduced pressure, the residue was dissolved in dichloromethane and washed with water. The organic phase was evaporated and the residue was dried under reduced pressure to afford 1-(3-chlorophenylsulfonyl)-3-(4-(1-(4-methoxybenzyl)-1H-tetrazol-5-yl)phenyl)-1H-indazole (146 mg, crude) as a brown oil which was used in the next step without any further purification.
      ESI MS m/z 557 [M + H]+
    3. iii) The product obtained in the previous step (81 mg) was dissolved in 1 ml trifluoroacetic acid and stirred for 2 days at room temperature. The solvent was evaporated under reduced pressure and the residue was purified by preparative HPLC using eluent sytem 1 then eluent system 2 to afford 3-(4-(1H-tetrazol-5-yl)phenyl)-1-(3-chlorophenylsulfonyl)-1H-indazole (26 mg) as a white powder:
      ESI MS m/z 437 [M + H]+
    Example 21
  • Following a procedure analogous to that described in Example 20, the following compounds were prepared.
    • 21A: methyl 3-(3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-ylsulfonyl)thiophene-2-carboxylate
  • ESI MS = m/z 467 [M+H]+
    Figure imgb0107
    • 21B: 3-(4-(1H-tetrazol-5-yl)phenyl)-1-(2-bromo-4-fluorophenylsulfonyl)-1H-indazole
  • Figure imgb0108
     ESI MS = m/z 499/501 [M+H]+
    • 21C: 3-(4-(1H-tetrazol-5-yl)phenyl)-1-(3-bromo-5-chlorothiophen-2-ylsulfonyl)-1H-indazole
  • Figure imgb0109
     ESI MS = m/z 523 [M+H]+
    • 21D: 4-(3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-ylsulfonyl)-3,5-dimethylisoxazole
  • Figure imgb0110
     ESI MS = m/z 422 [M+H]+
    • Example 22 (3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-yl)(2,6-dichlorophenyl)methanone
  • Figure imgb0111
    1. i) To a solution of a mixture of regio-isomers of 3-(4-(1-(4-Methoxybenzyl)-1H-tetrazol-5-yl)phenyl)-1H-indazole (Example 20, step i) (50 mg, 0.13 mmol) was dissolved in anhydrous THF (1 ml). After addition of t-BuOK (16 mg, 0.14 mmol,) the reaction mixture was stirred at room temperature for 15 min. Subsequently, 2,6-dichlorobenzoyl chloride (21 µl, 0.14 mmol) was added and the reaction mixture was stirred for another 2h at room temperature. The solvent was evaporated under reduced pressure, the residue was dissolved in dichloromethane and washed with water, an aqueous solution of 5% K2CO3 and water. The organic solvent was evaporated under reduced pressure and the residue was dried in vacuo. The product was purified by preparative HPLC to afford (2,6-dichlorophenyl)(3-(4-(1-(4-methoxybenzyl)-1H-tetrazol-5-yl)phenyl)-1H-indazol-1-yl)methanone as a mixture of 2 regioisomers in a 98 to 2 ratio (59 mg, 74%).
      ESI MS m/z 555 [M + H]+.
    2. ii) Following a procedure analogous to that described in Example 20, step iii, the product obtained in the previous step was converted to the title compound (3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-yl)(2,6-dichlorophenyl)methanone (16 mg).
      ESI MS m/z 435 [M + H]+.
    Example 23
  • Following a procedure analogous to that described in Example 22, the following compound was prepared.
    Org 356723-0
    Figure imgb0112
    • (3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-yl)(2,3-dichlorophenyl)methanone
  • ESI MS = m/z [M+H]+
    • Example 24A: Preparation of sodium 4-(1-(2-chloro-6-(trifluoromethyl) benzoyl)-4-fluoro-1H-indazol-3-yl)-3-fluorobenzoate (24A)
  • Figure imgb0113
  • i) Preparation of 4-fluoro-3-iodo-1H-indazole (A-2). To a solution of 4-fluoroindazole A-1 (5.00 g, 36.7 mmol) in DMF (80 mL) was added I2 (18.6 g, 73.5 mmol) and KOH (7.73 g, 134 mmol) successively at rt. After 2 h, the reaction mixture was poured into aq. 10% NaHSO3 (200 mL) and extracted with EtOAc (200 mL*3). The combined organic layers were washed with H2O and brine, dried over Na2SO4, and concentrated. The crude solid was washed with PE to give the title compound as a yellow solid. LCMS (ESI) calc'd for C7H5FIN2 [M+H]+: 262.9, found: 262.9.
  • ii) Preparation of (2-chloro-6-(trifluoromethyl)phenyl)(4-fluoro-3-iodo-1H-indazol-1-yl)methanone (A-4). To a flask was added compound A-2 (5.24 g, 20 mmol), compound A-3 (4.86 g, 20 mmol), DMAP (2.44 g, 20 mmol) and DCM (30 mL), followed by the addition of TEA (5.8 mL, 40 mmol) slowly. The reaction mixture was stirred at rt for 24 h. The mixture was diluted with H2O, and the organic layer was separated. The aqueous layer was extracted with CH2Cl2. The combined organics were washed with H2O, brine, dried over Na2SO4, and concentrated. The residue was purified by flash chromatography (Pentane/EtOAc) to afford the title compound. LCMS (ESI) calc'd for C15H7ClF4IN2O [M+H]+: 468.9, found: 468.9.
  • iii) Preparation of methyl 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4- fluoro-1H-indazol-3-yl)-3-fluorobenzoate (A-5). To a mixture of A-4 (300 mg, 0.64 mmol), 2-fluoro-4-(methoxycarbonyl)phenylboronic acid (190 mg, 0.96 mmol), Pd(dppf)Cl2 (52 mg, 0.064 mmol) and KOAc (190 mg, 1.92 mmol) was added dioxane (10 ml) and H2O (2 ml), and the mixture was heated at 90 °C under microwave for 2 h. The mixture was cooled down, diluted with CH2Cl2 (50 ml). The organic layer was separated, washed with brine, dried over Na2SO4, concentrated. The residue was purified by flash chromatography (Pentane/EtOAc) to give the title compound. LCMS (ESI) calc'd for C23H13ClF5N2O3 [M+H]+, 495, found: 495.
  • iv) Preparation of 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H- indazol-3-yl)-3-fluorobenzoic acid (A-6). To a solution of A-5 (180 mg, 0.36 mmol) in THF (5mL) and H2O (5mL) was added LiOH (350 mg, 1.44 mmol), and the mixture was stirred at rt for 24 h. The mixture was neutralized with 2N HCl to PH = 3∼4. The mixture was then concentrated under reduced pressure. The residue was filtered and washed with H2O to afford the title compound as white solid. LCMS (ESI): calc'd for C22H11ClF5N2O3 [M+H]+: 481, found: 481; 1H NMR (400 MHz, CDCl3) δ 8.45-8.47 (1H, d), 7.88-7.95 (2H, m), 7.66-7.71 (3H, m), 7.58-7.64 (2H, m), 7.13-7.17 (1H, m).
  • v) Preparation of sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4- fluoro-1H-indazol-3-yl)-3-fluorobenzoate (24A). To a suspension of compound A-6 (160 mg, 0.33 mmol) in H2O (10 mL) was added 0.1M NaOH (3.3 ml, 0.33 mmol) and the mixture was kept stirring at 0 °C for 30 mins. The reaction mixture was dried under lyophilization to afford the title compound. LCMS (ESI) calc'd for C22H11ClF5N2O3 [M-Na+2H]+: 481, found: 481; 1HNMR (400 MHz, DMSO) δ 8.36-8.38 (1H, d), 7.96-8.03 (2H, m), 7.66-7.71 (1H, m), 7.85-7.89 (1H, m), 7.72-7.74 (1H, m), 7.65(1H, s), 7.40-7.45(2H, m).
    • Example 24B: Preparation of sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl) -1H-indazol-3- yl)benzoate (24B)
  • Figure imgb0114
  • i) Preparation of (3-bromo-1H-indazol-1-yl)(2-chloro-6-(trifluoromethyl) phenyl)methanone (B-2). To a solution of 3-bromo-1H-indazole (2 g, 0.75mmol), DMAP (1 g, 8.5 mmol) and Et3N (1.85 ml, 12.7 mmol) in CH2Cl2 (20 mL) at 0°C was added a solution of compound A-3 (4 g, 20.4 mmol) in CH2Cl2 (5 mL). The mixture was stirred at rt for 24 h, diluted with CH2Cl2, washed with 1M HCl. The organic layer was washed with sat. NaHCO3 and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by flash chromatography (PE/EA=10/1) to give the title compound. LCMS (ESI) calc'd for C15H8BrClF3N2O [M+H]: 404.9, Found: 404.9.
  • ii) Preparation of methyl 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H- indazol-3-yl)benzoate (B-3). A mixture of compound B-2 (3.0 g, 7.4 mmol), 4-(methoxycarbonyl)phenylboronic acid (1.6 g, 8.9 mmol), Pd(PPh3)4 (0.43g, 0.37 mmol) and K2CO3 (2.04 g, 10.8 mmol) in dioxane (10 mL) and H2O (2 mL) was heated at 140°C for 2 h under microwave. The mixture was cooled down, diluted with CH2Cl2 and H2O. The organic layer was washed with brine, dried over Na2SO4 and concentrated. The residue was purified by flash chromatography (PE/EA = 10/1) to give the title compound as a yellow solid. LCMS (ESI) calc'd for C23H15ClF3N2O3 [M+H]+: 459, found: 459.
  • iii) Preparation of 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3- yl)benzoic acid (B-4). A mixture of compound B-3 (1.3 g, 2.8 mmol) and LiOH (0.35 g, 8.4 mmol) in THF (5 mL) and H2O (5 mL) was stirred at rt for 24 h. Then the mixture was neutralized with AcOH to PH < 7, diluted with CH2Cl2 and H2O. The organic layer was separated and washed with brine, dried over Na2SO4 and concentrated. The residue was purified by prep HPLC to give the title compound as a white solid. LCMS (ESI) calc'd for C22H13ClF3N2O3 [M+H]+: 445, found: 445; 1H NMR (400 MHz, CDCl3) δ 8.68-8.71 (1H, d), 8.19-8.21 (2H, m), 8.03-8.05 (1H, d), 7.94-7.96 (2H, m), 7.70-7.75 (3H, m), 7.26-7.63 (2H, m).
  • iv) Preparation of sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H- indazol-3-yl)benzoate (24B). To a suspension of compound B-4 (0.87g, 2.0 mmol) in H2O (10 mL) at 0 °C was added 0.1 M NaOH (2.0 ml, 2.0 mmol) and the mixture was kept stirring at at 0°C for 30 mins. The mixture was dried under lyophilization to give the title compound. 1H NMR (400 MHz, DMSO) δ 8.54-8.56 (1H, d), 8.22-8.24 (1H, d), 8.03-8.05 (1H, d), 7.98-8.00 (3H, m), 7.82-7.88 (2H, m), 7.71-7.73 (2H, m), 7.63-7.67 (1H, t).
    • Example 24C: Preparation of sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl) -1H-pyrazolo [4,3-b]pyridin-3-yl)-3-fluorobenzoate (24C)
  • Figure imgb0115
  • i) Preparation of (3-bromo-1H-pyrazolo[4,3-b]pyridin-1-yl)(2-chloro-6-(trifluoromethyl)phenyl)methanone (C-2). To a mixture of compound A-3 (1.2 g, 5.0 mmol), compound C-1 (1.0 g, 5.0 mmol), and DMAP (0.61 g, 5.0 mmol) in CH2Cl2 (20 mL) was added TEA (0.55 g, 5.5 mmol) dropwise. The mixture was stirred at rt for 24 h., diluted with H2O, and the organic layer was separated. The aqueous layer was extracted with CH2Cl2. The combined organics were washed with H2O brine, dried over Na2SO4, and concentrated. The residue was purified by column chromatography (PE/EA from 50/1 to 10/1) to give the title solid. LCMS (ESI) calc'd for C14H7BrClF3N3O [M+H]+: 405.9, found: 405.9.
  • ii) Preparation of 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b] pyridin-3-yl)-3-fluorobenzoic acid (C-3). A mixture of C-2 (120 mg, 0.3 mmol), 2-fluoro-4-(methoxycarbonyl)phenylboronic acid (89 mg, 0.45 mmol), Pd(PPh3)4 (18 mg, 0.015 mmol) and K2CO3 (128 mg, 0.75 mmol) in dioxane (3 mL) and H2O (0.6 mL) was heated at 140°C for 3 h under microwave. The mixture was cooled down and diluted with CH2Cl2 and H2O. The organic layer was washed with brine, dried over Na2SO4 and concentrated. The residue was purified by flash chromatography (PE/EA=1/1) to give the title compound as a yellow solid. LCMS (ESI) calc'd for C22H13ClF4N3O3 [M+H]+: 464, found: 464; 1H NMR (400 MHz, DMSO) δ 13.51 (1H, s), 8.98-8.91 (2H, m), 8.42-8.38 (2H, t), 8.06-7.95 (3H, m), 7.90-7.87 (2H, m), 7.87-7.80 (1H, m).
  • iii) Preparation of sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoate (24C). To a suspension of compound C-3 (135 mg, 0.29 mmol) in H2O (20 mL) was added 0.1 M NaOH (2.9 ml, 0.29 mmol) at 0 °C, and the mixture was kept stirring for 30 min at 0 °C. The mixture was then dried under lyophilization to give the title compound. LCMS (ESI) calc'd for C21H11ClF4N3O3 [M-Na+2H]+: 464, found: 464, 1H NMR (400 MHz, CD3OD) δ 8.95-8.93 (1H, m), 8.89-8.87 (1H, m), 8.13-8.09 (1H, t), 7.90-7.87 (3H, m), 7.81-7.75 (3H, m).
  • The following examples shown in TABLE 2 were prepared following similar procedures described for Examples #24A, B, C in Schemes A-C, which can be achieved by those of ordinary skill in the art. TABLE 2
    Figure imgb0116
    Ex. IUPAC name A ring P Q NMR or LCMS [M+H]+ (found)
    24D (2-chloro-6-(trifluoromethyl)ph enyl)(4-fluoro-3-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-1H-indazol-1-yl)methanone
    Figure imgb0117
    Figure imgb0118
    Figure imgb0119
         		585
    24E 3-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid
    Figure imgb0120
    Figure imgb0121
    Figure imgb0122
         		463
    24H 2-chloro-4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid
    Figure imgb0123
    Figure imgb0124
    Figure imgb0125
         		497
    24I Sodium 3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)benzoate
    Figure imgb0126
    Figure imgb0127
    Figure imgb0128
         		497
    24K 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluoro-5-methylbenzoic acid
    Figure imgb0129
    Figure imgb0130
    Figure imgb0131
         		495
    24L 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-3-methylbenzoic acid
    Figure imgb0132
    Figure imgb0133
    Figure imgb0134
         		477
    24M 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-2-methoxybenzoic acid
    Figure imgb0135
    Figure imgb0136
    Figure imgb0137
         		494
    24N 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluorobenzoic acid
    Figure imgb0138
    Figure imgb0139
    Figure imgb0140
         		481
    24O sodium 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluorobenzoate
    Figure imgb0141
    Figure imgb0142
    Figure imgb0143
         		481 [M-Na+2H]+
    24P 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-2-methylbenzoic acid
    Figure imgb0144
    Figure imgb0145
    Figure imgb0146
         		483
    24Q 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-3-methoxybenzoic
    Figure imgb0147
    Figure imgb0148
    Figure imgb0149
         		493
    acid
    24R 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-2,6-difluorobenzoic acid
    Figure imgb0150
    Figure imgb0151
    Figure imgb0152
         		499
    24S 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-2-isopropylbenzoic acid
    Figure imgb0153
    Figure imgb0154
    Figure imgb0155
         		505
    24T 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-3,5-dimethoxybenzoic acid
    Figure imgb0156
    Figure imgb0157
    Figure imgb0158
         		523
    24U 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-2-cyano benzoic acid
    Figure imgb0159
    Figure imgb0160
    Figure imgb0161
         		488
    24V 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-2,3-difluorobenzoic acid
    Figure imgb0162
    Figure imgb0163
    Figure imgb0164
         		499
    24W 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-2,5-difluorobenzoic acid
    Figure imgb0165
    Figure imgb0166
    Figure imgb0167
         		499
    24X 2-chloro-4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-5-fluorobenzoic acid
    Figure imgb0168
    Figure imgb0169
    Figure imgb0170
         		515
    24Y 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-5-fluoro-2-methoxybenzoic acid
    Figure imgb0171
    Figure imgb0172
    Figure imgb0173
         		511
    24Z 5-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl)-2-hydroxybenzoic acid
    Figure imgb0174
    Figure imgb0175
    Figure imgb0176
         		479
    24AA 3-fluoro-4-(4-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0177
    Figure imgb0178
    Figure imgb0179
         		427
    24AB 4-(4-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0180
    Figure imgb0181
    Figure imgb0182
         		409
    24AC 3-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl) benzoic acid
    Figure imgb0183
    Figure imgb0184
    Figure imgb0185
         		446
    24AE (2-chloro-6-(trifluoromethyl)ph enyl)(3-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methanone
    Figure imgb0186
    Figure imgb0187
    Figure imgb0188
         		568
    24AF 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-methylbenzoic acid
    Figure imgb0189
    Figure imgb0190
    Figure imgb0191
         		460
    24AG 3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid
    Figure imgb0192
    Figure imgb0193
    Figure imgb0194
         		480
    24AH 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-fluorobenzoic acid
    Figure imgb0195
    Figure imgb0196
    Figure imgb0197
         		464
    24AI 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-methoxybenzoic acid
    Figure imgb0198
    Figure imgb0199
    Figure imgb0200
         		476
    24AJ 2-chloro-4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-5-fluorobenzoic acid
    Figure imgb0201
    Figure imgb0202
    Figure imgb0203
         		498
    24AK 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2,5-difluorobenzoic acid
    Figure imgb0204
    Figure imgb0205
    Figure imgb0206
         		482
    24AL 5-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-hydroxybenzoic acid
    Figure imgb0207
    Figure imgb0208
    Figure imgb0209
         		462
    24A M 4-(1-(2-fluoro-6-methoxybenzoyl)-1H-pyrazolo [4,3-b]pyridin-3-yl)benzoic acid
    Figure imgb0210
    Figure imgb0211
    Figure imgb0212
         		392
    24AN 3-fluoro-4-(1-(2-fluoro-6-methoxybenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid
    Figure imgb0213
    Figure imgb0214
    Figure imgb0215
         		410
    24AO 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-(trifluoromethyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0216
    Figure imgb0217
    Figure imgb0218
         		513
    24AP 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-indazol-3-yl)-2-isopropylbenzoic acid
    Figure imgb0219
    Figure imgb0220
    Figure imgb0221
         		487
    24AQ sodium 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-indazol-3-yl)-2-fluoro benzoate
    Figure imgb0222
    Figure imgb0223
    Figure imgb0224
         		463 [M-Na+2H]+
    24AR sodium 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-indazol-3-yl)-3-fluoro benzoate
    Figure imgb0225
    Figure imgb0226
    Figure imgb0227
         		463 [M-Na+2H]+
    24AS 3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0228
    Figure imgb0229
    Figure imgb0230
         		480
    24AT 3-fluoro-4-(1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0231
    Figure imgb0232
    Figure imgb0233
         		409
    24AU sodium 3-fluoro-4-(1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoate
    Figure imgb0234
    Figure imgb0235
    Figure imgb0236
         		409 [M-Na+2H]+
    24AV 4-(7-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0237
    Figure imgb0238
    Figure imgb0239
         		409
    24A W 3-fluoro-4-(7-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0240
    Figure imgb0241
    Figure imgb0242
         		427
    24AX 4-(6-bromo-1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-1H-indazol-3-yl) benzoic acid
    Figure imgb0243
    Figure imgb0244
    Figure imgb0245
         		543
    24AY 4-(6-bromo-1-(2-chloro-6-(trifluoromethyl)be nzoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0246
    Figure imgb0247
    Figure imgb0248
         		1H NMR (400 MHz, DMSO) δ 13.25 (1H, s), 8.72 (1H, s),8.23 (1H, d, J=8.4 Hz), 8.01-8.11 (4H, m), 7.86-7.96 (4H, m)
    24AZ 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-6-methoxy-1H-indazol-3-yl) benzoic acid
    Figure imgb0249
    Figure imgb0250
    Figure imgb0251
         		493
    24BA 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-6-hydroxy-1H-indazol-3-yl)benzoic acid
    Figure imgb0252
    Figure imgb0253
    Figure imgb0254
         		461
    24BB 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-6-hydroxy-1H-indazol-3-yl)-3-fluorobenzoic acid
    Figure imgb0255
    Figure imgb0256
    Figure imgb0257
         		479
    24BC 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-6-hydroxy-1H-indazol-3-yl)benzoic acid
    Figure imgb0258
    Figure imgb0259
    Figure imgb0260
         		479
    24BD 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-4-fluoro-6-hydroxy-1H-indazol-3-yl)-3-fluorobenzoic acid
    Figure imgb0261
    Figure imgb0262
    Figure imgb0263
         		497
    24BE 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-6-(hydroxymethyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0264
    Figure imgb0265
    Figure imgb0266
         		475
    24BF 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-6-(hydroxymethyl)-1H-indazol-3-yl)-3-fluorobenzoic acid
    Figure imgb0267
    Figure imgb0268
    Figure imgb0269
         		493
    24BG 4-(1-(2-chloro-6-(trifluoromethyl)be nzoyl)-6-(methoxymethyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0270
    Figure imgb0271
    Figure imgb0272
         		489
    • Example 25A: Preparation of sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl) -6-(2-hydroxy ethylcarbamoyl)-1H-indazol-3-yl)benzoate (25A)
  • Figure imgb0273
    • i) Preparation of methyl 1H-indazole-6-carboxylate (D-2).
  • To a solution of methyl 3-amino-4-methylbenzoate D-1 (5.0 g, 30 mmol) in AcOH (140 mL) at 0 °C was added a solution of sodium nitrite (2.1 g, 30 mmol) in H2O (3.5 mL). After addition, the mixture was stirred at rt for 24 h. Then half of the solvent was removed under reduced pressure and the resulting mixture was diluted with H2O, and extracted with EtOAc. The combined orgnaics were washed H2O and brine, and concentrated to give the title compound. LCMS (ESI) calc'd for C9H9N2O2 [M+H]+: 177, found 177.
    • ii) Preparation of methyl 3-iodo-1H-indazole-6-carboxylate (D-3).
  • To a solution of methyl 1H-indazole-6-carboxylate D-2 (5.0 g, 28 mmol) in DMAC (50 mL) at 0 °C was added iodine (14.4 g, 56.7 mmol) and potassium hydroxide (6.3 g, 114 mmol) portionwise. After addition, the mixture was kept stirring for 1 h, then quenched with aq. Na2S2O3 and extracted with EtOAc. The combined organics were concentrated and trituated with hexane. The precipitate was collected by filtration to afford the title compound as a brown solid. LCMS (ESI) calc'd for C9H8IN2O2 [M+H]+: 302.9, found: 302.9.
    • iii): Preparation of methyl 1-(2-chloro-6-(trifluoromethyl)benzoyl)-3-iodo-1H-indazole-6-carboxylate (D-4).
  • To a solution of methyl 3-iodo-1H-indazole-6-carboxylate D-3 (11.7 g, 38.7 mmol), DMAP (4.72 g, 38.7 mmol) in CH2Cl2 (30 mL) was added Et3N (11.2 mL, 77 mmol) dropwise. The reaction mixture was stirred at rt for 24 h, diluted with H2O, and the organic layer was separated. The aqueous layer was extracted with CH2Cl2 twice. The combined organics were washed with H2O, brine, dried over Na2SO4, concentrated. The residue was purified by column chromatography (PE /EtOAc from 50/1 to 10/1) to give the title compound. LCMS (ESI) calc'd for C17H10ClF3IN2O3 [M+H]+: 508.9, found: 508.9.
    • iv): Preparation of 1-(2-chloro-6-(trifluoromethyl)benzoyl)-3-iodo-1H-indazole -6-carboxylic acid (D-5).
  • To a solution of D-4 (16.5 g, 32.5 mmol) in THF (10 mL) and H2O (50 ml) was added LiOH (3.40 g, 162 mmol), and the mixture was stirred at rt for 24 h. The solvent was removed under reduced pressure and the residue was taken up in H2O, and neutralized with 5% aqueous HCl to PH = 4∼5. The white precipitate was collected by filtration, washed with H2O and hexane to give the title compound as an off white solid. LCMS (ESI) calc. C16H8ClF3IN2O3 [M+H]+: 494.9, found: 494.9.
    • v) Preparation of 1-(2-chloro-6-(trifluoromethyl)benzoyl)-3-(4-(methoxy carbonyl)phenyl)-1H-indazole-6-carboxylic acid (D-6).
  • A mixture of D-5 (300 mg, 0.61 mmol), 4-(methoxycarbonyl)phenylboronic acid (165 mg, 0.92 mmol), Pd(dppf)Cl2 (50 mg, 0.061 mmol) and KOAc (181 mg, 1.83mmol) in dioxane (10 mL) and H2O (2 mL) was heated at 95 °C for 2 h under microwave. The mixture was then cooled to rt, diluted with EtOAc and H2O. The organic layer was washed with brine, dried over Na2SO4 and concentrated. The residue was purified by flash chromatography (PE/EtOAc =20/1) to give the title compound as a white solid. LCMS (ESI) calc'd for C24H15ClF3N2O5 [M+H]+: 503.1, found: 503.1.
    • vi) Preparation of methyl 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)benzoate (D-7).
  • To a solution of compound D-6 (180 mg, 0.36mmol) in CH2Cl2 (15 mL) was added PYAOP (374 mg, 0.72mmol), followed by the addition of Et3N (0.16mL, 1.1 mmol). The mixture was stirred at rt for 2 h, diluted with EtOAc. The organic layer was separated, washed with brine, dried over Na2SO4, concentrated to give the title compound as a white solid. LCMS (ESI) calc'd for C26H20ClF3N3O5 [M+H]+: 546.1, Found: 546.1.
    • vii) Preparation of 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxy ethylcarbamoyl)-1H-indazol-3-yl)benzoic acid (D-8).
  • A mixture of D-7 (191mg, 0.35 mmol) and LiOH (42mg, 1.75 mmol) in THF (10 mL) and H2O (5 mL) was stirred at rt for 2 h. The solvent was removed under reduced pressure, and the residue was dissolved in H2O and neutralized with aqueous 5% HCl to PH = 4-5. The precipitated was collected by filtration, washed with H2O and hexane to the title compound as an off-white solid. LCMS (ESI) calc'd for C25H18ClF3N3O5 [M+H]+: 532.1, found: 532.1; 1H NMR (400 MHz, MeOD) δ 9.109 (1H, s), 8.29-8.31(1H, d, J = 8.4 Hz), 8.17-8.19 (2H, d, J = 8.4 Hz), 8.07-8.10 (1H, m), 7.97-8.00 (2H, d, J = 8.8 Hz), 7.88-7.99 (2H, m), 7.78-7.82 (1H, m), 3.79-3.82 (2H, m), 3.60-3.63 (2H, m).
    • viii) Preparation of sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)benzoate (25A)
  • To a suspension of compound D-8 (185 mg, 0.35 mmol) in H2O (10 mL) was added 0.1M NaOH (3.5 ml, 0.35 mmol) at 0 °C, and the mixture was kept stirring for 30 mins. The mixture was then dried under lyophilizaiton to give the title compound. LCMS (ESI) calc. C25H18ClF3N3O5 [M-Na+2H]+: 532, found: 532; 1H NMR (400 MHz, MeOD) δ 9.09 (1H, s), 8.28-8.30 (1H, d, J = 8.8 Hz), 8.05-8.09 (3H, m), 7.86-7.91 (4H, m), 7.77-7.86 (1H, m), 3.79-3.82 (2H, m), 3.60-3.63 (2H, m).
  • The following examples shown in TABLE 3 were prepared following similar procedures described for Example #25A in Scheme D, which can be achieved by those of ordinary skill in the art. TABLE 3
    Figure imgb0274
    Ex. IUPAC name
    Figure imgb0275
         		P Q LCMS [M+H]+ (found)
    25B 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(dimethylcarba moyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0276
    Figure imgb0277
    Figure imgb0278
         		516
    25C 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0279
    Figure imgb0280
    Figure imgb0281
         		532
    25D sodium 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(2-hydroxyethylca rbamoyl)-1H-indazol-3-yl)benzoate
    Figure imgb0282
    Figure imgb0283
    Figure imgb0284
         		554
    25E 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(dimethylcarba moyl)-1H-indazol-3-yl)-3-fluorobenzoic acid
    Figure imgb0285
    Figure imgb0286
    Figure imgb0287
         		534
    25F sodium 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(dimethylcarba moyl)-1H-indazol-3-yl)-3-fluorobenzoate
    Figure imgb0288
    Figure imgb0289
    Figure imgb0290
         		556
    25G 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(2-hydroxyethylca rbamoyl)-1H-indazol-3-yl)-2-fluorobenzoic acid
    Figure imgb0291
    Figure imgb0292
    Figure imgb0293
         		550
    25H 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(2-hydroxyethylca rbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid
    Figure imgb0294
    Figure imgb0295
    Figure imgb0296
         		550
    25I 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(dimethylcarba moyl)-1H-indazol-3-yl)-2-fluorobenzoic acid
    Figure imgb0297
    Figure imgb0298
    Figure imgb0299
         		534
    25J 3-chloro-4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(dimethylcarba moyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0300
    Figure imgb0301
    Figure imgb0302
         		550
    25K 3-chloro-4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(2-hydroxyethylca rbamoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0303
    Figure imgb0304
    Figure imgb0305
         		566
    25L 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(3-hydroxypropylc arbamoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0306
    Figure imgb0307
    Figure imgb0308
         		546
    25M 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(3-hydroxypropylc arbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid
    Figure imgb0309
    Figure imgb0310
    Figure imgb0311
         		564
    25N 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(3-methoxypropyl carbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid
    Figure imgb0312
    Figure imgb0313
    Figure imgb0314
         		580
    250 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(2-hydroxypropylc arbamoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0315
    Figure imgb0316
    Figure imgb0317
         		546
    25P 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(4-hydroxybutylca rbamoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0318
    Figure imgb0319
    Figure imgb0320
         		560
    25Q 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-((2-hydroxyethyl)( methyl)carbam oyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0321
    Figure imgb0322
    Figure imgb0323
         		546
    25R 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-((2-hydroxyethyl)( methyl)carbam oyl)-1H-indazol-3-yl)-3-fluorobenzoic acid
    Figure imgb0324
    Figure imgb0325
    Figure imgb0326
         		564
    25S 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-((2-methoxyethyl)( methyl)carbam oyl)-1H-indazol-3-yl)-3-fluorobenzoic acid
    Figure imgb0327
    Figure imgb0328
    Figure imgb0329
         		578
    25T 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(3-fluoroazetidine-1-carbonyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0330
    Figure imgb0331
    Figure imgb0332
         		546
    25U 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(3,3-difluoroazetidin e-1-carbonyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0333
    Figure imgb0334
    Figure imgb0335
         		564
    25V 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(pyrrolidine-1-carbonyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0336
    Figure imgb0337
    Figure imgb0338
         		542
    25 W 4-(6-(azetidine-1-carbonyl)-1-(2-chloro-6-(trifluoromethyl )benzoyl)-1H-indazol-3-yl)benzoic acid
    Figure imgb0339
    Figure imgb0340
    Figure imgb0341
         		528
    • Example 26: Preparation of 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-hydroxybenzoic acid (26A), 2-acetoxy-4-(1-(2-chloro-6-(trifluoromethyl) benzoyl)-4-fluoro-1H-indazol-3-yl) benzoic acid (26B) and sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-hydroxy benzoate (26C)
  • Figure imgb0342
    • i) Preparation of 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-hydroxybenzoic acid (26A)
  • To a solution of compound E-1 (prepared following a similar procedure in Scheme A) (100 mg, 0.19 mmol) in DCM (10 mL) was added BBr3 (1M, 0.37 mL, 0.37 mmol) at rt, and the mixture was kept stirring for 48 h. Then MeOH (∼10 mL) was added to quench excess BBr3 and the mixture was concentrated under reduced pressure. The residue was purified by prep-HPLC to give the title compound as a yellow solid. LCMS (ESI) calc'd for C22H12ClF4N2O4 [M+H]+: 479, found: 479; 1H NMR (400 MHz, MeOD) δ 8.46 (1H, d, J=8.4 Hz), 7.95-7.76 (5H, m), 7.35-7.29 (3H, m).
    • ii) Preparation of 2-acetoxy-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid (26B)
  • A suspension of compound 26A (48 mg, 0.1 mmol), Ac2O (0.8 mL) and MgI2 (28 mg, 0.1 mmol) in anhydrous ethyl ether (3 mL) was refluxed at 40 °C for 0.5 h. The reaction was cooled to rt, quenched with H2O, extracted with ether, and concentrated. The crude product was dissolved in THF (10 mL) /H2O (10 mL) and refluxed at 80 °C for 1 h. The mixture was cooled to rt, diluted with H2O, and extracted with EtOAc. The combined organic extracts were concentrated and purified by flash chromatography PE/EA (5/1) to give the title compound as a white solid. LCMS (ESI): calc'd for C22H12ClF4N2O4 [M+H]+: 521, found: 521, 1H NMR (400 MHz, MeOD) δ 8.47 (1H, d, J=8.0 Hz), 8.11 (1H, d, J=8.0 Hz), 7.90-7.76 (5H, m), 7.53 (1H, t, J=1.6 Hz), 3.34 (1H, q, J=8.0 Hz), 2.31 (3H, s).
    • iii) Preparation of sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-hydroxybenzoate (26C)
  • To a suspension of compound 26A (48 mg, 0.1 mmol) in H2O (20 mL) was added 0.1 M NaOH (1 mL), and the mixture was sonicated for ∼10 mins. The mixture was then dried under lyophilizaiton to give the title compound. LCMS (ESI) calc'd for C22H11ClF4N2NaO4 [M+H]+: 501, found: 501; 1H NMR (400 MHz, MeOD) δ 8.45 (1H, d, J=8.0), 7.91-7.76 (5H, m), 7.31 (1H, q, J=8.0 Hz), 7.20-7.17 (2H, m).
  • The following examples shown in TABLE 4 were prepared following similar procedures described for Examples #26A, B, C in Scheme E, which can be achieved by those of ordinary skill in the art. TABLE 4
    Figure imgb0343
    IUPAC name A ring P Q LCMS [M+H]+ (found)
    26D 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluoro-6-hydroxybenzoic acid
    Figure imgb0344
    Figure imgb0345
    Figure imgb0346
         		497
    26E 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-4-fluoro-1H-indazol-3-yl)-3-hydroxybenzoic acid
    Figure imgb0347
    Figure imgb0348
    Figure imgb0349
         		479
    26F 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-4-fluoro-1H-indazol-3-yl)-5-fluoro-2-hydroxybenzoic acid
    Figure imgb0350
    Figure imgb0351
    Figure imgb0352
         		497
    26G 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-4-fluoro-1H-indazol-3-yl)-3,6-difluoro-2-hydroxybenzoic acid
    Figure imgb0353
    Figure imgb0354
    Figure imgb0355
         		515
    26H 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-hydroxybenzoic acid
    Figure imgb0356
    Figure imgb0357
    Figure imgb0358
         		462
    26I 2-acetoxy-4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid
    Figure imgb0359
    Figure imgb0360
    Figure imgb0361
         		504
    26J 4-(1-(2-chloro-6-(trifluoromethyl )benzoyl)-6-(dimethylcarba moyl)-1H-indazol-3-yl)-2-hydroxybenzoic acid
    Figure imgb0362
    Figure imgb0363
    Figure imgb0364
         		532
    • Example 27A: Preparation of 4-(6-(aminomethyl)-1-(2-chloro-6-(trifluoromethyl) benzoyl)-1H-indazol-3-yl)benzoic acid (27A)
  • Figure imgb0365
    • i) Preparation of methyl 4-(6-carbamoyl-1-(2-chloro-6-(trifluoromethyl) benzoyl)-1H-indazol-3-yl)benzoate (F-2)
  • To a solution of compound D-6 (180 mg, 0.36 mmol) in DCM (15 mL) was added PYAOP (374 mg, 0.72mmol), followed by the addition of TEA (0.16 mL, 1.1 mmol). The mixture was stirred at rt for 2 h, diluted with EtOAc, washed with brine, dried over Na2SO4 and concentrated to give the title compound. LCMS (ESI) calc'd for C24H16ClF3N3O4 [M+H]+: 502, found: 502.1.
    • ii) Preparation of (6-(aminomethyl)-3-(4-(hydroxymethyl)phenyl)-1H-indazol-l-yl)(2-chloro-6-(trifluoromethyl)phenyl)methanone (F-3)
  • To a solution of compound F-2 (175 mg, 0.35 mmol) in THF (20 mL) was added BH3.THF (1.75 mL, 1.75 mmol) and the mixture was refluxed for 12 h. Then MeOH was added to quench the excess BH3, and the mixture was concentrated under reduced pressure to give the title compound as a white solid. LCMS (ESI): calc'd for C23H18ClF3N3O2 [M+H]+: 460.1, found: 460.1.
    • iii) Preparation of tert-butyl (1-(2-chloro-6-(trifluoromethyl)benzoyl)-3-(4-(hydroxymethyl)phenyl)-1H-indazol-6-yl)methylcarbamate (F-4)
  • To a solution of compound F-3 (138 mg, 0.30 mmol) in CH2Cl2 (20 mL) was added (Boc)2O (138 mg, 0.30 mmol), followed by the addition of excess. The mixture was stirred at rt for 2 h. The mixture was diluted with H2O, extracted with EtOAc. The combined organics were washed with H2O, brine, dried over Na2SO4, concentrated to give the title compound. LCMS (ESI) calc. C28H26ClF3N3O4 [M+H]+: 560.1, found: 560.1.
    • iv) Preparation of 4-(6-((tert-butoxycarbonylamino)methyl)-1-(2-chloro-6-(trifl uoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid (F-5)
  • To a solution of compound F-4 (162 mg, 0.29 mmol) in acetone (10 mL) was added Jones reagent (2 mL), and the mixture was kept stirring at rt for 12 h. MeOH (20 mL) was added to quenched excess Jones reagent, and the mixture was filtered and rinsed with EtOAc. The organic layer was separated and concentrated to give the title compound. LCMS (ESI): calc'd for C28H24ClF3N3O5 [M+H]+: 574.1, Found: 574.1.
    • v) Preparation of 4-(6-(aminomethyl)-1-(2-chloro-6-(trifluoromethyl) benzoyl) -1H-indazol-3-yl)benzoic acid (27A)
  • To a solution of compound F-5 (100 mg, 0.17 mmol) in CH2Cl2 (10 mL) was added excess amount of TFA. The mixture was stirred at rt for 2 h. The mixture was concentrated, diluted with H2O, and extracted with EtOAc. The combined organics were washed with H2O, brine, dried over Na2SO4 and concentrated to give the title compound. LCMS (ESI): calc'd for C23H16ClF3N3O3 [M+H]+: 474.1, found: 474.1; 1H NMR (400 MHz, MeOD) δ 8.76 (1H, s), 8.23-8.25 (1H, m), 8.04-8.06 (2H, d, J = 6.8Hz), 7.88-7.91 (2H, m), 7.77-7.85 (3H, m), 7.66-7.68 (1H, d, J = 8.8 Hz), 4.35 (2H, s).
  • The following examples shown in TABLE 5 were prepared following similar procedures described for Example #27A in Scheme F, which can be achieved by those of ordinary skill in the art. TABLE 5
    Figure imgb0366
    Ex. IUPAC name
    Figure imgb0367
         		P Q LCMS [M+H]+ (found)
    27B 4-(6-(aminomethyl)-1-(2-chloro-6-(trifluoromethyl) benzoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid
    Figure imgb0368
    Figure imgb0369
    Figure imgb0370
         		492
    • Example 28: Preparation of 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-in dazol-3-yl)-2-(difluoromethyl)benzoic acid
  • Figure imgb0371
    • i) Preparation of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzo furan-1(3H)-one (G-1)
  • A mixture of 5-bromoisobenzofuran-1(3H)-one (1.5 g, 7.0 mmol), 4,4,4',4', 5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (2.1 g, 8.5 mmol), KOAc (2.1 g, 21 mmol), dppf (0.16 g, 0.28 mmol) and Pd(dppf)Cl2 (0.26 g, 0.35 mmol) in dioxane (30ml) was heated at 100 °C for 4 h. The mixture was cooled down and concentrated under reduced pressure. The residue was diluted with H2O, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, and concentrated. The residue was purified by flash chromatography (PE: EA = 5:1) to give the title compound as a white solid. LCMS (ESI):calc. C14H18BO4 [M+H]+: 261, found: 261.
    • ii) 5-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)isobenzo furan-1 (3H)-one (G-2)
  • A mixture of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isobenzofuran-1(3H)-one (G-1) (0.97 g, 2.48 mmol), (3-bromo-1H-indazol-1-yl)(2-chloro-6-(trifluoro methyl)phenyl)methanone (1.0 g, 2.48 mmol), K2CO3(1.03 g, 7.44 mmol) and Pd(PPh3)4 (0.143 g, 0.12 mmol) were suspended in 1,4-dioxane (15 mL) and H2O (3 mL). The reaction mixture was heated at 100 °C in a microwave reactor for 2 h. The reaction mixture was cooled to rt and diluted with H2O. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The residue was purified by flash chromatography (PE: EA = 4:1) to afford the title compound as a pale yellow oil. LCMS (ESI) calc'd for C23H13ClF3N2O3 [M+H]+: 457, found: 457.
    • iii) Preparation of benzyl 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-2-(hydroxymethyl)benzoate (G-3)
  • A mixture of 5-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)isobenzo furan-1(3H)-one (G-2) (0.6 g, 1.32 mmol) and LiOH (0.16 g, 6.58 mmol) in THF (6 mL) and H2O (3mL) was stirred at rt for 3 h. The solvent was removed under reduced pressure, and the residue was dissolved in DMF (10 mL), followed by the addition of BnBr (0.78 mL, 6.6 mmol). The resulting mixture was stirred at rt for 3 h. The mixture was diluted with H2O, and EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by flash chromatography (PE: EA = 4:1) to give the title compound as a colorless oil. LCMS (ESI) calc'd for C30H19ClF5N2O3 for [M+H]+: 585, found: 585.
    • iv) Preparation of benzyl 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol -3-yl)-2-formylbenzoate (G-4)
  • To a mixture of benzyl 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-2-(hydroxymethyl)benzoate (G-3) (0.4 g, 0.71 mmol) in DCM (10 mL) was added Dess-Martin periodinane (0.45 g, 1.07 mmol), and the mixture was stirred at rt for 24 h. The mixture was diluted with H2O and extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The resulting crude oil was used in the next step without further purification. LCMS (ESI)' calc'd for C30H19ClF3N2O4 [M+H]+: 563, found: 563.
    • v) Preparation of benzyl 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-2-(difluoromethyl)benzoate (G-5)
  • To a solution of compound (G-4) (0.35 g, 0.62 mmol) in DCM (6 mL) at 0 °C was added a solution of DAST (0.42 mL, 3.1mmol) in DCM (4 mL) dropwise. The mixture was warmed to rt and stirred for 2 h. The reaction mixture was then diluted with H2O, and extracted with DCM. The combined organics were washed with brine, dried over Na2SO4, and concentrated. The residue was purified by flash chromatography (PE: EA = 10:1) to give the title compound as a white solid. LCMS (ESI) calc'd for C30H19ClF5N2O3 [M+H]+: 585, found: 585.
    • vi) 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-2-(difluoromethyl) benzoic acid (28)
  • A mixture of compound (G-5) (0.17 mg, 0.30 mmol) and LiOH (63 mg, 1.5 mmol) in THF (6 mL) and H2O (3 mL) was stirred at rt for 24 h. The mixture was acidified with 2M HCl to PH = ∼3, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The residue was purified with prep-HPLC to give the title compound as a white solid. LCMS (ESI) calc'd for C23H13ClF5N2O3 [M+H]+: 495, found: 495; 1H NMR (400 MHz, CDCl3) δ 8.70 (1H, d, J = 8 Hz), 8.35 (1H, s), 8.25 (1H, d, J = 8Hz), 8.02-8.05 (2H, m), 7.71-7.77 (3H, m), 7.49-7.64 (3H, m).
    • Example 29: Preparation of 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-cyano-1H-indazol-3-yl)benzoic acid
  • Figure imgb0372
    • i) Preparation of methyl 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-cyano-1H-indazol-3-yl)benzoate (H-2)
  • To a solution of compound H-1 (100 mg, 0.186 mmol) (prepared according to a similar procedure in Scheme A) in DMF (2 mL) was added Zn(CN)2 (44 mg, 0.37 mmol) and Pd(PPh3)4 (22 mg, 0.019 mmol). The mixture was purged with N2 and then stirred at 100 °C for 1 h under micorwave. The reaction mixture was cooled down to rt and diluted with H2O, and extracted with EtOAc. The combined organics were dried over anhydrous Na2SO4, filtered and concentrated. The crude solid was purified by Prep-TLC (20*20cm)(PE/EA=3/l) to obtain the title compound as a brown solid. LCMS (ESI) calc'd for C24H14F3N3P3Cl [M+H]+: 484, Found: 484.
    • ii) Preparation of 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-cyano-1H-indazol-3-yl)benzoic acid (29)
  • A mixture of compound H-2 (49 mg, 0.10 mmol), and LiOH (37 mg, 0.88 mmol) in dioxane (10 mL) and H2O (2 mL) was stirred at rt for 24 h. The mixture was acidified with AcOH to PH = ∼4, and extracted with DCM. The combined organics were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by prep HPLC to give the title compound as a white solid. LCMS (ESI) calc'd for C23H12F4N3O3Cl [M+H]+: 470, found: 470; 1H NMR (400 MHz, DMSO) δ 13.23 (1H, s), 8.99 (1H, s), 8.49 (1H, d, J=8.4 Hz), 8.03-8.12 (5H, m), 7.89-7.98 (3H, m).
    • Biological Assays
  • The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using e.g. biochemical TR-FRET assay. In such an assay, interaction of cofactor-derived peptides with human RORgammaT-Ligand Binding Domain (LBD) can be measured. The TR-FRET technique is a sensitive biochemical proximity assay that will give information concerning the interaction of a ligand with the LBD, in the presence of cofactor derived peptides (Zhou et al., Methods 25:54-61, 2001).
  • To identify novel antagonists of RORgammaT, an assay was developed which employs the interaction of RORgammaT with its co-activator peptide SRC1_2. This peptide mimics the recruitment of co-activators to RORgammaT through its interaction with the LXXLL (eg NR box) motifs (Xie et al., J. Immunol. 175: 3800-09, 2005; Kurebayashi et al., Biochem. Biophys. Res. Commun. 315: 919-27, 2004; Jin et al., Mol. Endocrinology 24:923-29, 2010). The assay was run following three slightly different protocols, i.e. Protocol A, Protocol B, and Protocol C, which are described below. The TR-FRET assay following Protocol A is described below and the results thereof shown in Table 1 below.
    • TR-FRET assay (Protocol A)
  • In the current setting, a peptide from Steroid Receptor Co-factor 1 box 2 (SRC1_2) is aminoterminal biotinylated (biotinyl-CPSSHSSLTERHKILHRLLQEGSPS, NEOMPS, France) and the applied RORgamma-LBD contains a 6-His and GST tag. The 6His(GST)RORgamma-LBD was expressed and purified from baculovirus infected Sf-21 insect cells (Bac-to-BAC, Invitrogen) and purified using glutathione sepharose chromatography (GE healthcare). Biotin and His function as anchoring points for streptavidin-allophycocyanin (Strep-APC, Perkin Elmer, C130-100) and anti-His-Europium Cryptate (Perkin Elmer, AD0111), respectively. Since energy transfer between the streptavidin and His-coupled labels APC and europium cryptate can only take place when these labels are in close proximity, measurement of energy transfer in a mixture of biotinylated peptide, His-GR-LBD, streptavidin-APC and anti-His-Europium Cryptate will be indicative for RORy-LBD/peptide binding. Final assay conditions in 50 µl are: TR-FRET buffer [50 mM KCl, 50 mM TRIS, 1 mM Na-EDTA, 0.1 mM DTT, (pH 7.0)]; 6His(GST)RORgamma-LBD 10 nM, Anti-6His-Eu 1.25 nM, SRC1_2 peptide 0.1 µM, Strep-APC 8 nM. Changes in peptide binding caused by dose-curves of compounds added to the reaction mixture (DMSO concentration 0.1 %), can likewise be monitored. Fluorescence emission at 665 nm (excitation wavelength 340 nm) was read in each well of 384 well plates (Perkin Elmer, 60007299) using an Envision fluorescence reader in Time Resolved mode (Perkin Elmer) after overnight incubation at 4°C. Dose-response data are curve-fitted (IBDS Software, ActivityBase) and pEC50 values calculated. pEC50 values for Examples 1-23 using Protocol A are provided in Table 6 below. All compounds of the invention have a pEC50 of 4 or higher. Preferred are compounds with a pEC50 of more than 5. Table 6
    Example pEC50
    1 7.97
    2 6.61
    3 7.73
    4 8.08
    5 6.76
    6A 7.87
    6B 6.65
    7 7.85
    8 5.31
    9 5.03
    10 7.64
    11A 6.47
    11B 7.35
    11C 6.29
    11D 6.28
    11E 7.57
    11F 7.4
    11G 7.22
    11H 7.15
    11I 7.14
    11J 5.72
    11K 7.67
    11L 7.58
    11M 7.98
    11N 7.59
    12 7.17
    13A 6.81
    13B 7.1
    13C 7.12
    13D 7.28
    13E 7.58
    13F 6.78
    14 5.71
    15A 6.56
    15B 6.74
    15C 7.85
    15D 5.35
    15E 6.29
    17 5.91
    18 5.48
    16 6.02
    20 5.45
    21A 6.41
    21B 6.24
    21C 6.21
    21D 6.13
    22 5.3
    23 5.99
    • TR-Fret assay (Protocol B)
  • HIS-tagged RORγ-LBD was recombinantly expressed in SF9 cells using a baculovirus expression system. The protein was not purified. Cells were lysed and the lysate was used as a source for RORγ-LBD for the assay. A 1:80 dilution of RORγ-LBD lysate in assay buffer (25 mM HEPES pH 7.0, 100 mM NaCl, 0.01% Tween, 0.1% BSA) was prepared and 5 µL was added to each well (RORγ-LBD final concentration ∼10 nM). Control wells received lysate from SF9 cells not expressing RORγ-LBD.
    Compounds to be tested were diluted to 100x final test concentration in DMSO and further diluted to 4x final test concentration using assay buffer to provide the test compound mixture. An aliquot (5 µL) of the test compound mixture was added to each well.
  • A 4x stock of biotinylated-LXXLL peptide from SRC1-2 (Biotin-CPSSHSSLTERHKILHRLLQEGSPS) was prepared in assay buffer and a 5 µL aliquot added to each well (450 nM final concentration). A 4x solution of europium tagged anti-HIS antibody (2 nM final concentration) and APC conjugated streptavidin (60 nM final concentration) were prepared and a 5 µL aliquot added to each well.
    The final assay mixture was incubated for 4 hours to overnight, and the fluorescence signal was measured on an Envision plate reader: (Excitation filter = 340 nm; APC emission = 665 nm; Europium emission = 615 nm; dichroic mirror = D400/D630; delay time = 100 µs, integration time = 200 µs).
  • IC50 values for test compounds were calculated from the quotient of the fluorescence signal at 665 nm divided by the fluorescence signal at 615 nm using GraphPad Prism software.
    • TR-Fret assay (Protocol C)
  • HIS-tagged RORγ-LBD protein was expressed in SF9 cells using a baculovirus expression system. The RORγ-LBD protein was purified by glutathione sepharose chromatography. Separately, SF9 cells not expressing any recombinant protein were lysed and the lysate was added to the purified RORγ-LBD at 0.25 µl lysate (from 10,000 SF9 cells)/nM purified protein. The mixture was then diluted in assay buffer (50 mM Tris pH 7.0, 50 mM KCl, 1 mM EDTA, 0.1 mM DTT) to obtain RORγ-LBD final concentration of 3 nM in 384-well assay plate.
  • Compounds to be tested were injected to the assay plate using Acoustic Droplet Ejection technology by Echo 550 liquid handler (Labcyte, CA).
  • A stock of biotinylated-LXXLL peptide from coactivator SRC1 (Biotin-CPSSHSSLTERHKILHRLLQEGSPS) was prepared in assay buffer and added to each well (100 nM final concentration). A solution of Europium tagged anti-HIS antibody (1.25 nM final concentration) and APC conjugated streptavidin (8 nM final concentration) were also added to each well.
  • The final assay mixture was incubated for overnight at 4°C, and the fluorescence signal was measured on an Envision plate reader: (Excitation filter = 340 nm; APC emission = 665 nm; Europium emission = 615 nm; dichroic mirror = D400/D630; delay time = 100 µs, integration time = 200 µs).IC50 values for test compounds were calculated from the quotient of the fluorescence signal at 665 nm divided by the fluorescence signal at 615 nm.
  • Table 7 below tabulates the biological data disclosed for Examples 24A-29 as a range of Fret IC50 values, which was reported as ranges according to the annotation delineated below:
    • * IC50 <50 nM
    • ** IC50 >50 and <500 nM
    • *** IC50 >500 and <10000 nM
    • **** IC50 >10000 nM
    Table 7
    Examples Fret IC50 Assay protocol
    24A * B
    24B * B
    24C * B
    24D *** B
    24E *** B
    24F *** B
    24G *** B
    24H * B
    24I * B
    24J ** B
    24K * B
    24L * B
    24M * B
    24N * B
    24O * B
    24P * B
    24Q ** B
    24R * B
    24S *** B
    24T **** B
    24U * B
    24V * B
    24W * B
    24X ** B
    24Y * B
    24Z **** B
    24AA * B
    24AB * B
    24AC *** B
    24AD *** B
    24AE *** B
    24AF * B
    24AG * B
    24AH * B
    24AI ** B
    24AJ ** B
    24AK * B
    24AL **** C
    24AM * B
    24AN * B
    24AO * B
    24AP *** B
    24AQ * B
    24AR * B
    24AS * C
    24AT * B
    24AU * C
    24AV ** C
    24AW ** C
    24AX * B
    24AY ** B
    24AZ ** B
    24BA * B
    24BB * B
    24BC *** B
    24BD *** B
    24BE * B
    24BF * B
    24BG ** C
    25A * B
    25B * B
    25C * B
    25D * B
    25E * B
    25F * B
    25G ** B
    25H * B
    25I ** B
    25J * B
    25K * B
    25L * B
    25M * B
    25N * C
    250 * B
    25P * B
    25Q * B
    25R * B
    25S * C
    25T * C
    25U * C
    25V * C
    25W * C
    26A * B
    26B * B
    26C * B
    26D * B
    26E * B
    26F * C
    26G * C
    26H * B
    26I * B
    26J * B
    27A * B
    27B * B
    28 * B
    29 ** B

Claims (16)

  1. A compound according to Formula I
    Figure imgb0373
     or a pharmaceutically acceptable salt or solvate thereof wherein,
    X is C(O), SO or SO2,
    Y is N or CH;
    n = 0, 1, 2, 3 or 4;
    A4-A7 are independently N or CR4, CR5, CR6 or CR7, respectively, with the proviso that no more than two of the four positions A4-A7 can be simultaneously N;
    R1 is (i) (C3-7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogens; (ii) (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogens; or (iii) (C6-14)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy are optionally substituted with one or more halogens;
    R2 is C(O)OH, 5-tetrazoylyl, HOC(CF3)2, or (C1-10)alkylsulfoxyaminocarbonyl;
    R3 is hydrogen, halogen, cyano, nitro, hydroxy, (C1-3)alkylC(O)O-, (C1-4)alkyl, or (C1-4)alkoxy, wherein (C1-4)alkyl and (C1-4)alkoxy are optionally substituted with one or more halogen;
    R4-R7 independently are H, halogen, amino, cyano, hydroxy, (C1-3)alkoxy, (C1-4)alkyl, (C0-10)alkyl)aminocarbonyl, (di)(C1-6)alkylaminocarbonyl or amino(C1-4)alkyl, wherein (C1-3)alkoxy, (C1-4)alkyl, (C0-10)alkyl)aminocarbonyl, (di)(C1-6)alkylaminocarbonyl and amino(C1-4)alkyl are optionally substituted with one or more halogen, hydroxyl or (C1-3)alkoxy; or a group having the formula
    Figure imgb0374
     optionally substituted with one or more of the following: (C1-10)alkyl, halogen, amino, cyano, hydroxy, (C1-3)alkoxy, and wherein m is 1, 2, 3, or 4.
  2. The compound of claim 1 having Formula Ia
    Figure imgb0375
     or a pharmaceutically acceptable salt or solvate thereof
    wherein
    X, Y and A4-A7 are as defined in claim 1;
    R1 is (C3-7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from halogen, amino, cyano, hydroxy, H2NC(O)-, or (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, all optionally substituted with one or more halogens; or
    R1 is (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, or (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, all optionally substituted with one or more halogens or;
    R1 is (C6-14)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, or (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, all optionally substituted with one or more halogens;
    R2 is C(O)OH, 5-tetrazoylyl, or HOC(CF3)2;
    R3 is independently selected from hydrogen, halogen, cyano, nitro or (C1-4)alkyl, optionally substituted with one or more halogens; and
    R4-R7 independently are H, halogen, amino, cyano, hydroxy, (C1-3)alkoxy, (C1-4)alkyl, optionally substituted with one or more halogens.
  3. The compound of claim 1, wherein A4, A5, A6, A7 are selected from the group consisting of: (i) CR4, CR5, CR6, CR7; (ii) N, CR5, CR6, CR7; and (iii) CR4, N, CR6, CR7.
  4. The compound of claim 3, wherein A4, A5, A6, A7 is (i) CR4, CR5, CR6, CR7, or (ii) N, CR5, CR6, CR7; and Y is N.
  5. The compound of claim 4, wherein
    X is C(O) or SO2;
    R1 is (i) (C3-7)cycloalkyl or (C3-5)heterocycloalkyl, both optionally substituted with one or more groups selected from (C1-4)alkyl or halogen; (ii) (C2-9)heteroaryl, optionally substituted with one or more groups selected from halogen, amino or (C1-4)alkyl; or (iii) (C6-14)aryl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C1-3)alkoxycarbonyl, (C1-4)alkyl, (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogens, optionally
    wherein R1 is (C2-9)heteroaryl or (C6-14)aryl, both optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C1-3)-alkoxycarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogens, optionally wherein R1 is phenyl, naphthyl, pyridinyl, quinolinyl, benzooxadiazolyl, thiophenyl, or isoxazolyl, each optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C1-3)alkoxycarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogens, optionally
    wherein R1 is phenyl, optionally substituted with one or more groups selected from halogen, amino, cyano, nitro, hydroxy, (C1-3)alkoxycarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (C1-4)alkyl and (C1-3)alkoxy are optionally substituted with one or more halogens.
  6. The compound of any preceding claim, wherein R2 is C(O)OH.
  7. The compound of any of claims 3-6 having Formula Ib
    Figure imgb0376
     or a pharmaceutically acceptable salt or solvate thereof.
  8. The compound of claim 7 having Formula Ic
    Figure imgb0377
     or a pharmaceutically acceptable salt or solvate thereof wherein,
    X is C(O) or SO2
    R8 is selected from halogen, amino, cyano, nitro, hydroxy, H2NC(O)-, (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy, wherein (C1-3)alkoxycarbonyl, (di)(C1-6)alkylaminocarbonyl, (C1-4)alkyl or (C1-3)alkoxy are optionally substituted with one or more halogens; and
    x is 0, 1, 2, 3, 4 or 5.
  9. The compound of claim 8 having Formula Id
    Figure imgb0378
     or a pharmaceutically acceptable salt or solvate thereof.
  10. The compound of claim 9 having Formula Ie
    Figure imgb0379
     or a pharmaceutically acceptable salt or solvate thereof.
  11. A compound according to claim 1 selected from:
    4-(1-(2,6-dichlorobenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,6-dichlorobenzoyl)-5-fluoro-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,6-dichlorobenzoyl)-7-fluoro-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,6-dichlorobenzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,6-dichlorobenzoyl)-6-fluoro-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,6-dichlorobenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    4-(1-(2-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    4-(1-(2,6-dichlorobenzoyl)-1H-pyrrolo[3,2-b]pyridin-3-yl)benzoic acid;
    4-(1-(2,6-dichlorobenzoyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid;
    1,1,1,3,3,3-hexafluoro-2-(4-(1-(2-(trifluoromethyl)phenylsulfonyl)-1H-indazol-3-yl)phenyl)propan-2-ol;
    4-(1-(2-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(3,5-dichloroisonicotinoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-bromobenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-(methoxycarbonyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(cyclohexanecarbonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-bromo-6-chlorobenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-fluoro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,4,6-trichlorobenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,6-dimethylbenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-ethoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,3-dichlorobenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chlorobenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-methyl-6-nitrobenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-(trifluoromethyl)phenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(quinolin-8-ylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-bromophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,5-dichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(3-chloro-2-methylphenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,3-dichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,3,4-trichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-cyanophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-(trifluoromethoxy)phenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(naphthalen-1-ylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2,6-dichlorophenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(benzo[c][1,2,5]oxadiazol-4-ylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-cyano-5-methylphenylsulfonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(3,5-dimethylphenylsulfonyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    4-(1-(3,5-dimethylphenylsulfonyl)-1H-indazol-3-yl)-2-(trifluoromethyl)benzoic acid;
    4-(1-(2-chlorophenylsulfonyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)benzoic acid;
    3-(4-(1H-tetrazol-5-yl)phenyl)-1-(3-chlorophenylsulfonyl)-1H-indazole;
    methyl 3-(3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-ylsulfonyl)thiophene-2-carboxylate;
    3-(4-(1H-tetrazol-5-yl)phenyl)-1-(2-bromo-4-fluorophenylsulfonyl)-1H-indazole;
    3-(4-(1H-tetrazol-5-yl)phenyl)-1-(3-bromo-5-chlorothiophen-2-ylsulfonyl)-1H-indazole;
    4-(3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-ylsulfonyl)-3,5-dimethylisoxazole;
    (3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-yl)(2,6-dichlorophenyl)methanone;
    (3-(4-(1H-tetrazol-5-yl)phenyl)-1H-indazol-1-yl)(2,3-dichlorophenyl)methanone;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3-fluorobenzoic acid;
    Sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3-fluorobenzoate;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoate;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoic acid;
    sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoate;
    (2-chloro-6-(trifluoromethyl)phenyl)(4-fluoro-3-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-1 H-indazol-1-yl)methanone;
    3-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid;
    2-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid;
    Sodium 3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)benzoate;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluoro-5-methylbenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3-methylbenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-methoxybenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluorobenzoic acid;
    sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluorobenzoate;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-methylbenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3-methoxybenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2,6-difluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-isopropylbenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3,5-dimethoxybenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-cyano benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2,3-difluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2,5-difluorobenzoic acid;
    2-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-5-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-5-fluoro-2-methoxybenzoic acid;
    5-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-hydroxybenzoic acid;
    3-fluoro-4-(4-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(4-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    3-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl) benzoic acid;
    (2-chloro-6-(trifluoromethyl)phenyl)(3-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-1H-pyrazolo[4,3-b]pyridin-1-yl)methanone;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-methylbenzoic acid;
    3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-methoxybenzoic acid;
    2-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-5-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2,5-difluorobenzoic acid;
    5-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-hydroxybenzoic acid;
    4-(1-(2-fluoro-6-methoxybenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    3-fluoro-4-(1-(2-fluoro-6-methoxybenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-(trifluoromethyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-2-isopropylbenzoic acid;
    sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-2-fluoro benzoate;
    sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-3-fluoro benzoate;
    3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    3-fluoro-4-(1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    sodium 3-fluoro-4-(1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoate;
    4-(7-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    3-fluoro-4-(7-fluoro-1-(2-fluoro-6-methoxybenzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(6-bromo-1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl) benzoic acid;
    4-(6-bromo-1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-methoxy-1H-indazol-3-yl) benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-1H-indazol-3-yl)benzoic acid;
    sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-1H-indazol-3-yl) benzoate;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-hydroxy-1H-indazol-3-yl)-3-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-hydroxy-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-6-hydroxy-1H-indazol-3-yl)-3-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(hydroxymethyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(hydroxymethyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(methoxymethyl)-1H-indazol-3-yl)benzoic acid;
    1-(2-chloro-6-(trifluoromethyl)benzoyl)-3-(4-(methoxy carbonyl)phenyl)-1H-indazole-6-carboxylic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxy ethylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)benzoate;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)benzoate;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)-3-fluorobenzoate;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)-2-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)-2-fluorobenzoic acid;
    3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    3-chloro-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxyethylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-hydroxypropylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-hydroxypropylcarbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-methoxypropylcarbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(2-hydroxypropylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(4-hydroxybutylcarbamoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-hydroxyethyl)(methyl)carbamoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-hydroxyethyl)(methyl)carbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-((2-methoxyethyl)(methyl)carbamoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3-fluoroazetidine-1-carbonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(3,3-difluoroazetidine-1-carbonyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(pyrrolidine-1-carbonyl)-1H-indazol-3-yl)benzoic acid;
    4-(6-(azetidine-1-carbonyl)-1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-hydroxybenzoic acid;
    2-acetoxy-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)benzoic acid;
    sodium 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-hydroxybenzoate;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-2-fluoro-6-hydroxybenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3-hydroxybenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-5-fluoro-2-hydroxybenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)-3,6-difluoro-2-hydroxybenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-2-hydroxybenzoic acid;
    2-acetoxy-4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-(dimethylcarbamoyl)-1H-indazol-3-yl)-2-hydroxybenzoic acid;
    4-(6-(aminomethyl)-1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid;
    4-(6-(aminomethyl)-1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-3-fluorobenzoic acid;
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)-2-(difluoro methyl)benzoic acid; and
    4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-6-cyano-1H-indazol-3-yl)benzoic acid.
  12. A compound selected from:
    2-(3-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)phenyl)acetic acid;
    2-(4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-4-fluoro-1H-indazol-3-yl)phenyl)acetic acid; and
    2-(4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl) phenyl)acetic acid.
  13. A pharmaceutical composition comprising a compound of any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable excipients, optionally wherein the pharmaceutical composition further comprises at least one additional therapeutically active agent.
  14. A compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.
  15. A compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt or solvate thereof, for use in treating a disease or condition mediated by Retinoic acid receptor-related Orphan Receptor gamma t (RORgammaT) in a subject.
  16. The compound for use of claim 15, wherein the disease or condition is an autoimmune disease or inflammatory disease, optionally wherein the disease or condition is multiple sclerosis, inflammatory bowel disease, Crohn's disease, psoriasis, rheumatoid arthritis, asthma, osteoarthritis, Kawasaki disease, Hashimoto's thyroiditis or mucosal leishmaniasis.
EP12744370.3A 2011-02-11 2012-02-10 Rorgammat inhibitors Active EP2683693B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12744370.3A EP2683693B1 (en) 2011-02-11 2012-02-10 Rorgammat inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11154188A EP2487159A1 (en) 2011-02-11 2011-02-11 RorgammaT inhibitors
PCT/CN2012/071017 WO2012106995A1 (en) 2011-02-11 2012-02-10 Rorgammat inhibitors
EP12744370.3A EP2683693B1 (en) 2011-02-11 2012-02-10 Rorgammat inhibitors

Publications (3)

Publication Number Publication Date
EP2683693A1 EP2683693A1 (en) 2014-01-15
EP2683693A4 EP2683693A4 (en) 2014-10-08
EP2683693B1 true EP2683693B1 (en) 2017-04-05

Family

ID=43901458

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11154188A Withdrawn EP2487159A1 (en) 2011-02-11 2011-02-11 RorgammaT inhibitors
EP12744370.3A Active EP2683693B1 (en) 2011-02-11 2012-02-10 Rorgammat inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11154188A Withdrawn EP2487159A1 (en) 2011-02-11 2011-02-11 RorgammaT inhibitors

Country Status (11)

Country Link
US (3) US9095583B2 (en)
EP (2) EP2487159A1 (en)
JP (1) JP5934721B2 (en)
KR (1) KR20140044791A (en)
CN (1) CN103748076A (en)
AU (1) AU2012214029A1 (en)
BR (1) BR112013020352A2 (en)
CA (1) CA2828059A1 (en)
MX (1) MX2013009149A (en)
RU (1) RU2013141528A (en)
WO (1) WO2012106995A1 (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102087313B1 (en) 2010-08-10 2020-03-11 렘펙스 파머수티클스 인코퍼레이티드 Method for preparing cyclic boronic acid ester derivatives
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
WO2013079223A1 (en) 2011-12-02 2013-06-06 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rorϒ, nr1f3) activity and for the treatment of chronic inflammatory and autoimmune diseases
AU2013259624B2 (en) * 2012-05-08 2017-10-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
US9657033B2 (en) * 2012-05-08 2017-05-23 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6225178B2 (en) 2012-05-31 2017-11-01 フェネックス ファーマシューティカルス アーゲー Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators of the orphan nuclear receptor RORγ
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
IL289834B1 (en) 2012-06-13 2024-03-01 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
JO3215B1 (en) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag Carboxamide or Sulfonamide Substituted Nitrogen-Containing 5-Membered Heterocycles as Modulators for the Orphan Nuclear Receptor RORy
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026327A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112015016001A2 (en) 2013-01-04 2017-07-11 Rempex Pharmaceuticals Inc compounds, pharmaceutical compositions and their uses and method for treating or preventing bacterial infection
MX2015008627A (en) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Boronic acid derivatives and therapeutic uses thereof.
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
SI2986610T1 (en) 2013-04-19 2018-04-30 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
US9745297B2 (en) * 2013-07-30 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
WO2015035032A1 (en) * 2013-09-05 2015-03-12 Boehringer Ingelheim International Gmbh Bicylic compounds as modulators of rorgamma
CN105531274A (en) * 2013-09-11 2016-04-27 豪夫迈·罗氏有限公司 Keto-imidazopyridine derivatives as rorc modulators
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
EP3057949B1 (en) * 2013-10-15 2019-06-05 Janssen Pharmaceutica NV Secondary alcohol quinolinyl modulators of ror gamma t
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
BR112016008215A2 (en) * 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv roryt alkyl-linked quinolinyl modulators
WO2015057626A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv QUINOLINYL MODULATORS OF RORyT
TW201605797A (en) * 2013-12-10 2016-02-16 葛蘭馬克製藥公司 Bicyclic heteroarylcompounds as ROR gamma modulators
CN104530014B (en) * 2013-12-25 2018-03-20 中国科学院广州生物医药与健康研究院 Sulfamide compound of the dihydrobenzo of 2 oxo 1,2 [cd] indoles 6 and combinations thereof and application
WO2015101928A1 (en) * 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3110429A4 (en) 2014-02-27 2018-02-21 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
WO2015139621A1 (en) * 2014-03-18 2015-09-24 北京韩美药品有限公司 4-heteroaryl substituted benzoic acid or benzamides compound
WO2015171610A2 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
DK3140310T3 (en) 2014-05-05 2019-10-21 Rempex Pharmaceuticals Inc SYNTHESIS OF BORONATE SALTS AND USE THEREOF
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
WO2015179308A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6700203B2 (en) 2014-07-01 2020-05-27 レンペックス・ファーマシューティカルズ・インコーポレイテッド Boronic acid derivatives and their therapeutic use
CN107074852B (en) 2014-10-14 2019-08-16 生命医药有限责任公司 The pyrrolin and pyridine inhibitors of ROR- γ
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
GB201419015D0 (en) * 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US10435402B2 (en) 2015-01-08 2019-10-08 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
ES2751669T3 (en) 2015-02-20 2020-04-01 Incyte Corp Bicyclic heterocycles as FGFR inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JP2018513123A (en) 2015-03-12 2018-05-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods for treating cancer using ROR gamma inhibitors
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10849992B1 (en) * 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
WO2016198908A1 (en) * 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
MX2017015980A (en) * 2015-06-09 2018-04-20 Abbvie Inc Nuclear receptor modulators.
MX2017016134A (en) 2015-06-11 2018-08-15 Lycera Corp Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease.
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
CN108137585B (en) * 2015-09-21 2021-10-22 普莱希科公司 Heterocyclic compounds and their use
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
JP2018531958A (en) * 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Heteroaryl-substituted benzoic acids and their use as RORγT inhibitors
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
BR112018010018A2 (en) 2015-11-20 2018-11-21 Vitae Pharmaceuticals Inc ror-gamma modulators
CN105412929B (en) * 2015-11-27 2018-03-20 肖定璋 Applications of the UTR of IL7R 3 ' in regulation and control retinoic acid-related orphan nuclear receptor expression
TN2018000188A1 (en) 2015-12-15 2019-10-04 Astrazeneca Ab Isoindole compounds
KR20180135885A (en) * 2016-01-21 2018-12-21 즈보 바이오폴라 창쉥 파마수티컬 컴퍼니 리미티드 Bruton tyrosine kinase inhibitor
US10793566B2 (en) 2016-01-21 2020-10-06 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
TW202220968A (en) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 Modulators of ror-gamma
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
MY196909A (en) 2016-06-30 2023-05-09 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
WO2018084120A1 (en) * 2016-11-01 2018-05-11 学校法人東京理科大学 Benzoic acid derivative and dehydration-condensation agent, and methods for producing ester and lactone
JP2020111510A (en) * 2017-03-29 2020-07-27 科研製薬株式会社 Indazole derivative and medicament containing the same
KR102615821B1 (en) * 2017-04-11 2023-12-21 선샤인 레이크 파르마 컴퍼니 리미티드 Fluorine-substituted indazole compounds and uses thereof
IT201700041723A1 (en) 2017-04-14 2018-10-14 Italfarmaco Spa New HDAC6 selective inhibitors
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
KR20200019176A (en) * 2017-06-12 2020-02-21 싸이프러스 바이오-테크 컴퍼니 리미티드 Multi-Application Insect Repellent Additives
EP3638661A1 (en) 2017-06-14 2020-04-22 Astrazeneca AB 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of ror gamma
AU2018307919B2 (en) 2017-07-24 2022-12-01 Vitae Pharmaceuticals, Llc Inhibitors of RORϒ
CN109485595B (en) * 2017-09-12 2022-05-27 江苏恒瑞医药股份有限公司 Hydrophilic group substituted indole formamide derivative, preparation method and medical application thereof
BR112020007138B1 (en) 2017-10-11 2023-03-21 Qpex Biopharma, Inc BORONIC ACID DERIVATIVES, SYNTHESIS METHODS, PHARMACEUTICAL COMPOSITION AND THEIR USE
JP6557436B1 (en) 2018-03-12 2019-08-07 アッヴィ・インコーポレイテッド Inhibitors of tyrosine kinase 2-mediated signaling
EP3781576A4 (en) 2018-04-20 2022-03-02 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
MX2020011639A (en) 2018-05-04 2021-02-15 Incyte Corp Salts of an fgfr inhibitor.
EP3788047A2 (en) 2018-05-04 2021-03-10 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022007163A2 (en) 2019-10-14 2022-08-23 Incyte Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220131900A (en) 2019-12-04 2022-09-29 인사이트 코포레이션 Derivatives of FGFR inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670447A (en) 1983-08-22 1987-06-02 Hoechst-Roussel Pharmaceuticals Inc. Antipsychotic 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US4751235A (en) * 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
PT95899A (en) * 1989-11-17 1991-09-13 Glaxo Group Ltd PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6133290A (en) 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
GB0117577D0 (en) 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
MXPA06011327A (en) * 2004-03-30 2006-12-15 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases.
SI2332940T1 (en) * 2004-03-30 2013-03-29 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
US7417063B2 (en) * 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
PA8640701A1 (en) 2004-08-03 2006-09-08 Wyeth Corp USEFUL INDAZOLS FOR TREATMENT OF CARDIOVASCULAR DISEASES
CA2583428A1 (en) * 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
SE0402762D0 (en) 2004-11-11 2004-11-11 Astrazeneca Ab Indazole sulphonamide derivatives
CN100516049C (en) 2004-11-16 2009-07-22 永信药品工业股份有限公司 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as anti-angiogenic agents
JP4954086B2 (en) * 2004-12-08 2012-06-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 1H-pyrrolo [2,3-B] pyridine
US7696229B2 (en) 2006-02-17 2010-04-13 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
JP4675801B2 (en) * 2006-03-06 2011-04-27 日本メナード化粧品株式会社 ROR activator
MX2008011220A (en) 2006-03-07 2008-09-11 Array Biopharma Inc Heterobicyclic pyrazole compounds and methods of use.
AU2007257841A1 (en) * 2006-06-09 2007-12-21 Icos Corporation Substituted phenyl acetic acids as DP-2 antagonists
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
EP2134685B1 (en) 2007-04-16 2015-09-02 AbbVie Inc. 7-nonsubstituted indole derivatives as mcl-1 inhibitors
GB0708141D0 (en) * 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
AR067326A1 (en) 2007-05-11 2009-10-07 Novartis Ag IMIDAZOPIRIDINES AND PIRROLO -PIRIMIDINES REPLACED AS INHIBITORS OF LIPIDO KINASE
AU2008262412A1 (en) 2007-06-05 2008-12-18 Merck Sharp & Dohme Corp. Polycyclic indazole derivatives and their use as ERK inhibitors for the treatment of cancer
WO2009015067A2 (en) * 2007-07-25 2009-01-29 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
FR2933609B1 (en) * 2008-07-10 2010-08-27 Fournier Lab Sa USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE TREATMENT OF PARKINSON'S DISEASE.
EP2181710A1 (en) 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
EP2379561B1 (en) * 2008-11-25 2015-11-04 University Of Rochester Mlk inhibitors and methods of use
WO2010150837A1 (en) * 2009-06-25 2010-12-29 第一三共株式会社 Indoline derivative
EP2459184A1 (en) * 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
JP2013514385A (en) 2009-12-18 2013-04-25 ヤンセン ファーマシューティカ エヌ．ベー． Substituted aminothiazolone indazoles as estrogen-related receptor alpha modulators
WO2011103189A1 (en) 2010-02-16 2011-08-25 Uwm Research Foundation, Inc. Methods of reducing virulence in bacteria
EP2571361A4 (en) 2010-05-19 2013-11-13 Univ North Carolina Pyrazolopyrimidine compounds for the treatment of cancer
US9512111B2 (en) 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
KR20120063283A (en) 2010-12-07 2012-06-15 제일약품주식회사 Novel pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
CN103429598B (en) * 2010-12-22 2018-03-30 慕尼黑路德维希马克西米利安斯大学 Organozinc complex and its preparation and application
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
JP2014166961A (en) 2011-06-20 2014-09-11 Dainippon Sumitomo Pharma Co Ltd Novel indazole derivative
WO2014026329A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026328A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof

Also Published As

Publication number Publication date
US9884043B2 (en) 2018-02-06
AU2012214029A8 (en) 2013-10-17
EP2487159A1 (en) 2012-08-15
JP5934721B2 (en) 2016-06-15
AU2012214029A1 (en) 2013-08-29
CN103748076A (en) 2014-04-23
CA2828059A1 (en) 2012-08-16
US9603838B2 (en) 2017-03-28
EP2683693A4 (en) 2014-10-08
US20150297566A1 (en) 2015-10-22
RU2013141528A (en) 2015-03-20
KR20140044791A (en) 2014-04-15
WO2012106995A1 (en) 2012-08-16
JP2014509316A (en) 2014-04-17
BR112013020352A2 (en) 2017-08-08
US20140038942A1 (en) 2014-02-06
EP2683693A1 (en) 2014-01-15
MX2013009149A (en) 2014-02-17
US9095583B2 (en) 2015-08-04
US20170340610A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
EP2683693B1 (en) Rorgammat inhibitors
EP2884976B1 (en) 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EP2884977B1 (en) N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US10196354B2 (en) 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
EP2920149B1 (en) 3-aminocycloalkyl compounds as ror-gamma-t inhibitors and uses thereof
EP3368535B1 (en) Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130910

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140909

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 413/14 20060101ALI20140903BHEP

Ipc: C07D 401/06 20060101ALI20140903BHEP

Ipc: A61P 29/00 20060101ALI20140903BHEP

Ipc: C07D 409/14 20060101ALI20140903BHEP

Ipc: C07D 231/56 20060101AFI20140903BHEP

Ipc: C07D 413/12 20060101ALI20140903BHEP

Ipc: A61K 31/4162 20060101ALI20140903BHEP

Ipc: C07D 401/12 20060101ALI20140903BHEP

Ipc: C07D 403/10 20060101ALI20140903BHEP

Ipc: A61K 31/416 20060101ALI20140903BHEP

Ipc: C07D 471/04 20060101ALI20140903BHEP

17Q First examination report despatched

Effective date: 20151106

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160510

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20161007

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 881699

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012030771

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170405

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 881699

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170706

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170805

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012030771

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

26N No opposition filed

Effective date: 20180108

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120210

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170405

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170405

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602012030771

Country of ref document: DE

Representative=s name: KILBURN & STRODE LLP, NL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012030771

Country of ref document: DE

Owner name: MERCK SHARP & DOHME LLC, RAHWAY, US

Free format text: FORMER OWNERS: MERCK SHARP & DOHME B.V., HAARLEM, NL; MERCK SHARP & DOHME CORP., RAHWAY, N.J., US

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012030771

Country of ref document: DE

Owner name: MERCK SHARP & DOHME B.V., NL

Free format text: FORMER OWNERS: MERCK SHARP & DOHME B.V., HAARLEM, NL; MERCK SHARP & DOHME CORP., RAHWAY, N.J., US

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20220908 AND 20220914

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230109

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230111

Year of fee payment: 12

Ref country code: DE

Payment date: 20230111

Year of fee payment: 12